iKang Healthcare (KANG) 20-F 27 Jul 15 2015 FY Annual report (foreign) Financial data

Document and Entity Information

Document and Entity Information - Mar. 31, 2015 - shares	Total
Entity Registrant Name	iKang Healthcare Group, Inc.
Entity Central Index Key	1,524,190
Document Type	20-F
Document Period End Date	Mar. 31, 2015
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Class A common shares
Entity Common Stock, Shares Outstanding	33,556,439
Class C common shares
Entity Common Stock, Shares Outstanding	805,100

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2015	Mar. 31, 2014
Current assets
Cash and cash equivalents	$ 97,336	$ 30,221
Restricted cash	54,417	16,007
Term deposits	14,621
Accounts receivable, net of allowance for doubtful accounts of $4,330 and $8,055 as of March 31, 2014 and 2015, respectively	59,650	37,619
Inventories	2,661	1,693
Deferred tax assets-current	5,949	3,991
Prepaid expenses and other current assets	44,031	20,012
Amounts due from a related party		1,287
Total current assets	278,665	110,830
Restricted cash-non-current		2,153
Property and equipment, net	105,022	63,644
Acquired intangible assets, net	30,634	17,530
Goodwill	72,101	41,412
Cost method investment	129	129
Equity method investment	0	6,220
Deferred tax assets-non-current	2,212	2,007
Rental deposit and other non-current assets	10,238	6,301
TOTAL ASSETS	499,001	250,226
Current liabilities
Accounts payable (including accounts payable of the consolidated VIEs and VIEs' subsidiaries without recourse to iKang Healthcare Group, Inc. of $14,599 and $19,530 of March 31, 2014 and 2015, respectively)	23,526	16,965
Accrued expenses and other current liabilities (including accrued expenses and other current liabilities of the consolidated VIEs and VIEs' subsidiaries without recourse to iKang Healthcare Group, Inc. of $17,126 and $30,631 of March 31, 2014 and 2015, respectively)	36,790	24,275
Income tax payable (including income tax payable of the consolidated VIEs and VIEs' subsidiaries without recourse to iKang Healthcare Group, Inc.of $5,299 and $6,254 of March 31, 2014 and 2015, respectively)	7,539	6,382
Amounts due to a related party (including amounts due to a related party of the consolidated VIEs and VIEs' subsidiaries without recourse to iKangHealthcare Group, Inc. of $8,049 and nil of March 31, 2014 and2015, respectively)		8,049
Deferred revenues (including deferred revenues of the consolidated VIEs and VIEs' subsidiaries without recourse to iKang Healthcare Group, Inc.of $22,234 and $31,786 of March 31, 2014 and 2015, respectively)	38,457	29,523
Deferred government subsidy-current (including deferred government subsidy - current of the consolidated VIEs and VIEs' subsidiaries without recourse to iKang Healthcare Group, Inc. of $47 and $63 of March 31, 2014 and 2015, respectively)	63	47
Short term borrowings (including short term borrowings of the consolidated VIEs and VIEs' subsidiaries without recourse to iKang Healthcare Group, Inc. of $17,717 and $56,772 of March 31, 2014 and 2015, respectively)	56,772	18,201
Total current liabilities	163,147	103,442
Deferred government subsidy - non-current (including deferred government subsidy-non-current of the consolidated VIEs and VIEs' subsidiaries without recourse to iKang Healthcare Group, Inc of $63 and nil of March 31, 2014 and 2015, respectively)		63
Long term borrowings (including long term borrowings consolidated VIEs and VIEs' subsidiaries without recourse to iKang Healthcare Group, Inc. of $1,865 and nil of March 31, 2014 and 2015, respectively)		1,865
Deferred tax liabilities-non-current (including deferred tax liabilities-non-current of the consolidated VIEs and VIEs' subsidiaries without recourse to iKang Healthcare Group, Inc. of $2,929 and $6,670 of March 31, 2014 and 2015, respectively)	7,506	3,478
TOTAL LIABILITIES	$ 170,653	$ 108,848
Commitments and contingencies (Note 22)
iKang Guobin Healthcare Group, Inc. shareholders' equity
Additional paid-in capital	$ 419,862	$ 1,342
Statutory reserve	8,399	5,005
Accumulated deficit	(113,410)	(137,129)
Accumulated other comprehensive income	3,936	3,764
Total iKang Healthcare Group, Inc. shareholders' (deficit)/equity	319,130	(126,957)
Non-controlling interests	9,218	3,818
TOTAL (DEFICIT)/ EQUITY	328,348	(123,139)
TOTAL LIABILITIES, MEZZANINE EQUITY AND EQUITY	499,001	250,226
Series A convertible redeemable participating preferred shares
Mezzanine equity
Convertible redeemable participating preferred shares		6,496
Series B convertible redeemable participating preferred shares
Mezzanine equity
Convertible redeemable participating preferred shares		6,512
Series C1 convertible redeemable participating preferred shares
Mezzanine equity
Convertible redeemable participating preferred shares		5,700
Series C2 convertible redeemable participating preferred shares
Mezzanine equity
Convertible redeemable participating preferred shares		1,709
Series C3 convertible redeemable participating preferred shares
Mezzanine equity
Convertible redeemable participating preferred shares		4,157
Series D1 convertible redeemable participating preferred shares
Mezzanine equity
Convertible redeemable participating preferred shares		29,750
Series D2 convertible redeemable participating preferred shares
Mezzanine equity
Convertible redeemable participating preferred shares		11,300
Series E convertible redeemable participating preferred shares
Mezzanine equity
Convertible redeemable participating preferred shares		54,098
Series F convertible redeemable participating preferred shares
Mezzanine equity
Convertible redeemable participating preferred shares		144,795
Class A common shares
iKang Guobin Healthcare Group, Inc. shareholders' equity
Common shares	335	45
Class B common shares
iKang Guobin Healthcare Group, Inc. shareholders' equity
Common shares		$ 16
Class C common shares
iKang Guobin Healthcare Group, Inc. shareholders' equity
Common shares	$ 8

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2015	Mar. 31, 2014
Allowance for doubtful accounts receivable	$ 8,055	$ 4,330
Accounts payable	23,526	16,965
Accrued expenses and other current liabilities	36,790	24,275
Income tax payable	7,539	6,382
Amount due to related parties		8,049
Deferred revenues	38,457	29,523
Deferred government subsidy-current	63	47
Short term borrowings	56,772	18,201
Deferred government subsidy - non-current		63
Long term borrowings		1,865
Deferred tax liabilities-non-current	7,506	$ 3,478
Common shares, par value (in dollars per share)		$ 0.01
Consolidated VIEs without recourse to iKang Healthcare Group, Inc.
Accounts payable	19,530	$ 14,599
Accrued expenses and other current liabilities	30,631	17,126
Income tax payable	6,254	5,299
Amount due to related parties	0	8,049
Deferred revenues	31,786	22,234
Deferred government subsidy-current	63	47
Short term borrowings	56,772	17,717
Deferred government subsidy - non-current	0	63
Long term borrowings	0	1,865
Deferred tax liabilities-non-current	$ 6,670	$ 2,929
Series A convertible redeemable participating preferred shares
Convertible redeemable participating preferred shares, par value (in dollars per share)	$ 0.01	$ 0.01
Convertible redeemable participating preferred shares, authorized	0	1,094,668
Convertible redeemable participating preferred shares, issued	0	1,094,668
Convertible redeemable participating preferred shares, outstanding	0	1,094,668
Convertible redeemable participating preferred shares, liquidation value	$ 0	$ 1,970
Series B convertible redeemable participating preferred shares
Convertible redeemable participating preferred shares, par value (in dollars per share)	$ 0.01	$ 0.01
Convertible redeemable participating preferred shares, authorized	0	686,368
Convertible redeemable participating preferred shares, issued	0	686,368
Convertible redeemable participating preferred shares, outstanding	0	686,368
Convertible redeemable participating preferred shares, liquidation value	$ 0	$ 2,162
Series C1 convertible redeemable participating preferred shares
Convertible redeemable participating preferred shares, par value (in dollars per share)	$ 0.01	$ 0.01
Convertible redeemable participating preferred shares, authorized	0	794,250
Convertible redeemable participating preferred shares, issued	0	794,250
Convertible redeemable participating preferred shares, outstanding	0	794,250
Convertible redeemable participating preferred shares, liquidation value	$ 0	$ 1,893
Series C2 convertible redeemable participating preferred shares
Convertible redeemable participating preferred shares, par value (in dollars per share)	$ 0.01	$ 0.01
Convertible redeemable participating preferred shares, authorized	0	126,286
Convertible redeemable participating preferred shares, issued	0	126,286
Convertible redeemable participating preferred shares, outstanding	0	126,286
Convertible redeemable participating preferred shares, liquidation value	$ 0	$ 568
Series C3 convertible redeemable participating preferred shares
Convertible redeemable participating preferred shares, par value (in dollars per share)	$ 0.01	$ 0.01
Convertible redeemable participating preferred shares, authorized	0	1,024,318
Convertible redeemable participating preferred shares, issued	0	1,024,318
Convertible redeemable participating preferred shares, outstanding	0	1,024,318
Convertible redeemable participating preferred shares, liquidation value	$ 0	$ 1,382
Series D1 convertible redeemable participating preferred shares
Convertible redeemable participating preferred shares, par value (in dollars per share)	$ 0.01	$ 0.01
Convertible redeemable participating preferred shares, authorized	0	3,488,864
Convertible redeemable participating preferred shares, issued	0	3,488,864
Convertible redeemable participating preferred shares, outstanding	0	3,488,864
Convertible redeemable participating preferred shares, liquidation value	$ 0	$ 10,083
Series D2 convertible redeemable participating preferred shares
Convertible redeemable participating preferred shares, par value (in dollars per share)	$ 0.01	$ 0.01
Convertible redeemable participating preferred shares, authorized	0	2,072,624
Convertible redeemable participating preferred shares, issued	0	2,072,624
Convertible redeemable participating preferred shares, outstanding	0	2,072,624
Convertible redeemable participating preferred shares, liquidation value	$ 0	$ 2,798
Series E convertible redeemable participating preferred shares
Convertible redeemable participating preferred shares, par value (in dollars per share)	$ 0.01	$ 0.01
Convertible redeemable participating preferred shares, authorized	0	4,289,457
Convertible redeemable participating preferred shares, issued	0	4,289,457
Convertible redeemable participating preferred shares, outstanding	0	4,289,457
Convertible redeemable participating preferred shares, liquidation value	$ 0	$ 22,056
Series F convertible redeemable participating preferred shares
Convertible redeemable participating preferred shares, par value (in dollars per share)	$ 0.01	$ 0.01
Convertible redeemable participating preferred shares, authorized	0	7,204,680
Convertible redeemable participating preferred shares, issued	0	7,204,680
Convertible redeemable participating preferred shares, outstanding	0	7,204,680
Convertible redeemable participating preferred shares, liquidation value	$ 0	$ 93,639
Class A common shares
Common shares, par value (in dollars per share)	$ 0.01	$ 0.01
Common shares, authorized	37,648,485	37,648,485
Common shares, issued	33,556,439	4,599,674
Common shares, outstanding	33,556,439	4,599,674
Class B common shares
Common shares, par value (in dollars per share)	$ 0.01	$ 0.01
Common shares, authorized	1,570,000	1,570,000
Common shares, issued	0	1,570,000
Common shares, outstanding	0	1,570,000
Class C common shares
Common shares, par value (in dollars per share)	$ 0.01	$ 0.01
Common shares, authorized	2,000,000	0
Common shares, issued	805,100	0
Common shares, outstanding	805,100	0

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
CONSOLIDATED STATEMENTS OF OPERATIONS
Net revenues	$ 290,781	$ 202,304	$ 133,871
Cost of revenues	154,943	106,405	71,079
Gross profit	135,838	95,899	62,792
Operating expenses:
Selling and marketing expenses	41,059	28,879	18,486
General and administrative expenses (including share-based compensation expenses of $2,273, $930 and $9,153 in 2013, 2014 and 2015, respectively)	52,331	32,053	23,447
Research and development expenses	1,401	1,603	1,270
Total operating expenses	94,791	62,535	43,203
Income from operations	41,047	33,364	19,589
Gain/(loss) from forward contracts	(8)	57
Interest expense	(2,466)	(1,331)	(1,106)
Interest income	699	93	100
Other income	883
Income before provision for income taxes and (loss)/gain from equity method investment	40,155	32,183	18,583
Income tax expenses	13,280	10,101	6,134
Income before (loss)/gain from equity method investment	26,875	22,082	12,449
(Loss)/gain from equity method investment	521	(156)
Net income	27,396	21,926	12,449
Less: Net income attributable to non-controlling interest	283	319	338
Net income attributable to iKang Healthcare Group, Inc.	27,113	21,607	12,111
Deemed dividend to preferred shareholders	100	20,436	84,306
Undistributed earnings allocated to preferred shareholders	201	7,310	2,818
Net (loss)/income attributable to common and preferred shareholders of iKang Healthcare Group, Inc	$ 26,812	$ (6,139)	$ (75,013)
Net (loss)/income per share attributable to common shareholders of iKang Healthcare Group, Inc.
Basic (in dollars per share)	$ 0.82	$ (0.97)	$ (11.22)
Diluted (in dollars per share)	$ 0.79	$ (0.97)	$ (11.22)
Weighted average shares used in calculating net (loss) income per common share
Basic (in shares)	32,884,357	6,340,005	6,683,678
Diluted (in shares)	34,114,872	6,340,005	6,683,678

CONSOLIDATED STATEMENTS OF OPE5

CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
CONSOLIDATED STATEMENTS OF OPERATIONS
Share-based compensation	$ 9,153	$ 930	$ 2,273

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Net income	$ 27,396	$ 21,926	$ 12,449
Other comprehensive income/(loss):
foreign currency translation adjustment	196	(779)	568
Comprehensive income	27,592	21,147	13,017
Less: comprehensive income attributable to non-controlling interest	307	298	322
Comprehensive income attributable iKang Healthcare Group, Inc.	$ 27,285	$ 20,849	$ 12,695

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGE IN EQUITY (DEFICIT) - USD ($) $ in Thousands	iKang's shareholder's equity/(deficit)IPO	iKang's shareholder's equity/(deficit)Green Shoe	iKang's shareholder's equity/(deficit)Shanghai Jianwei Management	iKang's shareholder's equity/(deficit)iKang Shanghai Lujiazui	iKang's shareholder's equity/(deficit)WA Health Care	iKang's shareholder's equity/(deficit)	CommonIPO	CommonGreen Shoe	Common	Additional paid-in capitalIPO	Additional paid-in capitalGreen Shoe	Additional paid-in capitalShanghai Jianwei Management	Additional paid-in capitaliKang Shanghai Lujiazui	Additional paid-in capitalWA Health Care	Additional paid-in capital	Statutory reserve	Accumulated deficitShanghai Jianwei Management	Accumulated deficit	Accumulated other comprehensive income	Non-controlling InterestShanghai Jianwei Management	Non-controlling InterestBeijing Jiandatong	Non-controlling InterestiKang Changzhou	Non-controlling InterestMediFast	Non-controlling InterestiKang Shanghai Lujiazui	Non-controlling InterestiKang Shanghai Gubei	Non-controlling InterestWA Health Care	Non-controlling Interest	IPO	Green Shoe	Beijing Jiandatong	iKang Changzhou	MediFast	iKang Shanghai Lujiazui	iKang Shanghai Gubei	WA Health Care	Total
Balance at Mar. 31, 2012						$ (52,212)			$ 67						$ 4,711	$ 971		$ (61,899)	$ 3,938								$ 708									$ (51,504)
Balance (in shares) at Mar. 31, 2012									6,686,490
Increase (Decrease) in Stockholders' Equity
Provision for statutory reserve																1,296		(1,296)																		1,296
Redesignation to Series F convertible redeemable participating preferred shares						(2,645)			$ (2)						(2,643)																					(2,645)
Redesignation to Series F convertible redeemable participating preferred shares (in shares)									(205,245)
Share-based compensation expenses						2,273									2,273																					2,273
Deemed dividend on convertible redeemable preferred shares - accretion of redemption premium						(84,306)												(84,306)																		(84,306)
Net income						12,111												12,111									338									12,449
Foreign currency translation adjustment						584													584								(16)									568
Balance at Mar. 31, 2013						(124,195)			$ 65						4,341	2,267		(135,390)	4,522								1,030									(123,165)
Balance (in shares) at Mar. 31, 2013									6,481,245
Increase (Decrease) in Stockholders' Equity
Provision for statutory reserve																2,738		(2,738)																		2,738
iKang Healthcare Group, Inc. one common share of $0.01 entered into a share swap agreement									1
Redesignation to Series F convertible redeemable participating preferred shares						(3,749)			$ (4)						(3,745)																					(3,749)
Redesignation to Series F convertible redeemable participating preferred shares (in shares)									(311,572)
Share-based compensation expenses						930									930																					930
Addition of non-controlling interest in connection with acquisition			$ (172)														$ (172)			$ 172	$ 82	$ 732	$ 1,690							$ 82	$ 732	$ 1,690
Dividend distribution to non-controlling interest holder																									$ (44)									$ (44)
Deemed dividend on convertible redeemable preferred shares - accretion of redemption premium						(20,436)												(20,436)																		(20,436)
Purchase of non-controlling interest				$ (184)									$ (184)											$ (142)									$ (326)			(142)
Net income						21,607												21,607									319									21,926
Foreign currency translation adjustment						(758)													(758)								(21)									(779)
Balance at Mar. 31, 2014						(126,957)			$ 61						1,342	5,005		(137,129)	3,764								3,818									(123,139)
Balance (in shares) at Mar. 31, 2014									6,169,674
Increase (Decrease) in Stockholders' Equity
Provision for statutory reserve																3,394		(3,394)																		3,394
Conversion of participating convertible redeemable preferred shares to common shares						264,509			$ 208						264,301																					264,509
Conversion of participating convertible redeemable preferred shares to common shares (in shares)									20,781,515
Share-based compensation expenses						9,153									9,153																					9,153
Issuance of common shares	$ 132,937	$ 13,399					$ 52	$ 5		$ 132,885	$ 13,394																	$ 132,937	$ 13,399
Issuance of common shares (in shares)							5,215,794	514,556
Issuance of common shares in connection with exercise of options						822			$ 1						821																					$ 822
Issuance of common shares in connection with exercise of options (in shares)									80,000																											277,319
Issuance of common shares in connection with share-based compensation arrangement						16			$ 16																											$ 16
Issuance of ordinary shares in connection with share-based compensation arrangements (in shares)									1,600,000
Addition of non-controlling interest in connection with acquisition																										$ 3,388									$ 3,388
Capital contribution of non-controlling interest holder			$ (50)		$ (1,984)							$ (50)		$ (1,984)						$ 50	$ 58					$ 1,984				$ 58
Dividend distribution to non-controlling interest holder																							$ (387)									$ (387)
Deemed dividend on convertible redeemable preferred shares - accretion of redemption premium																																				(100)
Net income						27,113												27,113									283									27,396
Foreign currency translation adjustment						172													172								24									196
Balance at Mar. 31, 2015						$ 319,130			$ 343						$ 419,862	$ 8,399		$ (113,410)	$ 3,936								$ 9,218									$ 328,348
Balance (in shares) at Mar. 31, 2015									34,361,539

CONSOLIDATED STATEMENTS OF CHA8

CONSOLIDATED STATEMENTS OF CHANGE IN EQUITY (DEFICIT) (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
CONSOLIDATED STATEMENTS OF CHANGE IN EQUITY (DEFICIT)
Common shares, par value (in dollars per share)		$ 0.01
Offering costs	$ 2,882

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES
Net income	$ 27,396	$ 21,926	$ 12,449
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation and amortization	19,912	10,759	7,710
Share-based compensation	9,153	930	2,273
Loss on disposal of property and equipment	1	163	475
Provision for doubtful account	3,758	1,100	1,800
(Loss)/gain from equity method investment	(521)	156
Fair value change of previously held 33% equity interest of Shanghai Huajian Health Examination Management Co., Ltd	(883)
Changes in assets and liabilities
Accounts receivable	(22,324)	(3,802)	(12,986)
Inventories	(698)	(459)	(97)
Prepaid expenses and other current assets	(5,300)	(1,193)	176
Amount due from a related party			(477)
Deferred tax assets	(2,147)	(1,232)	(1,081)
Rental deposit and other long-term assets	(2,253)	(1,485)	(1,429)
Accounts payable	6,115	(955)	1,864
Accrued expenses and other current liabilities	2,123	2,884	3,071
Income tax payable	1,129	3,824	528
Deferred revenues	6,546	1,774	1,589
Deferred government subsidy	(47)	(79)	(62)
Deferred tax liabilities	(863)	(512)	(118)
Net cash generated from operating activities	41,097	34,303	16,314
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment	(39,767)	(35,838)	(9,979)
Proceeds from disposal of property and equipment		13	94
Purchase of assets	(339)
Prepayments for business acquisition	(22,222)
Restricted cash	(36,232)	(18,429)
Term deposits	(14,621)
Payments for business acquisitions (net of cash acquired of $4, $2,749 and $1,270 for years ended March 31, 2013, 2014 and 2015, respectively)	(34,432)	(41,311)	(6,038)
Payment of loan receivable	(740)
Loan provided to related parties		(4,306)
Repayment of loan by a related party	1,291	3,483
Net cash used in investing activities	(147,062)	(96,714)	(16,058)
CASH FLOW FROM FINANCING ACTIVITIES
Proceeds from issuance of convertible redeemable preferred shares		25,181	45,000
Proceeds from redesignation of convertible redeemable preferred shares		669
Proceeds from redesignation of Class A common shares		612
Proceeds from exercise of share options	824
Proceeds from issuance of common shares upon initial public offering	135,819
Proceeds from issuance of common shares upon Green Shoe	13,399
Payments for business acquisitions	(1,329)	(3,010)
Payments for assets acquisitions	(32)
Payments of initial public offering costs	(3,574)
Payments for professional fees in connection of issuance of series F convertible preferred shares		(2,847)
Proceeds from convertible loan			2,000
Repayment of convertible loan		(2,000)
Proceeds from short-term borrowings	59,404	20,298	7,800
Proceeds from long-term borrowing		1,901
Repayments short-term borrowings	(20,860)	(7,383)	(3,976)
Repayments long-term borrowing	(1,869)
Net cash provided by financing activities	173,570	29,342	50,824
Effect of exchange rate on cash and cash equivalent	(490)	136	199
Net increase (decrease) in cash and cash equivalent	67,115	(32,933)	51,279
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR	30,221	63,154	11,875
CASH AND CASH EQUIVALENTS AT END OF THE YEAR	97,336	30,221	63,154
Supplemental cash flow information
Income tax paid	13,678	8,224	6,850
Interest paid	2,392	1,068	308
Supplemental non-cash financing and investing activities
Payable for purchase of non-controlling interest of Shanghai Guobin Medical Center Co., Ltd.		(8,049)	(12,379)
Payable for business acquisitions	(10,763)	(3,628)	(505)
Payable for assets acquisitions	(1,032)		(32)
Payable for purchase of property and equipment	(7,902)	(8,568)	(3,645)
iKang Shanghai Lujiazui
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of non-controlling interest of Shanghai iKang Guobin Blue Cross Clinic Co., Ltd.		(326)
iKang Shenzhen Kefa
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of assets			(135)
iKang Changzhou
CASH FLOW FROM FINANCING ACTIVITIES
Capital contribution from non-controlling interest holder		732
Beijing Jiandatong
CASH FLOW FROM FINANCING ACTIVITIES
Capital contribution from non-controlling interest holder	58
MediFast
CASH FLOW FROM FINANCING ACTIVITIES
Dividend distribution to non-controlling interest shareholder	(193)
iKang Shanghai Xikang Road
Adjustments to reconcile net income to net cash provided by operating activities
Amortization of discount on payable purchase of non-controlling interest of Shanghai Guobin Medical Center Co., Ltd		504	$ 629
CASH FLOW FROM FINANCING ACTIVITIES
Purchase of non-controlling interest of Shanghai Guobin Medical Center Co., Ltd.	$ (8,077)	(4,767)
Dividend distribution to non-controlling interest shareholder		$ (44)

CONSOLIDATED STATEMENTS OF CA10

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Cash acquired	$ 1,270	$ 2,749	$ 4

ORGANIZATION AND PRINCIPAL ACTI

ORGANIZATION AND PRINCIPAL ACTIVITIES	12 Months Ended
	Mar. 31, 2015
ORGANIZATION AND PRINCIPAL ACTIVITIES
ORGANIZATION AND PRINCIPAL ACTIVITIES	1. ORGANIZATION AND PRINCIPAL ACTIVITIES iKang Healthcare Group, Inc. (the “Company”), was incorporated on May 25, 2011 as a limited liability company in the Cayman Islands. The Company has no operations and has been created for the initial public offering (“IPO”) purpose. On March 1, 2014, the Company entered into a share swap agreement and became the ultimate holding company of iKang Guobin Healthcare Group, Inc. with the completion of the one to one share exchange to the existing shareholders of iKang Guobin Healthcare Group, Inc. for all shares of equivalent classes. The Company, its subsidiaries, its variable interest entities (“VIEs”) and its VIEs’ subsidiaries (collectively the “Group”) are primarily engaged in providing medical examination services, disease screening services, and other healthcare related services in the People’s Republic of China (the “PRC”). As of March 31, 2015, details of the Group’s subsidiaries, VIEs and the VIEs’ subsidiaries were as follows: Percentage of Later date of beneficial interest incorporation/ Place of by iKang Names acquisition incorporation Healthcare Group, Inc. Principal activities Subsidiaries: iKang Guobin Healthcare Group, Inc.(“iKang Guobin”) December 24, 2003 BVI % Holding company ShanghaiMed iKang, Inc. (“Beijing iKang”) February 27, 2004 PRC % Sales of healthcare service Shanghai iKang Co., Ltd. (“Shanghai iKang”) December 27, 2004 PRC % Sales of healthcare service iKang Zhejiang, Inc. (“iKang Zhejiang BVI”) April 5, 2006 BVI % Holding company iKang HealthManagement (Zhejiang) Co., Ltd. (“Zhejiang iKang”) July 11, 2006 PRC % Sales of healthcare service Bayley & Jackson (China) Medical Services Limited (“Bayley & Jackson (Hong Kong)”) October 10, 2006 Hong Kong % Holding company Beijing Bayley & Jackson Clinic Co., Ltd. (“iKang Beijing Ritan”) October 10, 2006 PRC % Medical examinations & clinical services Yuanhua Healthcare Limited (“Yuanhua HK”) July 31, 2013 Hong Kong % Holding company MediFast (Hong Kong) Limited (“MediFast”) January 14, 2014 Hong Kong % Medical examinations & clinical services Yuanhua Medical Consultancy Services (Shanghai) Co., Ltd. (“Yuanhua WFOE”) July 31, 2013 PRC % Sales of healthcare service WA Centers HK Limited (“WA Health Care “) March 3, 2015 Hong Kong % Holding company iKang(Shanghai) Financing Lease Co., Ltd. (“iKang(Shanghai) Financing Lease”) December 19, 2014 PRC % Lease services VIEs: iKang Healthcare Technology Group Co., Ltd. (formerly named as “Shanghai iKang Guobin Holding Co., Ltd.”) (“iKang Holding”) April 27, 2007 PRC % Holding company Hangzhou iKang Guobin Clinic Co., Ltd. (“iKang Hangzhou Xixi”) September 26, 2010 PRC % Medical examinations Shanghai Yuanhua Information Technology Co., Ltd. (“Yuanhua Information”) July 31, 2013 PRC % Holding company Jiandatong Health Technology (Beijing) Co., Ltd. (“Beijing Jiandatong”) April 1, 2013 PRC % Sales of healthcare service VIEs’ subsidiaries: iKang Guobin Healthcare Group Co., Ltd. (formerly named as “Beijing iKang Online Technology Co., Ltd.”) (“iKang Online”) September 13, 2004 PRC % Sales of healthcare service Beijing iKang Medical Examination APP Co., Ltd. (formerly named as “Beijing iKang Guobin Health Technology Co., Ltd.”) (“iKang Technology”) February 3, 2005 PRC % Sales of healthcare service Shenzhen iKang Co., Ltd. (“Shenzhen iKang”) July 12, 2006 PRC % Sales of healthcare service Shanghai Yalong Daoyi Services Co., Ltd. (“Yalong Daoyi”) December 20, 2006 PRC % Sales of healthcare service Guangzhou iKang Guobin Health Examination Co., Ltd. (“iKang Guangzhou Huanshi East/Tianhe”) April 27, 2007 PRC % Medical examinations Shanghai Guobin Medical Center Co., Ltd. (“iKang Shanghai Xikang Road”) April 27, 2007 PRC % Medical examinations & clinical services Shanghai Wangzu Guobin Medical Center Co., Ltd. (“iKang Shanghai Gubei”) April 27, 2007 PRC % Medical examinations Shanghai iKang Guobin Mingmen Clinic Co., Ltd. (“iKang Shanghai Pudong Avenue”) April 27, 2007 PRC % Medical examinations Shenzhen iKang Guobin Hospital Management Co., Ltd. (“Shenzhen Hospital Management”) September 10, 2007 PRC % Holding company Shenzhen iKang Guobin Puji Clinic Co., Ltd. (formerly named as “Shenzhen Puji Clinic”) (“iKang Shenzhen Nanshan”) September 10, 2007 PRC % Medical examinations & clinical services Beijing iKang Guobin Lidu Clinic Co., Ltd. (“iKang Beijing Lidu”) December 3, 2007 PRC % Medical examinations Nanjing Joycome Clinic Co., Ltd. (“iKang Nanjing Xinjiekou”) January 10, 2008 PRC % Medical examinations Shenzhen iKang Guobin Clinic Co., Ltd. (formerly named as “Shenzhen iKang Guobin Clinic”) (“iKang Shenzhen Luohu”) March 25, 2008 PRC % Medical examinations Beijing iKang Guobin Jianwai Clinic Co., Ltd. (“iKang Beijing Jianguomen”) September 9, 2008 PRC % Medical examinations Beijing iKang Guobin Zhongguan Clinic Co., Ltd. (“iKang Beijing Zhongguancun”) September 19, 2008 PRC % Medical examinations Beijing iKang Guobin Zhengqingyuan Clinic Co., Ltd. (“iKang Beijing Kunming Lake”) December 1, 2008 PRC % Medical examinations Beijing iKang Guobin Jiuxianqiao Clinic Co., Ltd. (“iKang Beijing Yansha East”) December 1, 2008 PRC % Medical examinations Shanghai iKang Guobin Renren Clinic Co., Ltd. (“iKang Shanghai Yangpu”) December 9, 2008 PRC % Medical examinations Chengdu iKang Guobin Health Examination Hospital Co., Ltd. (“iKang Chengdu Waishuangnan”) January 15, 2009 PRC % Medical examinations Shanghai iKang Guobin Blue Cross Clinic Co., Ltd. (“iKang Shanghai Lujiazui”) January 28, 2010 PRC % Medical examinations Shanghai Wenzhong Clinic Co., Ltd. (“Shanghai Wenzhong”) February 12, 2010 PRC % Medical examinations Beijing iKang Guobin Clinic Co., Ltd. (“iKang Beijing Xuanwumen”) August 5, 2010 PRC % Medical examinations Nanjing iKang Guobin Clinic Co., Ltd. (“iKang Nanjing Gulou”) January 19, 2011 PRC % Medical examinations Shenzhen Xinglin Clinic Co., Ltd. (formerly named as “Shenzhen Xinglin Clinic”) (“iKang Shenzhen Futian”) January 25, 2011 PRC % Medical examinations Fujian iKang Guobin Health Management Co., Ltd. (“Fujian iKang”) April 1, 2011 PRC % Sales of healthcare service Fuzhou iKang Guobin General Clinic Co., Ltd. (“iKang Fuzhou Gulou”) November 14, 2011 PRC % Medical examinations Beijing iKang Guobin Xinei Clinic Co., Ltd. (“iKang Beijing Xinei”) January 30, 2012 PRC % Medical examinations Shanghai iKang Guobin Fukang Clinic Co., Ltd. (“Yan’an West Road”) January 18, 2012 PRC % Medical examinations Shanghai iKang Guobin Zhonghuan Yipin Clinic Co., Ltd. (formerly named as “Shanghai Zhonghuan Yipin Clinic Co., Ltd.”) (“iKang Shanghai Zhonghuan”) January 21, 2012 PRC % Medical examinations Shanghai iKang Guobin Yipin Clinic Co., Ltd. (formerly named as “Shanghai Yipin Clinic Co., Ltd.”) (“iKang Shanghai Jing’an”) January 21, 2012 PRC % Medical examinations Shanghai iKang Guobin Waizhitan Clinic Co., Ltd. (“iKang Shanghai Yan’an East Road”) May 29, 2012 PRC % Medical examinations Shanghai iKang Guobin Jianwei Clinic Co., Ltd. (formerly named as “Shanghai Jianwei Clinic Co., Ltd.”) (“iKang Shanghai Jianwei”) August 17, 2012 PRC % Medical examinations Hangzhou iKang Guobin Wenhui Clinic Co., Ltd. (“iKang Hangzhou Wenhui”) September 3, 2012 PRC % Medical examinations Tianjin Heping Aibin Clinic Co., Ltd. (“iKang Tianjin Heping”) October 15, 2012 PRC % Medical examinations Suzhou iKang Guobin Clinic Co., Ltd. (formerly named as “Suzhou Aibin Clinic, Co., Ltd.”) (“iKang Suzhou”) November 13, 2012 PRC % Medical examinations Changchun iKang Guobin Jiachang General Clinic Co., Ltd. (“iKang Changchun”) November 5, 2012 PRC % Medical examinations Chengdu Jinjiang iKang Guobin Hongzhaobi Health Examination General Clinic Co., Ltd. (“iKang Chengdu Jinjiang”) December 21, 2012 PRC % Medical examinations Chongqing Aibin Clinic Co., Ltd. (“iKang Chongqing”) December 18, 2012 PRC % Medical examinations Guangzhou Wokang Medical Clinic (“iKang Guangzhou Wokang”) December 3, 2012 PRC % Medical examinations Shenzhen iKang Guobin Kefa Clinic Co., Ltd. (formerly named as “Shenzhen iKang Guobin Kefa Clinic”) (“Shenzhen Kefa”) March 26, 2013 PRC % Medical examinations Shanghai iKang Jianwei Health Management Co., Ltd. (“Shanghai Jianwei Management”) September 6, 2013 PRC % Sales of healthcare services Shanghai Yuanhua Clinic Co., Ltd. (“Yuanhua Clinic”) July 31, 2013 PRC % Medical examinations Nanjing iKang Jun’an Clinic Co., Ltd., (“iKang Nanjing Aoyang “) September 1, 2013 PRC % Medical examinations Nanjing Aibin Health Information Consultancy Co., Ltd. (“Nanjing Aoyang Shunkang”) September 1, 2013 PRC % Sales of healthcare service Jiangyin iKang Guobin Clinic Co., Ltd. (“iKang Jiangyin”) December 16, 2013 PRC % Medical examinations Zhejiang Huzhou Ailikang Investment Management Co., Ltd. (“Zhejiang Ailikang”) December 31, 2013 PRC % Sales of healthcare services Hangzhou iKang Jun’an Clinic Co., Ltd. (formerly named as “Hangzhou Aibo Huagang Clinic Co. Ltd.”) (“Hangzhou Aibo”) December 31, 2013 PRC % Medical examinations Beijing iKang Jun’an Clinic Co., Ltd. (“iKang Beijing Jun’an”) November 28, 2013 PRC % Medical examinations & clinical services Beijing iKang Guobin Yayun Clinic Co., Ltd. (“iKang Beijing Yayun”) December 5, 2013 PRC % Medical examinations Changzhou iKang Guobin Clinic Co., Ltd. (“iKang Changzhou”) March 14, 2014 PRC % Medical examinations Beijing iKang Guobin Baishi Clinic Co., Ltd. (“iKang Beijing Baishi”) April 16, 2014 PRC % Medical examinations Chengdu Gaoxin iKang Guobin Chengnan Clinic Co., Ltd. (“Chengdu Gaoxin iKang West City”) May 22, 2014 PRC % Medical examinations iKang Dental Hospital Management Co., Ltd. (“iKang Dental Hospital Management”) August 13, 2014 PRC % Management of dental services Beijing iKang Guobin Wanzhishou Clinic Co., Ltd. (“iKang Beijing Wanzhishou”) August 21, 2014 PRC % Medical examinations Shanghai Huajian Health Examination Management Co., Ltd. (“Shanghai Huajian Management”) July 1, 2014 PRC % Medical examinations Shanghai Huajian Clinic Co., Ltd.(“Shanghai Huajian”) July 1, 2014 PRC % Medical examinations Shanghai Jinxiu Huajian Clinic Co., Ltd.(“Shanghai Jinxiu Huajian”) July 1, 2014 PRC % Medical examinations Shanghai Jinshen Huajian Clinic Co., Ltd.(“Shanghai Jinshen Huajian”) July 1, 2014 PRC % Medical examinations Shenyang iKang Guobin Hospital(“iKang Shenyang Hospital”) November 14, 2014 PRC % Medical examinations Shenyang iKang Guobin Ningshan Hospital Co., Ltd. (“iKang Shenyang Ningshan Hospital”) November 19, 2014 PRC % Medical examinations Shenyang Golden iKang Guobin Hospital Co., Ltd. (“Gold iKang Shenyang Hospital”) December 19, 2014 PRC % Medical examinations Tianjin Hedong District iKang Guobin Dongrun Clinic Co., Ltd. (“iKang Tianjin Hedong Dongrun”) February 17, 2015 PRC % Medical examinations Tianjin Hexi District iKang Guobin Fenghui Clinic Co., Ltd. (“iKang Tianjin Hexi Fenghui”) February 17, 2015 PRC % Medical examinations Wuxi Woshi Hongtai Biotechnology Co., Ltd. (“Wuxi Woshi Hongtai”) March 3, 2015 PRC % Holding company Beijing Woshi Hongtai Investment Management Consultancy Co., Ltd. (“Beijing Woshi Hongtai”) March 3, 2015 PRC % Sales of healthcare services Beijing Zhenjing Clinic Co., Ltd.(“Beijing Zhenjing”) March 3, 2015 PRC % Medical examinations & clinical services Shanghai Zhenjing Hospital Management Co., Ltd. (“Shanghai Zhenjing Hospital Management”) March 3, 2015 PRC % Sales of healthcare services Shanghai Zhenjing Clinic Co., Ltd. (“Shanghai Zhenjing”) March 3, 2015 PRC % Medical examinations & clinical services The VIE arrangements Before January 31, 2012, PRC regulations limited business entities with direct foreign ownership of more than 70% to provide certain healthcare services in the PRC. To comply with related PRC regulations, the Company conducted the majority of its businesses through Beijing iKang and Zhejiang iKang, subsidiaries of the Group, and iKang Holding, iKang Holding’s subsidiaries and iKang Hangzhou Xixi, which are VIEs and VIEs’ subsidiaries (“VIE entities”) of the Company. Beijing iKang and Zhejiang iKang entered into a series of contractual arrangements with the VIEs and their shareholders, and through those contractual arrangements, as described below, the Company obtained the control and the right to substantially all of economic benefits of the VIE entities. In July 2013, iKang acquired 100% of Yuanhua, including Yuanhua BVI, Yuanhua WFOE, a variable interest entity, Yuanhua Information and Yuanhua Clinic, which provide medical examination related services in China. Yuanhua WFOE entered into a series of contractual arrangements with Yuanhua Information and Mr. Haiqing Hu and Mr. Lei Zhao through which Yuanhua WFOE gained effective control over the operation of Yuanhua Information and is able to receive substantially all the economic benefits of Yuanhua Information. In December 2013, Beijing iKang entered into a series of contractual arrangements with Beijing Jiandatong and Mr. Haiqing Hu through which Beijing iKang gained effective control over the operation of Beijing Jiandatong and is able to receive substantially all the economic benefits of Beijing Jiandatong. Starting from January 31, 2012, foreign-invested enterprises incorporated in the PRC are not expressly prohibited from providing healthcare services in the PRC; however, in order to operate under a foreign-invested enterprise, the Group needs to reapply for the licenses or permits required for conducting such business from the Ministry of Health and Ministry of Commerce, because currently most licenses of the Group to conduct healthcare services are held by PRC entities. As of March 31, 2015, the Group has not yet applied for such licenses or permits. Therefore the Group still operates through its VIE entities. Beijing iKang, Zhejiang iKang and Yuanhua WFOE have entered into the following contractual arrangements with iKang Holding, iKang Hangzhou Xixi, Beijing Jiandatong, Yuanhua Information and the shareholders of iKang Holding, iKang Hangzhou Xixi, Beijing Jiandatong and Yuanhua Information that enable the Company to (1) have power to direct the activities that most significantly affects the economic performance of the VIE entities, and (2) receive the economic benefits of the VIE entities that could be significant to the VIE entities. Accordingly, the Company is considered the primary beneficiary of the VIE entities and has consolidated the VIE entities’ financial results of operations, assets and liabilities in the Company’s consolidated financial statements. In making the conclusion that the Company is the primary beneficiary of the VIE entities, the Company believes the Company’s rights under the terms of the Exclusive Equity Option agreement provide it with a substantive kick out right. More specifically, the Company believes the terms of the Exclusive Equity Option agreement are valid, binding and enforceable under PRC laws and regulations currently in effect. The Company also believes that the minimum amount of consideration permitted by the applicable PRC law to exercise the option does not represent a financial barrier or disincentive for the Company to currently exercise its rights under the exclusive equity option agreement. The Company’s rights under the Exclusive Equity Option agreement give the Company the power to control the shareholders of iKang Holding, iKang Hangzhou Xixi, Beijing Jiandatong and Yuanhua Information and thus the power to direct the activities that most significantly impact the VIE entities economic performance. In addition, the Company’s rights under the Power of Attorney also reinforce the Company’s abilities to direct the activities that most significantly impact the VIE entities’ economic performance. The Company also believes that this ability to exercise control ensures that the VIE entities will continue to execute and renew the Exclusive Service agreement and pay service fees to the Company. By charging service fees in whatever amounts the Company deems fit, and by ensuring that the Exclusive Service agreements are executed and renewed indefinitely, the Company has the rights to receive substantially all of the economic benefits from the VIE entities. Agreements that provide the Company effective control over the VIE entities (1) Power of Attorney: Each registered shareholder of iKang Holding, iKang Hangzhou Xixi, Beijing Jiandatong and Yuanhua Information has executed a power of attorney agreement appointing Beijing iKang, Zhejiang iKang or Yuanhua WFOE to be the only and exclusive attorney, and irrevocably authorizing it to vote on each registered shareholder’s behalf on all of the matters concerning the VIE entities, that may require shareholders’ approval. The term of the power of attorney is perpetual and the contract can be terminated at the discretion of the wholly foreign owned enterprises (“WFOEs”). (2) Exclusive Equity Option Agreement: Beijing iKang, Zhejiang iKang and Yuanhua WFOE have the exclusive right to purchase the equity interests of the VIE entities from the registered legal equity owners at the lowest consideration allowed by PRC regulations as far as PRC regulations permit a transfer of legal ownership to foreign ownership. The term of the exclusive purchase right agreement is ten years and will be renewed on the expiration date by WFOEs and can be terminated at the discretion of the WFOEs. (3) Spousal Consent Under the Spousal Consent letters , the spouse of each married registered shareholder of iKang Holding and Beijing Jiandatong has signed a spousal consent letter, whereby the spouse agrees that (i) the equity interests of iKang Holding and Beijing Jiandatong owned by such shareholder will be disposed of only in accordance with the applicable Exclusive Equity Option Agreement, Equity Interest Pledge Agreement, and other related agreements executed by the shareholder, (ii) such equity interests do not constitute communal property with such shareholder and (iii) the spouse irrevocably and unconditionally waives all rights and benefits with respect to such equity interests, including the right to sue in any court and under all applicable laws. Agreements that transfer economic benefits to the Company (1) Exclusive Services Agreement : Beijing iKang, Zhejiang iKang, Yuanhua WFOE and registered shareholders irrevocably agree that Beijing iKang, Zhejiang iKang and Yuanhua WFOE shall be the exclusive technology and consulting service provider to the VIE entities in return for a service fee as determined by Beijing iKang, Zhejiang iKang and Yuanhua WFOE up to the entire net profit of the VIE entities. The terms of the services agreement are ten years, respectively, and this agreement will be automatically renewed on applicable expiration dates, and the agreement can be terminated at the discretion of the WFOEs. (2) Equity Interest Pledge Agreement: Shareholders of iKang Holding, iKang Hangzhou Xixi, Beijing Jiandatong and Yuanhua Information have pledged all of their equity interests in VIE entities with Beijing iKang, Zhejiang iKang and Yuanhua WFOE and Beijing iKang, Zhejiang iKang and Yuanhua WFOE are entitled to the rights to sell the pledged equity interests if the VIE entities or the shareholders default in their obligations. The term of the pledge agreement is as long as the service agreement; and it can be terminated when the service agreement is terminated. Through these contractual agreements, the Company has the ability to effectively control the VIE entities and is also able to receive substantially all the economic benefits of the VIE entities. Risk in relation to the VIE structure The Company believes that WFOE’s contractual arrangements with the VIEs are in compliance with PRC law and are legally enforceable. The shareholders of iKang Holding are also shareholders of the Company and therefore have no current interest in seeking to act contrary to the contractual arrangements. However, uncertainties in the PRC legal system could limit the Company’s ability to enforce these contractual arrangements and if the shareholders of the VIEs were to reduce their interest in the Company, their interests may diverge from that of the Company and that may potentially increase the risk that they would seek to act contrary to the contractual terms, for example by influencing the VIEs not to pay the service fees when required to do so. The Company’s ability to control the VIE entities also depends on the power of attorney Beijing iKang, Zhejiang iKang and Yuanhua WFOE have to vote on all matters requiring shareholder approval in the VIEs. As noted above, the Company believes this power of attorney is legally enforceable but may not be as effective as direct equity ownership. In addition, if the legal structure and contractual arrangements were found to be in violation of any existing PRC laws and regulations, the PRC government could: · revoke the Group’s business and operating licenses; · require the Group to discontinue or restrict operations; · restrict the Group’s right to collect revenues; · block the Group’s websites; · require the Group to restructure the operations in such a way as to compel the Group to establish a new enterprise, re-apply for the necessary licenses or relocate our businesses, staff and assets; · impose additional conditions or requirements with which the Group may not be able to comply; or · take other regulatory or enforcement actions against the Group that could be harmful to the Group’s business. The imposition of any of these penalties may result in a material and adverse effect on the Group’s ability to conduct the Group’s business. In addition, if the imposition of any of these penalties causes the Group to lose the rights to direct the activities of the VIE entities or the right to receive their economic benefits, the Group would no longer be able to consolidate the VIE entities. The Group does not believe that any penalties imposed or actions taken by the PRC Government would result in the liquidation of the Company, Beijing iKang, Zhejiang iKang, Yuanhua WFOE or the VIEs. The shareholders of the VIEs and the Company are as the following: (1) iKang Holding’s shareholders are Mr. Ligang Zhang and Mr. Boquan He, each of whom holds 50% of the equity interest in iKang Holding. (2) iKang Hangzhou Xixi’s shareholders are iKang Holding and Yalong Daoyi, which hold 80% and 20% of the equity interest in iKang Hangzhou Xixi, respectively. Yalong Daoyi is wholly-owned by iKang Holding. Therefore, iKang Holding owns the 100% equity interest in iKang Hangzhou Xixi. (3) Beijing Jiandatong’s shareholders is Mr. Haiqing Hu, who holds 80% of the equity interest in Beijing Jiandatong. (4) Yuanhua Information’s shareholders are Mr. Haiqing Hu and Mr. Lei Zhao, who hold 80% and 20% of the equity interest in Yuanhua Information, respectively. (5) Mr. Ligang Zhang and Mr. Boquan He are shareholders of the Company, who held 25.6% and 14.8% voting interest of the Company as of March 31, 2015, respectively. They own the equity interests in iKang Holding and iKang Hangzhou Xixi. Other than Mr. Ligang Zhang and Mr. Boquan He, none of the Company’s shareholders owns equity interests in iKang Holding and iKang Hangzhou Xixi. The two shareholders of iKang Holding are directors and shareholders of the Company. One of them is the Company’s CEO, and the managing director of the VIEs. Therefore they have no current interest in seeking to act contrary to the contractual arrangements. The interests of the VIEs’ shareholders may differ from the interests of the Company as a whole. The Company cannot assure that when conflicts of interest arise, the shareholders will act in the best interests of the Company or that conflicts of interests will be resolved in the Company’s favor. Currently, the Company does not have existing arrangements to address potential conflicts of interest the shareholders of the VIEs’ may encounter in their capacity as the beneficial owners and director of the VIE entities, on the one hand, and as beneficial owners and directors or officer of the Company, on the other hand. The Company believes the shareholders of the VIEs will not act contrary to any of the contractual arrangements and the exclusive equity option agreement provides the Company with a mechanism to remove the shareholders as the beneficial shareholders of the VIEs should they act to the detriment of the Company. The Company relies on the VIEs’ shareholders, as directors and officer of the Company, to fulfill their fiduciary duties and abide by laws of the PRC and BVI and act in the best interest of the Company. If the Company cannot resolve any conflicts of interest or disputes between the Company and the VIEs’ shareholders, the Company would have to rely on legal proceedings, which could result in disruption of its business, and there is substantial uncertainty as to the outcome of any such legal proceedings. The following financial statements amounts and balances of the VIE entities were included in the accompanying consolidated financial statements as of and for the years ended March 31(after inter-company elimination): As of March 31, 2014 2015 Cash and cash equivalents $ $ Account receivable and other current assets Total current assets Property and equipment, net Acquired intangible assets, net Other noncurrent assets Total non-current assets Total assets Deferred revenues Account payable and other current liabilities Total current liabilities Total non-current liabilities Total liabilities $ $ For the years ended March 31, 2013 2014 2015 Net revenues $ $ $ Net income $ $ $ For the years ended March 31, 2013 2014 2015 Net cash provided by operating activities $ $ $ Net cash used in investing activities $ ) $ ) $ ) Net cash provided by financing activities $ $ $ The VIE entities contributed an aggregate of 84.8%, 84.1% and 85.4% of the consolidated net revenues for the years ended March 31, 2013, 2014 and 2015, respectively. The Company’s operations not conducted through contractual arrangements with the VIE entities primarily consist of its high end health check services. As of the fiscal years ended March 31, 2014 and 2015, the VIE entities accounted for an aggregate of 71.4% and 58.0%, respectively, of the consolidated total assets, and 82.6% and 88.9%, respectively, of the consolidated total liabilities. The assets that were not associated with the VIE entities primarily consist of cash and cash equivalents, accounts receivable and prepaid expenses and other current assets. There are no terms in any arrangements, considering both explicit arrangements and implicit variable interests, that require the Company or its subsidiaries to provide financial support to the VIE entities. However, if the VIE entities ever need financial support, the Company or its subsidiaries may, at its option and subject to statutory limits and restrictions, provide financial support to its VIE entities through loans to the shareholders of the VIEs or entrustment loans to the VIE entities. Relevant PRC laws and regulations restrict the VIE entities from transferring a portion of its net assets, equivalent to the balance of its statutory reserve and its share capital, to the Company in the form of loans and advances or cash dividends. Please refer to Note 24 for disclosure of restricted net assets.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Mar. 31, 2015
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of presentation The consolidated financial statements of the Group have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”). Basis of consolidation The consolidated financial statements of the Group include the financial statements of iKang Guobin Healthcare Group Inc., its subsidiaries, its VIEs and its VIEs’ subsidiaries. All inter-company transactions and balances have been eliminated upon consolidation. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and revenues, costs and expenses in the financial statements and accompanying notes. Significant accounting estimates reflected in the Group’s consolidated financial statements include revenue recognition, allowance for doubtful accounts, the useful lives and impairment of property and equipment, the useful lives and impairment of intangible assets, impairment of goodwill, valuation allowance for deferred tax assets, share-based compensation and fair value of the common shares, convertible redeemable preferred shares and forward contracts. Cash and cash equivalents Cash and cash equivalents consist of cash on hand and demand deposits, which are unrestricted as to withdrawal and use, and which have maturities of three months or less when purchased. Restricted cash Restricted cash mainly consists of the cash deposit denominated in U.S. dollar in overseas accounts used to collateralize the locally borrowings in China to meet Group’s RMB funding needs, which is primarily to purchase property and equipment within China. Term deposits Term deposits consist of deposits placed with financial institutions with original maturity terms of greater than three months but less than one year. Accounts receivable and allowance for doubtful accounts Accounts receivable represents those receivables derived in the ordinary course of business. A general allowance for doubtful accounts is provided based on aging analyses of accounts receivable balances, historical bad debt rates, in addition to specific provisions established based on customers’ repayment patterns and customer credit worthiness. Financial instruments Financial instruments of the Group primarily consist of cash and cash equivalents, restricted cash, term deposits, accounts receivable, forward contracts, equity method investment, cost method investment, amount due from related parties, accounts payable, amount due to related parties, short-term borrowing and long-term borrowing. The carrying values of cash and cash equivalents, restricted cash, term deposits, accounts receivable, accounts payable, amounts due from related parties, and short-term borrowings approximate their fair values due to short-term maturities. For amounts due to related parties, they are carried at amortized cost using effective interest method. Effective interest method The effective interest method is a method of calculating the amortized cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the financial liability, or, where appropriate, a shorter period, to the net carrying amount on initial recognition. Interest expense is recognized on an effective interest basis. Fair value measurements Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Group considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability. Authoritative literature provides a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. An asset or liability categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement as follows: · Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. · Level 2 applies to assets or liabilities for which there are inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. · Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The Group measures certain assets, including long-term investments and intangible assets, at fair value on a nonrecurring basis when they are deemed to be impaired. The fair values of intangible assets are determined based on valuation techniques using the best information available, and may include management judgments, future performance projections, etc. An impairment charge to the intangible assets is recorded when their carrying amounts may not be recoverable. Fair value of financial instruments is discussed in Note 18. Significant risks and uncertainties The Group operates in an industry with rapid changes in regulations, customer demand and competition and believes that changes in any of the following areas could have a material adverse effect on the Group’s future financial position, results of operations, or cash flows: advances and trends in healthcare industry standards, changes in certain strategic relationships or customer relationships, regulatory or other PRC related factors, risks associated with the Group’s ability to keep and increase the customer base, and risks surrounding pending litigations. Foreign currency risk The Renminbi (“RMB”) is not a freely convertible currency. The State Administration for Foreign Exchange, under the authority of the People’s Bank of China, controls the conversion of RMB into foreign currencies. The value of the RMB is subject to changes in central government policies and to international economic and political developments affecting supply and demand in the China Foreign Exchange Trading System market. Cash and cash equivalents of the Group included aggregate amounts of $15,853 and $30,172 at March 31, 2014 and 2015, respectively, which were denominated in RMB. Concentration of credit risk Financial instruments that potentially expose the Group to concentration of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Group places their cash with financial institutions with high-credit ratings and quality. The Group conducts credit evaluations of customers and generally do not require collateral or other security from their customers. No customer accounted for 10% or more of total revenues for the years ended March 31, 2013, 2014 and 2015. No customer accounted for 10% or more of accounts receivable as of March 31, 2014 and 2015. Inventories Inventories are medical consumables and are stated at the lower of cost or market value. Inventories are written down for obsolescence to net realizable value based upon estimates of future demand and expiration date of inventories. The Group did not record a write-down of inventories for the years ended March 31, 2013, 2014 and 2015. Equity method investment The investee company over which the Group has the ability to exercise significant influence, but does not have a controlling interest, is accounted for using the equity method. Significant influence is generally considered to exist when the Group has an ownership interest in the voting stock of the investee between 20% and 50%, and other factors, such as representation in the investee’s Board of Directors, voting rights and the impact of commercial arrangements, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the affiliated company’s accounts are not reflected within the Group’s consolidated balance sheets and statements of operations; however, the Group’s share of the earnings or losses of the affiliated company is reflected in the caption “loss/(gain) from equity method investment” in the consolidated statements of operations. An impairment charge is recorded if the carrying amount of the investment exceeds its fair value and this condition is determined to be other-than temporary. The Group estimated the fair value of the investee company based on comparable quoted price for similar investment in active market, if applicable, or discounted cash flow approach which requires significant judgments, including the estimation of future cash flows, which is dependent on internal forecasts, the estimation of long term growth rate of a company’s business, the estimation of the useful life over which cash flows will occur, and the determination of the weighted average cost of capital. The Company did not record impairment losses on its equity method investment during the years ended March 31, 2013, 2014 and 2015. Property and equipment, net Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization are calculated on a straight-line basis over the following estimated useful lives: Computer equipment and application software 5 years Furniture and fixture 5 years Medical equipment 10 years Motor vehicles 5 years Leasehold improvement Shorter of useful life of the asset or the lease term Construction in progress represents unfinished leasehold improvement and installment of equipment for new clinics. Construction in progress will be transferred to leasehold improvement or property and equipment when it is finished. Depreciation is recorded at the time when assets are ready for the intended use. Intangible assets, net Intangible assets, other than goodwill, resulting from the acquisitions of entities accounted for using the purchase method of accounting are estimated by management based on the fair value of assets acquired. Identifiable intangible assets are carried at cost less accumulated amortization. Amortization of customer relationship is computed using the estimated attrition pattern of the acquired customers, and amortization of other finite-lived intangible assets is computed using the straight-line method over the following estimated average useful lives, which are as follows: Weighted average (years) range (years) Customer relationship 5.9 2.1~10.0 Non-compete agreement 3.0 2.0~3.0 Contract backlog 0.7 0.4~0.9 Operating license 2.9 0.3~5.0 Favorable lease contract 7.1 2.8~9.8 The weighted average estimated average useful life of the intangible assets with determinable lives is 5.6 years. Intangible assets-indefinite lives If an intangible asset is determined to have an indefinite life, it should not be amortized until its useful life is determined to be no longer indefinite. An intangible asset that is not subject to amortization is tested for impairment at least annually or if events or changes in circumstances indicate that the asset might be impaired. Such impairment test consists of the fair values of assets with their carrying value amounts and an impairment loss is recognized if and when the carrying amounts exceed the fair values. The estimates of fair values of intangible assets not subject to amortization are determined using various discounted cash flow valuation methodologies. Significant assumptions are inherent in this process, including estimates of discount rates. Impairment of long-lived assets and intangible assets with definite life Long-lived assets, such as property and equipment and definite-lived intangible assets are stated at cost less accumulated depreciation or amortization. Depreciation and amortization is computed principally using the straight-line method. The Group evaluates the recoverability of long-lived assets, including identifiable intangible assets, with determinable useful lives whenever events or changes in circumstances indicate that an intangible asset’s carrying amount may not be recoverable. The Group measures the carrying amount of long-lived assets against the estimated undiscounted future cash flows associated with it. Impairment exists when the sum of the expected future net cash flows is less than the carrying value of the asset being evaluated. Impairment loss is calculated as the amount by which the carrying value of the asset exceeds its fair value. Fair value is estimated based on various valuation techniques, including the discounted value of estimated future cash flows. The evaluation of asset impairment requires the Group to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results may differ from assumed and estimated amounts. Goodwill Goodwill represents the excess of the fair value of consideration paid over the fair value of identifiable net assets acquired in business combinations. Goodwill and intangible assets deemed to have indefinite useful lives are not amortized, but tested for impairment annually or more frequently if events and circumstances indicate that they might be impaired. Goodwill is tested for impairment at the reporting unit level on an annual basis (March 31 for the Group) and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. These events or circumstances could include a significant change in the stock prices, business climate, legal factors, operating performance indicators, competition, or sale or disposition of a significant portion of a reporting unit. In the evaluation of the goodwill for impairment, the Group may first assess qualitative factors to determine whether it is “more likely than not” that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. If it is more likely than not that the fair value of a reporting unit is less than its carrying amount, goodwill is then tested following a two-step process. The first step compares the fair value of each reporting unit to its carrying amount, including goodwill. If the fair value of each reporting unit exceeds its carrying amount, goodwill is not considered to be impaired and the second step will not be required. If the carrying amount of a reporting unit exceeds its fair value, the second step compares the implied fair value of goodwill to the carrying value of a reporting unit’s goodwill. The implied fair value of goodwill is determined in a manner similar to accounting for a business combination with the allocation of the assessed fair value determined in the first step to the assets and liabilities of the reporting unit. The excess of the fair value of the reporting unit over the amounts assigned to the assets and liabilities is the implied fair value of goodwill. An impairment loss is recognized for any excess in the carrying value of goodwill over the implied fair value of goodwill. Application of the goodwill impairment test requires judgment, including the identification of reporting units, assignment of assets and liabilities to reporting units, assignment of goodwill to reporting units, and determination of the fair value of each reporting unit. The estimation of fair value of each reporting unit using a discounted cash flow methodology also requires significant judgments, including estimation of future cash flows, which is dependent on internal forecasts, estimation of the long-term rate of growth for the Group’s business, estimation of the useful life over which cash flows will occur, and determination of the Group’s weighted average cost of capital. The estimates used to calculate the fair value of a reporting unit change from year to year based on operating results and market conditions. Changes in these estimates and assumptions could materially affect the determination of fair value and goodwill impairment for the reporting unit. The Group did not incur any impairment loss on goodwill for the years ended March 31, 2013, 2014 and 2015. Cost method investment For investment over which the Group does not have significant influence, the Group carries the investments at cost. The Group reviews the cost method investment for impairment whenever events or circumstances indicate that an other-than-temporary decline has occurred. The Group considers available quantitative and qualitative evidence in evaluating potential impairment of its cost method investment. If the cost of an investment exceeds the investment’s fair value, the Group considers, among other factors, general market conditions, government economic plans, the duration and the extent to which the fair value of the investment is less than the cost, and the Group’s intent and ability to hold the investment. Revenue recognition Revenue is stated net of business tax. The Group’s PRC subsidiaries and VIE entities are subject to a 5% business tax and related surcharges on the revenues earned from providing services and selling products in the PRC. Certain contracts under specific formalities are exempted from business tax in accordance with the PRC tax laws. The Group recognized $1,576, $2,084, and $2,156 business tax for the years ended March 31, 2013, 2014 and 2015, respectively. The Group recognizes revenues when persuasive evidence of an arrangement exists, service has been provided, the sales price is fixed or determinable, and collectability is reasonably assured. The Group offers medical examination and disease screening services and renders such services at the request of its customers. The Group recognizes revenues when the examination reports are issued and passed to the local couriers if hard copy reports are required by its customers, or when the examination reports are uploaded on line and can be viewed by the customers on line if hard copy reports are not required. The Group notifies its customers when their examination reports are delivered to the local couriers or ready to be viewed and downloaded on line. For individual customers, fees are collected before the performance of the services while corporate customers prepay a portion of service fees upon signing of the master contract, which is recognized as deferred revenue by the Group. All fees for services rendered are first charged against the corporate customer’s deferred revenues until it is entirely exhausted before the Group starts to invoice the corporate customers. The Group records accounts receivables from its corporate customers when the examination reports of the employees of corporate customers have been delivered or uploaded on line but the Group has not received remaining payments from the corporate customers. Sometimes the Group engages third-party providers to provide medical examination and disease screening services on behalf of the Group. The Group evaluates the services provided by third parties on behalf of the Group to determine whether to recognize the revenues on a gross or net basis. The determination is based upon an assessment as to whether the Group acts as a principal or agent when providing the services. All of the revenues involving third-party providers providing medical examination or disease screening services on behalf of the Group are currently accounted for on a gross basis since the Group is the primary obligor, has the latitude in establishing prices, discretion in third-party provider selection and the credit risks. The Group also provides packages of bundled services principally comprising combinations of medical examination, disease screening, health consultation and medical concierge services to its corporate customers, which normally expire within one year from the date of purchase and does not include right of return. The Group allocates revenues from the sale of bundled services to each component using the relative selling price of each component based on the Group’s best estimate. Revenue recognition criteria for components included in the bundled services is identical to as if the components are sold on a standalone basis. The Group recognizes revenue from dental services when the service is rendered and the service fee is collectable. Value added tax (“VAT”) In July 2012, the Ministry of Finance and the State Administration of Taxation jointly issued a circular regarding the pilot collection of VAT in lieu of business tax in certain areas and industries in the PRC. Such VAT pilot program were phased in Beijing, Jiangsu, Anhui, Fujian, Guangdong, Tianjin, Zhejiang, and Hubei between September and December 2012. Starting from September 1, 2012, certain subsidiaries became subject to VAT at the rate of 3% on certain service revenues which were previously subject to business tax. Non-monetary exchange The Group occasionally exchanges medical examination services with advertising agencies for advertising credits. The amount of deferred revenues and prepaid expenses is based on the fair value of the medical examination services surrendered which approximates the price the Group offers to the individual customers and is more readily determinable. The amounts of revenues recognized for non-monetary transactions were $972, $706 and $571 for the years ended March 31, 2013, 2014 and 2015, respectively. Direct costs attributable to the revenues have been immaterial. Cost of revenues Cost of revenues consist of expenditures incurred in the generation of the Group’s revenues, includes but not limited to salaries and welfare paid to physicians, nurses, purchase of medical consumables, depreciation and amortization, rental, and fees paid to third-party service providers. Research and development expenses Research and development expenses primarily consist of (i) salaries and benefits for research and development personnel, and (ii) office rental, general expenses and depreciation and amortization expenses associated with the research and development activities. The Group’s research and development activities primarily consist of the research and development of its information technology platform. Research and development expenses are expensed when incurred. Income taxes Current income taxes are provided for in accordance with the laws of the relevant tax authorities. Deferred income taxes are recognized when temporary differences exist between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements. Net operating loss carry forwards and credits are applied using enacted statutory tax rates applicable to future years. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more-likely-than-not that a portion of or all of the deferred tax assets will not be realized. The components of the deferred tax assets and liabilities are individually classified as current and non-current based on their characteristics. The impact of an uncertain income tax position on the income tax return is recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant tax authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Interest and penalties on income taxes will be classified as a component of the provisions for income taxes. The Group did not recognize any income tax due to uncertain tax position or incur any interest and penalties related to potential underpaid income tax expenses for the years ended March 31, 2013, 2014 or 2015, respectively. Share-based compensation Share-based payment transactions with employees, such as share options are measured based on the grant date fair value of the equity instrument. The Group recognizes the compensation costs net of an estimated forfeiture rate using the graded vesting attribution method over the requisite service period of the award, which is generally the vesting period of the award. The estimate of forfeitures will be adjusted over the requisite service period to the extent that actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of change and will also impact the amount of share compensation expense to be recognized in future periods. Share awards issued to non-employees, such as advisors, are measured at fair value at the earlier of the commitment date or the date the service is completed and recognized over the period the service is provided. Earnings (loss) per share Basic earnings (loss) per common share is computed by dividing net income (loss) attributable to common shareholders by the weighted average number of common shares outstanding during the period. The Group’s convertible redeemable preferred shares are participating securities as they participate in undistributed earnings on an as-if-converted basis. Accordingly, the Group uses the two-class method whereby undistributed net income is allocated on a pro rata basis to the common shares and preferred shares to the extent that each class may share in income for the period; whereas the undistributed net loss for the period is allocated to common shares only because preferred shares are not contractually obligated to share the loss. Diluted earnings per common share reflect the potential dilution that could occur if securities were exercised or converted into common shares. The Group had convertible redeemable preferred shares, and stock options, which could potentially dilute basic earnings per share. To calculate the number of shares for diluted income per share, the effect of the convertible redeemable preferred shares is computed using the as-if-converted method; the effect of the stock options is computed using the treasury stock method. Foreign currency translation The functional and reporting currency of the Company is the United States dollar (“U.S. dollar”). The financial records of the Group’s subsidiaries and VIE entities located in the PRC are maintained in their local currencies, the RMB, which are also the functional currencies of these entities. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency at the rates of exchange ruling at the balance sheet date. Transactions in currencies other than the functional currency during the year are converted into functional currency at the applicable rates of exchange prevailing when the transactions occurred. Transaction gains and losses are recognized in the statement of operations. The Group’s entities with functional currency of RMB translate their operating results and financial positions into the U.S. dollar, the Group’s reporting currency. Assets and liabilities are translated using the exchange rates in effect on the balance sheet date. Revenues, expenses, gains and losses are translated using the average rate for the year. Translation adjustments are reported as cumulative translation adjustments and are shown as a separate component of other comprehensive income. Comprehensive income Comprehensive income includes net income and cumulative foreign currency translation adjustments and is reported in the statement of shareholder’s equity (deficit). Operating leases Leases where the rewards and risks of ownership of assets primarily remain with the lessor are accounted for as operating leases. Payments made under operating leases are charged to the consolidated statements of operations on a straight-line basis over the lease periods. Newly adopted accounting pronouncements In July 2013, the FASB issued a pronouncement which provides guidance on financial statement presentation of an unrecognized tax benefits when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The FASB’s objective in issuing this ASU is to eliminate diversity in practice resulting from a lack of guidance on this topic in current U.S. GAAP. The amendments in this ASU state that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except as follows. To the extent a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. This ASU applies to all entities that have unrecognized tax benefits when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists at the reporting date. The amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. Early adoption is permitted. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date. Retrospective application is permitted. The adoption of this guidance did not have a significant effect on the Group’s consolidated financial statements. Recently issued accounting pronouncements not yet adopted In May 2014, the Financial Accounting Standards Board (“FASB”) issued a new pronouncement which affects any entity using U.S. GAAP that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). This Accounting Standards Update (“ASU”) will supersede the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance. This ASU also supersedes some cost guidance included in Subtopic 605-35, Revenue Recognition—Construction-Type and Production-Type Contracts. In addition, the existing requirements for the recognition of a gain or loss on the transfer of nonfinancial assets that are not in a contract with a customer (e.g., assets within the scope of Topic 360, Property, Plant, and Equipment, and intangible assets within the scope of Topic 350, Intangibles—Goodwill and Other) are amended to be consistent with the guidance on recognition and measurement (including the constraint on revenue) in this ASU. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. For a public entity, the amendments in this ASU are effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early application will be permitted. An entity should apply the amendments in this ASU using one of the following two methods: 1. Retrospectively to each prior reporting period p

ACQUISITIONS

ACQUISITIONS	12 Months Ended
	Mar. 31, 2015
ACQUISITIONS
ACQUISITIONS	3. ACQUISITIONS (1) Acquisition of iKang Shanghai Jianwei On August 17, 2012, the Group acquired 100% equity interest of iKang Shanghai Jianwei, which provides medical examination services with cash consideration of $1,249. Acquisition-related costs were nil. The transaction was accounted for as a business combination using the acquisition method of accounting. The fair value of identifiable intangible assets was determined by the Group with the assistance of an independent third-party valuation firm and the value of the purchase price was allocated to assets acquired and liabilities assumed as of the date of acquisition as follows: Estimated useful lives Net tangible assets: Current assets $ Non-current assets Deferred tax assets Total Intangible assets acquired: Customer relationship 5.3 years Operating license 1.4 years Goodwill Deferred tax liability ) Total Total consideration $ The goodwill represents excess of the fair value of the consideration paid over the fair value of the identifiable net assets acquired, and is mainly attributed to (a) the assembled work force and (b) the expected but unidentifiable business growth as a result of the synergy resulting from the acquisition. The acquired goodwill is not deductible for tax purpose. The operating results of the acquired business of iKang Shanghai Jianwei have been included in the Group’s consolidated financial statements since the date of acquisition. iKang Shanghai Jianwei contributed net revenue of $300, $1,122 and $3,116, and net loss of $647 and $773 and net income of $527 to the Group’s consolidated statements of operations in the years ended March 31, 2013, 2014 and 2015, respectively. (2) Acquisition of iKang Changchun On November 5, 2012, the Group acquired 100% equity interest of iKang Changchun, which provides medical examination services with cash consideration of $915. Acquisition-related costs were nil. The transaction was accounted for as a business combination using the acquisition method of accounting. The fair value of identifiable intangible assets was determined by the Group with the assistance of an independent third-party valuation firm and the value of the purchase price was allocated to assets acquired and liabilities assumed as of the date of acquisition as follows: Estimated useful lives Net tangible assets: Current assets $ Non-current assets Total Intangible assets acquired: Customer relationship 6.1 years Favorable lease contract 5.1 years Operating license 2.5 years Goodwill Deferred tax liability ) Total Total consideration $ The goodwill represents excess of the fair value of the consideration paid over the fair value of the identifiable net assets acquired, and is mainly attributed to (a) the assembled work force and (b) the expected but unidentifiable business growth as a result of the synergy resulting from the acquisition. The acquired goodwill is not deductible for tax purpose. The operating results of the acquired business of iKang Changchun have been included in the Group’s consolidated financial statements since the date of acquisition. iKang Changchun contributed net revenue of $25, $593 and $996, and net loss of $301, $832 and $384 to the Group’s consolidated statements of operations in the years ended March 31, 2013, 2014 and 2015, respectively. (3) Acquisition of iKang Guangzhou Wokang On December 3, 2012, the Group acquired 100% equity interest of iKang Guangzhou Wokang, which provides medical examination services with cash consideration of $2,986. Acquisition-related costs were nil. The transaction was accounted for as a business combination using the acquisition method of accounting. The fair value of identifiable intangible assets was determined by the Group with the assistance of an independent third-party valuation firm and the value of the purchase price was allocated to assets acquired and liabilities assumed as of the date of acquisition as follows: Estimated useful lives Net tangible assets: Current assets $ Non-current assets Current liabilities ) Total Intangible assets acquired: Customer relationship 6.0 years Favorable lease contract 9.8 years Operating license 3.1 years Goodwill Deferred tax liability ) Total Total consideration $ The goodwill represents excess of the fair value of the consideration paid over the fair value of the identifiable net assets acquired, and is mainly attributed to (a) the assembled work force and (b) the expected but unidentifiable business growth as a result of the synergy resulting from the acquisition. The acquired goodwill is not deductible for tax purpose. The operating results of the acquired business of iKang Guangzhou Wokang have been included in the Group’s consolidated financial statements since the date of acquisition. iKang Guangzhou Wokang contributed net revenue of $7, $2,737 and $ 4,184, and net loss of $273 and net income of $964 and $1,364 to the Group’s consolidated statements of operations in the years ended March 31, 2013, 2014 and 2015, respectively. (4) Acquisition of Yuanhua BVI, Yuanhua WFOE, Yuanhua information and Yuanhua Clinic (collectively, “Yuanhua”) On July 31, 2013, the Group acquired 100% equity interest of Yuanhua, which provides medical examination related services with cash consideration of $27,600. Acquisition-related costs were nil. The transaction was accounted for as a business combination using the acquisition method of accounting. The fair value of identifiable intangible assets was determined by the Group with the assistance of an independent third-party valuation firm and the value of the purchase price was allocated to assets acquired and liabilities assumed as of the date of acquisition as follows: Estimated useful lives Net tangible assets: Current assets $ Non-current assets Deferred tax assets Current liabilities ) Total Intangible assets acquired: Trade name Customer relationship 5.0-7.4 years Operating license 2.3 years Contract backlog 0.9 years Goodwill Deferred tax liability ) Total Total consideration $ The goodwill represents excess of the fair value of the consideration paid over the fair value of the identifiable net assets acquired, and is mainly attributed to (a) the assembled work force and (b) the expected but unidentifiable business growth as a result of the synergy resulting from the acquisition. The acquired goodwill is not deductible for tax purpose. The operating results of the acquired business of Yuanhua have been included in the Group’s consolidated financial statements since the date of acquisition. Yuanhua contributed net revenue of $10,091 and $15,757, and net loss of $1,023 and net income of $423 to the Group’s consolidated statements of operations in the years ended March 31, 2014 and 2015, respectively. (5) Acquisition of Nanjing Aoyang TCM Clinic Co., Ltd. and Nanjing Aoyang Shunkang Health Information Consultancy Co., Ltd. (collectively, “Nanjing Aoyang”) On September 1, 2013, the Group acquired 100% equity interest of Nanjing Aoyang, which provides medical examination services with cash consideration of $4,085. Acquisition-related costs were nil. The transaction was accounted for as a business combination using the acquisition method of accounting. The fair value of identifiable intangible assets was determined by the Group with the assistance of an independent third-party valuation firm and the value of the purchase price was allocated to assets acquired and liabilities assumed as of the date of acquisition as follows: Estimated useful life Net tangible assets: Current assets $ Non-current assets Total Intangible assets acquired: Operating license 1.3 years Goodwill Deferred tax liability ) Total Total consideration $ The goodwill represents excess of the fair value of the consideration paid over the fair value of the identifiable net assets acquired, and is mainly attributed to (a) the assembled work force and (b) the expected but unidentifiable business growth as a result of the synergy resulting from the acquisition. The acquired goodwill is not deductible for tax purpose. The operating results of the acquired business of Nanjing Aoyang have been included in the Group’s consolidated financial statements since the date of acquisition. Nanjing Aoyang contributed net revenue of $218 and $318, and net loss of $1,145 and $1,645 to the Group’s consolidated statements of operations in the years ended March 31, 2014 and 2015, respectively. (6) Acquisition of Zhejiang Huzhou Ailikang Investment Management Co. Ltd. (“Zhejiang Ailikang”) On December 31, 2013, the Group acquired 100% equity interest of Zhejiang Ailikang, which holds 100% equity of Hangzhou Aibo Huagang Clinic Co. Ltd., a company providing medical examination service, for cash consideration of $1,663. Acquisition-related costs were nil. The transaction was accounted for as a business combination using the acquisition method of accounting. The fair value of identifiable intangible assets was determined by the Group with the assistance of an independent third-party valuation firm and the value of the purchase price was allocated to assets acquired and liabilities assumed as of the date of acquisition as follows : Estimated useful lives Net tangible assets: Current assets $ Non-current assets Current liabilities ) Total ) Intangible assets acquired: Favorable lease contract 5.3 years Operating license 2.7 years Goodwill Deferred tax liability ) Total Total consideration $ The goodwill represents excess of the fair value of the consideration paid over the fair value of the identifiable net assets acquired, and is mainly attributed to (a) the assembled work force and (b) the expected but unidentifiable business growth as a result of the synergy resulting from the acquisition. The acquired goodwill is not deductible for tax purpose. The operating results of the acquired business of Zhejiang Ailikang have been included in the Group’s consolidated financial statements since the date of acquisition. Zhejiang Ailikang contributed net revenue of nil and $2, and net loss of $158 and $321 to the Group’s consolidated statements of operations in the years ended March 31, 2014 and 2015, respectively. (7) Acquisition of MediFast On January 14, 2014, the Group acquired 80% equity interest of MediFast, which provides medical examination, health management and medical services, with cash consideration of $8,113. Acquisition-related costs were nil. The transaction was accounted for as a business combination using the acquisition method of accounting. The fair value of identifiable intangible assets was determined by the Group with the assistance of an independent third-party valuation firm and the value of the purchase price was allocated to assets acquired and liabilities assumed as of the date of acquisition as follows: Estimated useful lives Net tangible assets: Current assets $ Non-current assets Current liabilities ) Total ) Intangible assets acquired: Customer relationship 5.0-10.0 years Non-compete agreement 3.0 years Trade-name Indefinite Goodwill Deferred tax liability ) Total Non-controlling interest ) Total consideration $ The goodwill represents excess of the fair value of the consideration paid over the fair value of the identifiable net assets acquired, and is mainly attributed to (a) the assembled work force and (b) the expected but unidentifiable business growth as a result of the synergy resulting from the acquisition. The acquired goodwill is not deductible for tax purpose. The operating results of the acquired business of MediFast have been included in the Group’s consolidated financial statements since the date of acquisition. MediFast contributed net revenue of $2,570 and $12,563, and net income of $328 and $486 to the Group’s consolidated statements of operations in the years ended March 31, 2014 and 2015, respectively. (8) Acquisition of Shanghai Huajian Management The Group purchased 33% equity interest of Shanghai Huajian Management from an individual shareholder in January 2014 with a consideration of $6,376. Subsequently, the Group signed agreements with two other shareholders of Shanghai Huajian Management to acquire the remaining 37% and 30% of Shanghai Huajian Management for cash considerations of $7,484 and $5,382 in May and June 2014 respectively. The acquisition of the above 67% equity interest of Shanghai Huajian Management was completed on July 1, 2014. Additionally, iKang granted 300,000 options to one of the former shareholders of Shanghai Huajian Management on August 1, 2014 pursuant to an agreement entered into on December 30, 2013. The exercise price for the option is $16.18 per share (or equivalent to $8.09 per ADS). The grant of the options was considered by management to be additional purchase consideration for Shanghai Huajian Management with a fair value of $7,202. On July 1, 2014, iKang obtained control of Shanghai Huajian Management. At the date of the acquisition, iKang’s existing 33% equity interest in Shanghai Huajian Management was remeasured to its fair value of $7,661, resulting in a gain of $883 recognized in the year ended March 31, 2015. The transaction was accounted for as a business combination using the acquisition method of accounting. The fair value of identifiable intangible assets was determined by the Group with the assistance of an independent third-party valuation firm and the value of the purchase price was allocated to assets acquired and liabilities assumed as of the date of acquisition as follows: Estimated useful lives Net tangible assets: Current assets $ Non-current assets Current liabilities ) Total Estimated useful lives Intangible assets acquired: Customer relationship 5.5 years Trade name Indefinite Operating license 3.0 years Goodwill Deferred tax liability ) Total Total fair value of business acquired $ The goodwill represents excess of the fair value of the consideration paid over the fair value of the identifiable net assets acquired, and is mainly attributed to (a) the assembled work force and (b) the expected but unidentifiable business growth as a result of the synergy resulting from the acquisition. The acquired goodwill is not deductible for tax purpose. The operating results of the acquired business of Shanghai Huajian Management have been included in the Group’s consolidated financial statements since the date of acquisition. Shanghai Huajian Management contributed net revenue of $10,772, and net loss of $676 to the Group’s consolidated statements of operations in the year ended March 31, 2015. (9) Acquisition of iKang Shenyang Hospital On November 14, 2014, the Group acquired 100% equity interest of iKang Shenyang Hospital, which provides medical examination services with cash consideration of $1,636. Acquisition-related costs were nil. The transaction was accounted for as a business combination using the acquisition method of accounting. The fair value of identifiable intangible assets was determined by the Group with the assistance of an independent third-party valuation firm and the value of the purchase price was allocated to assets acquired and liabilities assumed as of the date of acquisition as follows: Estimated useful life Net tangible assets: Non-current assets $ Total Intangible assets acquired: Operating license 4.0 years Goodwill Deferred tax liability ) Total Total consideration $ The goodwill represents excess of the fair value of the consideration paid over the fair value of the identifiable net assets acquired, and is mainly attributed to (a) the assembled work force and (b) the expected but unidentifiable business growth as a result of the synergy resulting from the acquisition. The acquired goodwill is not deductible for tax purpose. The operating results of the acquired business of iKang Shenyang Hospital have been included in the Group’s consolidated financial statements since the date of acquisition. iKang Shenyang Hospital contributed net revenue of $469, and net loss of $392 to the Group’s consolidated statements of operations in the year ended March 31, 2015. (10) Acquisition of iKang Shenyang Ningshan Hospital On November 19, 2014, the Group acquired 100% equity interest of iKang Shenyang Ningshan Hospital, which provides medical examination services with cash consideration of $1,628. Acquisition-related costs were nil. The transaction was accounted for as a business combination using the acquisition method of accounting. The fair value of identifiable intangible assets was determined by the Group with the assistance of an independent third-party valuation firm and the value of the purchase price was allocated to assets acquired and liabilities assumed as of the date of acquisition as follows: Estimated useful lives Net tangible assets: Non-current assets $ Total Intangible assets acquired: Favorable lease contract 2.8 years Operating license 5.0 years Goodwill Deferred tax liability ) Total Total consideration $ The goodwill represents excess of the fair value of the consideration paid over the fair value of the identifiable net assets acquired, and is mainly attributed to (a) the assembled work force and (b) the expected but unidentifiable business growth as a result of the synergy resulting from the acquisition. The acquired goodwill is not deductible for tax purpose. The operating results of the acquired business of iKang Shenyang Ningshan Hospital have been included in the Group’s consolidated financial statements since the date of acquisition. iKang Shenyang Ningshan Hospital contributed net revenue of $144, and net loss of $124 to the Group’s consolidated statements of operations in the year ended March 31, 2015. (11) Acquisition of Gold iKang Shenyang Hospital On December 19, 2014, the Group acquired 100% equity interest of Gold iKang Shenyang Hospital, which provides medical examination related services with cash consideration of $6,447. Acquisition-related costs were nil. The transaction was accounted for as a business combination using the acquisition method of accounting. The fair value of identifiable intangible assets was determined by the Group with the assistance of an independent third-party valuation firm and the value of the purchase price was allocated to assets acquired and liabilities assumed as of the date of acquisition as follows: Estimated useful lives Net tangible assets: Non-current assets $ Current liabilities ) Total Intangible assets acquired: Customer relationship 5.0 years Operating license 2.5 years Goodwill Deferred tax liability ) Total Total consideration $ The goodwill represents excess of the fair value of the consideration paid over the fair value of the identifiable net assets acquired, and is mainly attributed to (a) the assembled work force and (b) the expected but unidentifiable business growth as a result of the synergy resulting from the acquisition. The acquired goodwill is not deductible for tax purpose. The operating results of the acquired business of Gold iKang Shenyang Hospital have been included in the Group’s consolidated financial statements since the date of acquisition. Gold iKang Shenyang Hospital contributed net revenue of $44, and net loss of $475 to the Group’s consolidated statements of operations in the year ended March 31, 2015. (12) Acquisition of iKang Tianjin Hedong Dongrun On February 17, 2015, the Group acquired 100% equity interest of iKang Tianjin Hedong Dongrun, which provides medical examination services with cash consideration of $3,032. Acquisition-related costs were nil. The transaction was accounted for as a business combination using the acquisition method of accounting. The fair value of identifiable intangible assets was determined by the Group with the assistance of an independent third-party valuation firm and the value of the purchase price was allocated to assets acquired and liabilities assumed as of the date of acquisition as follows: Estimated useful lives Net tangible assets: Current assets $ Non-current assets Current liabilities ) Total Intangible assets acquired: Customer relationship 5.0 years Operating license 1.4 years Goodwill Deferred tax liability ) Total Total consideration $ The goodwill represents excess of the fair value of the consideration paid over the fair value of the identifiable net assets acquired, and is mainly attributed to (a) the assembled work force and (b) the expected but unidentifiable business growth as a result of the synergy resulting from the acquisition. The acquired goodwill is not deductible for tax purpose. The operating results of the acquired business of iKang Tianjin Hedong Dongrun have been included in the Group’s consolidated financial statements since the date of acquisition. iKang Tianjin Hedong Dongrun contributed net revenue of $30, and net loss of $47 to the Group’s consolidated statements of operations in the year ended March 31, 2015. (13) Acquisition of iKang Tianjin Hexi Fenghui On February 17, 2015, the Group acquired 100% equity interest of iKang Tianjin Hexi Fenghui, a company providing medical examination services, for cash consideration of $2,073. Acquisition-related costs were nil. The transaction was accounted for as a business combination using the acquisition method of accounting. The fair value of identifiable intangible assets was determined by the Group with the assistance of an independent third-party valuation firm and the value of the purchase price was allocated to assets acquired and liabilities assumed as of the date of acquisition as follows : Estimated useful lives Net tangible assets: Current assets $ Non-current assets Current liabilities ) Total Intangible assets acquired: Customer relationship 5.0 years Operating license 1.9 years Goodwill Deferred tax liability ) Total Total consideration $ The goodwill represents excess of the fair value of the consideration paid over the fair value of the identifiable net assets acquired, and is mainly attributed to (a) the assembled work force and (b) the expected but unidentifiable business growth as a result of the synergy resulting from the acquisition. The acquired goodwill is not deductible for tax purpose. The operating results of the acquired business of iKang Tianjin Hexi Fenghui have been included in the Group’s consolidated financial statements since the date of acquisition. iKang Tianjin Hexi Fenghui contributed net revenue of $59, and net loss of $73 to the Group’s consolidated statements of operations in the year ended March 31, 2015. (14) Acquisition of WA Health Care On March 3, 2015, the Group acquired 70% equity interest of WA Health Care, which provides high-end medical services and operates two medical centers in prime locations in Shanghai and Beijing, with cash consideration of $9,934. Acquisition-related costs were nil. The transaction was accounted for as a business combination using the acquisition method of accounting. The fair value of identifiable intangible assets was determined by the Group with the assistance of an independent third-party valuation firm and the value of the purchase price was allocated to assets acquired and liabilities assumed as of the date of acquisition as follows: Estimated useful lives Net tangible assets: Current assets $ Non-current assets Current liabilities ) Total Intangible assets acquired: Customer relationship 3.0 years Operating license 1.9-2.8 years Goodwill Deferred tax liability ) Total Non-controlling interest ) Total consideration $ The goodwill represents excess of the fair value of the consideration paid over the fair value of the identifiable net assets acquired, and is mainly attributed to (a) the assembled work force and (b) the expected but unidentifiable business growth as a result of the synergy resulting from the acquisition. The acquired goodwill is not deductible for tax purpose. The operating results of the acquired business of WA Health Care have been included in the Group’s consolidated financial statements since the date of acquisition. WA Health Care contributed net revenue of $494, and net loss of $203 to the Group’s consolidated statements of operations in the year ended March 31, 2015. (15) Pro forma information The following unaudited pro forma information summarizes the results of operations of the Group for the years ended March 31, 2013 and 2014 assuming that the acquisitions of iKang Shanghai Jianwei, iKang Changchun, iKang Guangzhou Wokang, Yuanhua, Nanjing Aoyang, Zhejiang Ailikang and MediFast occurred as of April 1, 2012. The following pro forma financial information is not necessarily indicative of the results that would have occurred had the acquisitions been completed at the beginning of the periods indicated, nor is it indicative of future operating results: Years ended March 31, 2013 2014 (Unaudited) (Unaudited) Pro forma net revenue $ $ Pro forma net income attributable to common shareholders of iKang Healthcare Group, Inc. $ $ The following unaudited pro forma information summarizes the results of operations of the Group for the years ended March 31, 2014 and 2015 assuming that the acquisitions of Yuanhua, Nanjing Aoyang, Zhejiang Ailikang, MediFast, Shanghai Huajian Management, iKang Shenyang Hospital, iKang Shenyang Ningshan Hospital, Gold iKang Shenyang Hospital, iKang Tianjin Hedong Dongrun, iKang Tianjin Hexi Fenghui and WA Health Care occurred as of April 1, 2013. The following pro forma financial information is not necessarily indicative of the results that would have occurred had the acquisitions been completed at the beginning of the periods indicated, nor is it indicative of future operating results: Years ended March 31, 2014 2015 (Unaudited) (Unaudited) Pro forma net revenue $ $ Pro forma net income attributable to common shareholders of iKang Healthcare Group, Inc. $ $ (16) Acquisition of Assets On March 26, 2013, the Group acquired the operating license of iKang Shenzhen Kefa with a cash consideration of $167. On September 22, 2014, the Group acquired the operating license of Foshan iKang Guobin Clinic Co., Ltd. with a cash consideration of $242. On October 15, 2014, the Group acquired the operating license of Suzhou Aoyang Clinic Co., Ltd. (“Suzhou Aoyang”) with a cash consideration of $1,129.

ACCOUNTS RECEIVABLE, NET

ACCOUNTS RECEIVABLE, NET	12 Months Ended
	Mar. 31, 2015
ACCOUNTS RECEIVABLE, NET
ACCOUNTS RECEIVABLE, NET	4. ACCOUNTS RECEIVABLE, NET Accounts receivable consists of the following: As of March 31, 2014 2015 Accounts receivable $ $ Less: allowance for doubtful accounts Accounts receivable, net $ $ Movement of allowance for doubtful accounts is as follows: As of March 31, 2013 2014 2015 Balance at beginning of year $ $ $ Charge to expenses Write off ) ) ) Exchange difference Balance at end of year $ $ $ The Group decides to write off a receivable and the corresponding provision when it determines that certain events indicate that there is no chance that an account receivable can be collected, such as liquidation of a customer or termination of cooperation.

INVENTORIES

INVENTORIES	12 Months Ended
	Mar. 31, 2015
INVENTORIES
INVENTORIES	5. INVENTORIES Inventories consist of the following: As of March 31, 2014 2015 Medical consumable $ $

PREPAID EXPENSES AND OTHER CURR

PREPAID EXPENSES AND OTHER CURRENT ASSETS	12 Months Ended
	Mar. 31, 2015
PREPAID EXPENSES AND OTHER CURRENT ASSETS
PREPAID EXPENSES AND OTHER CURRENT ASSETS	6. PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets consist of the following: As of March 31, 2014 2015 Prepaid acquisition fees (1) $ $ Advance to suppliers (2) Staff advance Prepaid rental expenses Prepaid expenses (3) Other receivable Interest income receivable — Deferred IPO cost — Change in fair value of the forward contracts (4) — $ $ (1) Prepaid acquisition fees represent advance payments for acquisitions. (2) Advance to suppliers represents advance payment to suppliers to purchase medical equipment and consumables. (3) Prepaid expenses mainly consist of amounts paid for professional fees and advertisement fees for which relating services have not been provided. (4) The Bayley & Jackson (Hong Kong) entered into two foreign currency exchange forward contracts with Bank of East Asia (“BEA”) in June and July 2013, respectively. Pursuant to those contracts, Bayley & Jackson (Hong Kong) bought two buy RMB20,000,000, sell USD foreign exchange forward contracts using the quoted exchange rates at 6.2825 and 6.2620, respectively. The Group carries the forward contracts at fair value in its balance sheet and the changes in the exchange forward contracts fair value during the each period end are recorded in the statement of the operations. The Group carries the forward contracts as assets at fair value at March 31, 2014. The Group measures the fair value of the forward contracts on a recurring basis based on a level 2 measure, i.e. the Group uses the market exchange rate to assess the fair value of the forward contracts and recognizes the changes in fair value attributable to the difference between the market exchange rate and contractual exchange rate in change in fair value of the forward contracts. For the year ended March 31, 2014 and 2015, the Group recorded a gain of $57 and a loss of $8 in change in fair value of the forward contracts, respectively. The forward contracts were settled in June 2014.

EQUITY-METHOD INVESTMENTS

EQUITY-METHOD INVESTMENTS	12 Months Ended
	Mar. 31, 2015
EQUITY-METHOD INVESTMENTS
EQUITY-METHOD INVESTMENTS	7. EQUITY-METHOD INVESTMENTS The carrying amount of Company’s equity method investments was $6,220 and nil as of March 31, 2014 and 2015, respectively. In January 2014, the Group acquired 33% equity interest of Shanghai Huajian Management from an individual shareholder with an aggregate price of $6,376. Subsequently, the Group signed agreements with other two shareholders of Shanghai Huajian Management to acquire the remaining 37% and 30% equity interest of Shanghai Huajian Management in May and June, 2014 respectively. On July 1, 2014, the acquisition of the above 67% equity interest of Shanghai Huajian Management was completed, and the acquisition was accounted for as a business combination using the acquisition method of accounting. This acquisition is discussed in Note 3 (8). The Group shared loss of nil and $156 from its equity method investment during the years ended March 31, 2013 and 2014, respectively, and shared gain of $521 during the year ended March 31, 2015.

PROPERTY AND EQUIPMENT, NET

PROPERTY AND EQUIPMENT, NET	12 Months Ended
	Mar. 31, 2015
PROPERTY AND EQUIPMENT, NET
PROPERTY AND EQUIPMENT, NET	8. PROPERTY AND EQUIPMENT, NET Property and equipment, net consists of the following: As of March 31, 2014 2015 Medical equipment $ $ Leasehold improvements Computer equipment and application software Furniture and fixtures Motor vehicles Construction in progress Less: accumulated depreciation and amortization $ $ Depreciation expenses charged to the consolidated statement of operations for the years ended March 31, 2013, 2014 and 2015 were $7,112, $8,874 and $14,691, respectively.

ACQUIRED INTANGIBLE ASSETS, NET

ACQUIRED INTANGIBLE ASSETS, NET	12 Months Ended
	Mar. 31, 2015
ACQUIRED INTANGIBLE ASSETS, NET
ACQUIRED INTANGIBLE ASSETS, NET	9. ACQUIRED INTANGIBLE ASSETS, NET The gross carrying amount, accumulated amortization and net carrying amount of the intangible assets are as follows: As of March 31, 2014 2015 Acquired intangible assets not subject to amortization Trade-name $ $ Acquired intangible assets subject to amortization Customer relationship Operating license Favorable lease contract Contract backlog Non-compete agreement Less: accumulated amortization Customer relationship Operating license Favorable lease contract Contract backlog Non-compete agreement Less: impairment Intangible assets, net $ $ Amortization expenses for the years ended March 31, 2013, 2014 and 2015 were $598, $1,885 and $5,221, respectively. Amortization expenses for the years ending March 31, 2016, 2017, 2018, 2019, 2020 and thereafter would be $6,345, $4,901, $3,150, $1,813, $1,265 and $1,557, respectively. No impairment loss was recognized on acquired intangible assets during the years ended March 31, 2013, 2014 and 2015.

GOODWILL

GOODWILL	12 Months Ended
	Mar. 31, 2015
GOODWILL.
GOODWILL	10. GOODWILL The changes in carrying amounts of goodwill for the years ended March 31, 2014 and 2015 were as follows: As of March 31, 2014 2015 Gross amount: Beginning balance $ $ Additions for the year by acquisitions of Shanghai Huajian Management — iKang Shenyang Hospital — iKang Shenyang Ningshan Hospital — Gold iKang Shenyang Hospital — iKang Tianjin Hedong Dongrun — iKang Tianjin Hexi Fenghui — WA Health Care — Nanjing Aoyang — Yuanhua — Shanghai Jianwei Management — Zhejiang Ailikang — MediFast — Exchange difference ) Ending balance Accumulated impairment loss: Beginning balance Exchange difference ) Ending balance Goodwill $ $

ACCRUED EXPENSES AND OTHER CURR

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	12 Months Ended
	Mar. 31, 2015
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	11. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accrued expenses and other current liabilities consist of the following: As of March 31, 2014 2015 Acquisitions consideration payable (1) $ $ Accrued payroll and welfare Accrued rental expense Other payables Other taxes payable Accrued social insurance Accrued outsourcing cost Dividend payable (2) — Interest expense payable Accrued IPO expenses — Accrued professional fees — $ $ (1) Acquisitions consideration payable consists of remaining payables to sellers of the acquired entities for the years ended March 31, 2014 and 2015, which were as follows: As of March 31, 2014 2015 iKang Shanghai Jianwei $ $ Nanjing Aoyang Yuanhua Zhejiang Ailikang MediFast — Shanghai Huajian Management Suzhou Aoyang — iKang Tianjin Hedong Dongrun — iKang Tianjin Hexi Fenghui — Gold iKang Shenyang Hospital — WA Health Care — $ $ (2) As of March 31, 2015, the balance represents the dividend payable for non-controlling interest shareholders of MediFast.

BANK BORROWINGS

BANK BORROWINGS	12 Months Ended
	Mar. 31, 2015
BANK BORROWINGS
BANK BORROWINGS	12. BANK BORROWINGS As of March 31, 2014 2015 Short term borrowings (1) $ $ Long term borrowings (2) — $ $ (1) On June 25, June 28, July 10, September 17 and December 19, 2013 , iKang Holding borrowed five one-year loans of $1,627, $1,304, $1,630, $1,606 and $4,941 respectively from BEA, to purchase the property and equipment and meet temporary working capital needs of the Group. The annual interest rates are the benchmark interest rate announced by the People’s Bank of China plus 10% of the benchmark interest rate. The loans were guaranteed by Beijing iKang and collateralized by restricted cash. As of March 31, 2014, the outstanding short term borrowings were $10,910 and they were repaid during the year ended March 31, 2015. In September 2013, iKang Online signed a ten-year loan framework agreement with an amount no more than $2,451 with BEA, to repay the loans from China Merchants Bank which was due in September 2013. On September 17, 2013, iKang Online borrowed a one-year loan of $2,410 according to the framework agreement. The annual interest rate was equal to the benchmark interest rate announced by the People’s Bank of China plus 10% of the benchmark interest rate. The loan was guaranteed by Beijing iKang and collateralized by restricted cash. As of March 31, 2014, the outstanding long term borrowings was $2,372 and it was repaid in August 2014. In March 2014, seven clinics in Beijing signed seven one-year loan framework agreements with an amount no more than $8,896 with Bank of Beijing, to meet temporary working capital needs of the Group. Clinics borrowed total $4,919 and $1,353 in March 2014 and April 2014 according to the framework agreement, respectively. The annual interest rate is the benchmark interest rate announced by the People’s Bank of China plus 15% of the benchmark interest rate. The loans were guaranteed by iKang Online and iKang Holdings. As of March 31, 2014 and 2015, the outstanding short term borrowing was $4,919 and nil, respectively. In April 2014, iKang Online signed a one-year loan framework agreement with an amount no more than $16,004 with BEA, to meet the property and equipment need of the Group. In May 2014, iKang Online borrowed 2 one-year loans in a total of $4,843 according to the framework agreement. The annual interest rate was equal to the benchmark interest rate announced by the People’s Bank of China plus 10% of the benchmark interest rate. The loan was guaranteed by B&J China and collateralized by restricted cash of $5,500. As of March 31, 2015, the outstanding short term borrowing was $4,839. In May 2014, iKang Holding signed a 2-year loan framework agreement with an amount no more than $8,060 with China Merchants Bank, to meet the working capital and property and equipment needs of the Group. In May 2014, iKang Holding borrowed one-year loans of total $4,290 according to the framework agreement, among which $155 and $1,084 was repaid in June and August 2014, respectively. In June 2014, iKang Holding borrowed a one-year loan of $1,437. The annual interest rate is the interest rate announced by the People’s Bank of China plus 20% of the benchmark interest rate. As of March 31, 2015, the outstanding short term borrowing was $4,485. In June 2014, iKang Online borrowed a one-year loan of $14,561 with Xiamen International Bank, to repay the loans from BEA which was due in June 2014 and paid remaining balance of the consideration to purchase 35% equity interest in iKang Shanghai Xikang Road. The annual interest rate is 2.585%. The loan was collateralized by restricted cash in an amount of $15,002. As of March 31, 2015, the outstanding short term borrowing was $14,551. In June 2014, iKang Online signed a one-year loan framework agreement with an amount no more than $32,099 with Xiamen International Bank, to satisfy the daily operating need of the Group. In July 2014, iKang Online borrowed three one-year loans in a total of $17,537 according to the framework agreement. The annual interest rate is 2.585%. The loans were collateralized by restricted cash in an amount of $18,067. As of March 31, 2015, the outstanding short term borrowing was $17,525. In August 2014, iKang Online signed a one-year loan framework agreement with an amount no more than $32,509 with Xiamen International Bank, to satisfy the daily operating need of the Group. In September, iKang Online borrowed a one-year loan of $15,383 according to the framework agreement. The annual interest rate is 2.585%. The loans were collateralized by restricted cash in an amount of $15,848. As of March 31, 2015, the outstanding short term borrowing was $15,372. (2) In June 2013, iKang Holding signed a ten-year loan framework agreement with total loan amounts no more than $3,268 with BEA, to meet the Group’s needs to purchase the property and equipment. On June 28, 2013, iKang Holding borrowed a two-year loan of $1,897 according to the framework agreement. The annual interest rate is the benchmark interest rate announced by the People’s Bank of China plus 10% of the benchmark interest rate. The loan was guaranteed by Beijing iKang and collateralized by restricted cash. As of March 31, 2014, the outstanding long term borrowings were $1,865 and it was repaid in July 2014. Interest expense incurred for the years ended March 31, 2013, 2014 and 2015 was $477, $827 and $2,466, respectively. The weighted average effective interest rate for the year ended March 31, 2013, 2014 and 2015 was 7.8%, 7.0% and 5.6%, respectively. The carrying values of short-term borrowings approximate their fair values due to short-term maturities. The carrying amounts of long term borrowing approximate its fair values as the borrowing bears fixed interest rate which approximates the market interest rate. The fair value of long term borrowing was $1,884 as of March 31, 2014. Long-term borrowing is categorized in Level 2 of the fair value hierarchy. As the Group has considerable cash and cash equivalents denominated in U.S. dollars in overseas accounts, the Group from time to time enters into “Pledge Overseas and Borrow Locally” transactions in China to meet its RMB funding needs, which is primarily to purchase property and equipment with cash within China. The parties to the transaction are typically one of the Group’s domestic entities, one of the Group’s overseas subsidiaries, and a bank which can offer services for both bank accounts onshore and offshore. The principal terms of the arrangement include the interest, the term of the loan which is typically one year, and the requirement of collateral in the form of a fixed deposit. Under this type of transaction, the Group receives RMB locally, and has a pledged asset in the form of a fixed deposit denominated in U.S. dollars or other currencies with an overseas bank account. The pledged deposit is recognized by an entity within the Group that is domiciled outside of the PRC, while a PRC entity within the Group borrows RMB. Banks which offer both overseas and PRC bank account services provide this type of arrangement to accommodate PRC companies which are in need of RMB in a more timely manner. The Group pays interest on the loan as well as certain transaction fees while it earns interest income from the fixed deposit in the overseas account at a rate similar to comparable investments. The Group’s domestic entity repays the RMB loan at the scheduled repayment dates. The restricted cash balance is not released proportionally to loan repayments. Beginning in February 2015, the Group started to utilize a new government policy in China for the Group’s currency conversion needs so that the Company can gradually convert and reserve RMB balances to support its future expansion. As a result, the Group may gradually reduce its “Pledge Overseas Borrow Locally” transactions in the future.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Mar. 31, 2015
INCOME TAXES
INCOME TAXES	13. INCOME TAXES Cayman Islands The Company is a tax-exempted company incorporated in the Cayman Islands and is not subject to tax on income or capital gains. British Virgin Islands (“BVI”) The iKang Guobin and iKang Zhejiang BVI are exempted from income tax in BVI, where they are incorporated. Hong Kong Bayley & Jackson (Hong Kong), Yuanhua HK, MediFast and WA Health Care are subject to Hong Kong Profits Tax at 16.5% on its activities conducted in Hong Kong. PRC Since January 1, 2008, the Company’s PRC subsidiaries, iKang Holding and its subsidiaries are subject to the 25% standard enterprise income tax (“EIT”). According to “Catalogue of Industries Encouraged to Develop in the Western Region”, iKang Chengdu Waishuangnan, iKang Chengdu Jinjiang, Chengdu Gaoxin iKang West City and iKang Chongqing were recognised as encouraged entities by relevant PRC government authorities in October 2014 and entitled to a preferential tax rate of 15% from October 1, 2014. iKang Shenzhen Nanshan, iKang Shenzhen Luohu, iKang Shenzhen Futian and Shenzhen Kefa are subject to income tax rate of 35% due to regulations set by local governments. Under the EIT Law and its implementation rules which became effective on January 1, 2008, dividends generated after January 1, 2008 and payable by a foreign-invested enterprise in PRC to its foreign investors who are non-resident enterprises are subject to a 10% withholding tax, unless any such foreign investor’s jurisdiction of incorporation has a tax treaty with PRC that provides for a different withholding arrangement. Under the taxation arrangement between the PRC and Hong Kong, a qualified Hong Kong tax resident which is the “beneficial owner” and directly holds 25% or more of the equity interest in a PRC-resident enterprise is entitled to a reduced withholding tax rate of 5%. The BVI, where the Company is incorporated, does not have a tax treaty with PRC. Since January 1, 2008, the relevant tax authorities of the Group’s subsidiaries have not conducted a tax examination on the Group’s PRC entities. In accordance with relevant PRC tax administration laws, tax years from 2009 to 2014 of the Group’s PRC subsidiaries and VIE entities, remain subject to tax audits as of March 31, 2015, at the tax authority’s discretion. Aggregate undistributed earnings of the Company’s subsidiaries located in the PRC that are available for distribution to the Company are approximately $4,246 as of March 31, 2015. The undistributed earnings of the Company’s subsidiaries located in the PRC are considered to be indefinitely reinvested, because the Group does not have any present plan to pay any cash dividends on its common shares in the foreseeable future and intends to retain most of its available funds and any future earnings for use in the operation and expansion of its business. Accordingly, no deferred tax liability has been accrued for the Chinese dividend withholding taxes that would be payable upon the distribution of those amounts to the Company as of March 31, 2015. Aggregate undistributed earnings of the Company’s VIEs and its VIEs’ subsidiaries located in the PRC that are available for distribution to the Company were approximately $90,876 as of March 31, 2015. A deferred tax liability should be recorded for taxable temporary differences attributable to the excess of financial reporting amounts over tax basis amount in domestic subsidiaries However, recognition is not required in situations where the tax law provides a means by which the reported amount of that investment can be recovered tax-free and the enterprise expects that it will ultimately use that means. The Company has not recorded any such deferred tax liability attributable to the undistributed earnings of its financial interest in VIEs because it believes such excess earnings can be distributed in a manner that would not be subject to income tax. Uncertainties exist with respect to how the current income tax law in the PRC applies to the Group’s overall operations, and more specifically, with regard to tax residency status. The EIT Law includes a provision specifying that legal entities organized outside of the PRC will be considered residents for Chinese Income tax purposes if the place of effective management or control is within the PRC. The implementation rules to the EIT Law provide that non-resident legal entities will be considered China residents if substantial and overall management and control over the manufacturing and business operations, personnel, accounting, properties, etc., occurs within the PRC. Despite the present uncertainties resulting from the limited PRC tax guidance on the issue, the Group does not believe that the legal entities organized outside of the PRC within the Group should be treated as residents for EIT law purposes. If the PRC tax authorities subsequently determine that the Company and its subsidiaries registered outside the PRC should be deemed resident enterprises, the Company and its subsidiaries registered outside the PRC will be subject to the PRC income taxes, at a rate of 25%. The current and deferred portions of income tax expenses included in the consolidated statements of operations, which were attributable to the Group’s PRC subsidiaries and VIE entities, are as follows: Years ended March 31, 2013 2014 2015 Current tax expenses $ $ $ Deferred tax benefits ) ) ) Income tax expenses $ $ $ The principal components of the deferred income tax assets and liabilities are as follows: As of March 31, 2014 2015 Current deferred tax assets: Accrued expenses $ $ Deferred revenue — Accrued payroll Bad debt provision Less: Valuation allowance ) ) Current deferred tax assets $ $ Non-current deferred tax assets: Depreciation and amortization $ $ Impairment of long-lived assets Net operating tax loss carry-forwards Less: Valuation allowance ) ) Non-current deferred tax assets $ $ As of March 31, 2014 2015 Non-current deferred tax liabilities: Intangible assets Non-current deferred tax liabilities $ $ The Group considers the following factors, among other matters, when determining whether some portion or all of the deferred tax assets will more likely than not be realized: the nature, frequency and severity of recent losses, forecasts of future profitability, the duration of statutory carryforward periods, the Group’s experience with tax attributes expiring unused and tax planning alternatives. The Group’s ability to realize deferred tax assets depends on its ability to generate sufficient taxable income within the carryforward periods provided for in the tax law. As of March 31, 2015, the Group’s PRC subsidiaries, VIEs and VIEs’ subsidiaries had a tax loss carry-forward amounted to $17,791 and would expire on various dates between March 31, 2015 and March 31, 2020. The Group does not file combined or consolidated tax returns, therefore, losses from individual subsidiaries or the VIE entities may not be used to offset other subsidiaries’ or VIE entities’ earnings within the Group. Valuation allowance is considered on each individual subsidiary and legal entity basis. Valuation allowances have been established in respect of certain deferred tax assets as it is considered more likely than not that the relevant deferred tax assets will not be realized in the foreseeable future. Reconciliation between the expense (benefit) of income taxes computed by applying the PRC tax rate to income (loss) before income taxes and the actual provision for income taxes is as follows: For the year ended March 31, 2013 2014 2015 Net income before provision for income taxes and (loss)//gain from equity method investment $ $ $ PRC statutory tax rate % % % Income tax at statutory tax rate Change in valuation allowance Expenses not deductible for tax purposes Effect of income tax rate difference for entities under individual income tax rate of 35% Loss utilized for entities under individual income tax rate of 35% ) ) ) Effect of income tax rate differences in other jurisdictions Tax holidays and preferential tax rates — — ) Income tax expenses $ $ $ The Group did not identify significant unrecognized tax benefits for the years ended March 31, 2013, 2014 and 2015. The Group did not incur any interest and penalties related to potential underpaid income tax expenses and also believed that uncertainty in income taxes did not have a significant impact on the unrecognized tax benefits within next twelve months.

COMMON SHARE

COMMON SHARE	12 Months Ended
	Mar. 31, 2015
COMMON SHARE
COMMON SHARE	14. COMMON SHARE Before the completion of the IPO in April 2014, the Class A and Class B common shares were owned by Mr. Ligang Zhang, his spouse and other shareholders. Immediately prior to the completion of the IPO, Class B common shares were automatically converted into Class A common shares on a one-for-one basis and 805,100 of the Group’s outstanding Class A common shares held by Time Intelligent Finance Limited were redesignated into Class C common shares. According to the Company’s Amended and Restated Articles of Association which became effective upon the completion of the IPO, the Company currently has two classes of authorized ordinary shares, Class A common shares and Class C common shares. All Class C common shares are held by Time Intelligent Finance Limited and beneficially owned by Mr. Ligang Zhang’s family trust. The rights of the holders of Class A and Class C common shares are identical, except with respect to voting and conversion rights. Each Class A common share is entitled to one vote per share, while each Class C common share is entitled to 15 votes per share and is convertible at any time into one Class A common share. Holders of Class A and Class C common shares shall at all times vote together as one class on all matters subject to a shareholders’ vote. On April 9, 2014, the Company completed its IPO in NASDAQ and a concurrent private placement. The Company newly issued 5,215,794 Class A ordinary shares, consisting of (i) 3,787,223 Class A common shares offered through IPO, and (ii) 1,428,571 Class A common shares issued in connection with the concurrent private placement. All of the Company’s preferred shares were automatically converted into 20,781,515 Class A common shares. On May 9, 2014, the Company issued an additional 514,556 Class A common shares to the investment bankers for excising the Green Shoe option.

CONVERTIBLE REDEEMABLE PREFERRE

CONVERTIBLE REDEEMABLE PREFERRED SHARES	12 Months Ended
	Mar. 31, 2015
CONVERTIBLE REDEEMABLE PREFERRED SHARES
CONVERTIBLE REDEEMABLE PREFERRED SHARES	15. CONVERTIBLE REDEEMABLE PREFERRED SHARES On March 31, 2013, there were 1,094,668 Series A convertible redeemable participating preferred shares (“Series A shares”), 686,368 Series B convertible redeemable participating preferred shares (“Series B shares”), 794,250 Series C1 convertible redeemable participating preferred shares (“Series C1 shares”), 126,286 convertible redeemable participating preferred shares (“Series C2 shares”), 1,024,318 Series C3 convertible redeemable participating preferred shares (“Series C3 shares”) (Series C1 shares, Series C2 shares and Series C3 shares are collectively referred to as “Series C shares”), 3,538,864 Series D1 convertible redeemable participating preferred shares (“Series D1 shares”), 2,307,536 Series D2 convertible redeemable participating preferred shares (“Series D2 shares”) (Series D1 shares and Series D2 shares are collectively referred to as “Series D shares”), 4,289,457 Series E convertible redeemable participating preferred shares (“Series E shares”) and 4,654,697 Series F shares outstanding. On August 28, 2013, the Company issued 1,953,499 Series F shares, which are under the same terms of Series F shares issued on March 28, 2013 to a group of investors for a consideration of $25,181. On October 16, 2013, a total number of 596,484 Class A common shares and Series D1 and D2 preferred shares held by certain existing shareholders were sold to a third party investor pursuant to the share purchase agreements dated September 12, 2013. The existing shares were sold for $12.0309 per share, which was the same as the selling price of existing shares to new investors in March 2013. The 596,484 sold shares were redesignated as 596,484 Series F shares immediately after the completion of the sale and purchase of the shares. The price agreed and paid by the purchaser of Series F shares was $14.1792 per share, which was determined by the Company and agreed by the purchaser based on the estimated equity value of the Company on the date of the share purchase agreement. Total sold price of $7,176 was paid by the purchaser to the sellers in October 2013. The difference of selling price and purchase price of the shares totaling $1,281 was paid by the purchaser to the Company in October 2013. The Company credited for the $1,281 to the series F shares. On April 9, 2014, 1,094,668 Series A shares, 686,368 Series B shares, 794,250 Series C1 shares, 126,286 Series C2 shares, 1,024,318 Series C3 shares, 3,488,864 Series D1 shares, 2,072,624 Series D2 shares, 4,289,457 Series E shares and 7,204,680 Series F shares preferred shares had been automatically converted into common shares after the closing of IPO. The Series A, B, C, D, E and F shares are collectively referred to as the preferred shares. Key terms of the preferred shares are summarized as follows: Redemption The original redemption price of the Series A, B, C, D and E shares equaled the sum of (i) the preferred share original issue price, and (ii) interest calculated at 10% per year compounded annually from the original preferred share issue date until original maturity on April 22, 2012. The Company recognized entire changes in the redemption value and adjusted the carrying value of the preferred shares to equal the redemption value immediately when the preferred shares were issued. As a result, $26,353 of redemption premium of the preferred shares was recorded as a deemed dividend upon issuance of those preferred shares. Series E shares which were originally redeemable upon or at any time after (i) November 28, 2011, if no qualified IPO or a company sale had occurred by such date, or (ii) February 28, 2011, in the event that any shareholder refused to participate in a company sale. Pursuant to a supplemental agreement entered into between the Company and the holders of Series E shares dated on July 14, 2011, Series E shares would be redeemable after April 22, 2012. hence additional redemption premium of $2,312 related to the period from the original redemption due date of July 14, 2011 to April 22, 2012 was charged as deemed dividend for the year ended March 31, 2012. After issuance of Series F shares and at the election of Series F shareholders, each Series F share shall be eligible to be redeemed if any of the following events occurs: (1) by March 28, 2017 , the Restructuring has been completed but a Qualified IPO has not been consummated; “Restructuring” means the transfer of all interests in the medical centers, clients, employees, contractors and all other assets held by the PRC Entities (other than direct or indirect wholly-owned subsidiaries of the Company) as of Series F shares issuance date and any such additional interests in medical centers, clients, employees, contractors and other acquired by the PRC Entities thereafter to a direct or indirect wholly owned subsidiary of the Company. (2) Other than as approved by the Company’s board of directors (including the affirmative votes of Series F share directors), the loss of control or the inability to consolidate over any subsidiaries or VIE entities of the Group that account for three percent (3%) or more of the then consolidated revenues or hold three percent (3%) or more of the then consolidated assets; (3) the Restructuring is not completed by the expiry of 18 months from the earlier of (i) the effective date of a Change of Law or (ii) the date of such announcement or promulgation of a Change of Law; “Change of Law” means any change of applicable Laws that would have a material adverse effect on the validity of, or on the rights (as a whole) granted under, the VIE arrangements. (4) the Restructuring is not completed within two years from the date of a Restricted Venue Resolution, or “Restricted Venue Resolution” means the resolution passed by the majority of the Company’s board of directors to proceed with an IPO upon the occurrence of Change of Law; (5) by March 28, 2017, the Restructuring has not been completed and a Qualified IPO has not been consummated. In the case of (1) to (4) above, the redemption price of the Series F shares equals to the sum of (i) the preferred share original issue price, and (ii) interest calculated at 10% per year compounded annually from the original preferred share issue date. In the case of (5) above, the redemption price of the Series F shares equals to the sum of (i) the preferred share original issue price, and (ii) interest calculated at 12% per year compounded annually from the original preferred share issue date. Upon the issuance of Series F shares, redemption of preferred shares other than Series F and E shares, shall require no less than five affirmative votes out of nine votes of the board directors, including the both affirmative votes of Series F shares directors. Series E shares can only be redeemed at the election of Series E preferred shareholders for cash at their redemption price when Series F shares are redeemed. Series B, C1, C2 and D1 shares are redeemable upon the second anniversary of the Series F issuance date and thereafter. Series A shares are redeemable at the election of the relevant classes of preferred shareholders for cash at their redemption price when Series F, E, B, C1, C2 and D1 shares are redeemed. Series C3 and D2 shares can only be redeemed when series F, E, B, C1, C2, D1 and A shares are redeemed at the election of the preferred shareholders. Upon the issuance of Series F shares, the redemption price of the Series A, B, C, D and E shares equals to the sum of (i) the preferred share original issue price, and (ii) interest calculated at 10% per year compounded annually from the original preferred share issue date until March 28, 2017. The Company recognized changes in the redemption value and adjusted the carrying value of the preferred shares to equal the entire redemption value immediately when the preferred shares were issued, as a result, $74,075 and $17,763 of redemption premium of the preferred shares was recorded as a deemed dividend for the years ended March 31, 2013 and 2014, respectively. Voting rights Preferred shareholders are entitled to the number of votes equal to the number of common shares into which such preferred shares could be converted at the record date. Dividends Whenever a dividend is declared by the board of directors of the Company, the preferred shares holders shall receive, in preference to any dividend on any common shares a non-cumulative dividend in an amount equal to 6% annually of the preferred shares’ original purchase price, as adjusted for stock splits, stock dividends, etc., and shall also participate on an as converted basis with respect to any dividends payable to the common shares. The sequence of dividend participating right of all series of preferred shares was as follows: (1) Series F (2) Series E (3) Series B, C1, C2 and D1 (4) Series A (5) Series C3 and D2 Conversion Each preferred share shall be convertible, at the option of the holder thereof, at any time after the preferred shares’ original date of issuance, into such number common shares as determined by dividing the preferred share original issue price by preferred share conversion price. The initial conversion ratio was one for one. The conversion price has a standard anti-dilution adjustment term for items such as stock splits and recapitalization. It also has a down-round provision, under which when the Company issues any additional shares at a price per share that is lower than the conversion price per share then in effect, the conversion price per share is adjusted down. There have been no such adjustments to the conversion price. Each preferred share would automatically be converted into ordinary shares at the then effective conversion price, upon the closing of a Qualified IPO. Qualified IPO” means (a) an IPO on the New York Stock Exchange, NASDAQ Stock Market, Main Board of The Stock Exchange of Hong Kong Limited, Shanghai Stock Exchange, Shenzhen Stock Exchange or other stock exchange approved by the Majority Preferred F Holders in writing, with: (i) if the IPO occurs on or before the first anniversary of the First Closing Date, a minimum pre-offering valuation of the Company of at least $555 million (representing for each Series F Preferred Share an annual compounded return, calculated from the First Closing Date, of no less than 50% on the Series F Original Purchase Price (as adjusted for stock dividends, stock splits, consolidation and the like)); (ii) if the IPO occurs after the first anniversary, but on or before the second anniversary of the First Closing Date, a minimum pre-offering valuation of the Company of at least $675 million (representing for each Series F Preferred Share an annual compounded return, calculated from the First Closing Date, of no less than 35% on the Series F Original Purchase Price (as adjusted for stock dividends, stock splits, consolidation and the like)); (iii) if the IPO occurs after the second anniversary, but on or before the third anniversary of the First Closing Date, a minimum pre-offering valuation of the Company of at least $723 million (representing for each Series F Preferred Share an annual compounded return, calculated from the First Closing Date, of no less than 25% on the Series F Original Purchase Price (as adjusted for stock dividends, stock splits, consolidation and the like)); or (iv) if the IPO occurs after the third anniversary of the First Closing Date, a minimum pre-offering valuation of the Company of at least $740 million, or (b) any other public offering as otherwise approved by the Majority Preferred F Holders and the holders representing at least seventy-five percent (75%) of the then outstanding Preferred Shares (voting together as a single class on an as-converted basis). Liquidation preference Upon occurrence of a liquidation event, an amount shall be paid with respect to each preferred share equal to 100% of the original purchase price, plus any declared but unpaid dividends, adjusted for any share dividends, combinations, splits, recapitalizations and the like. If, after liquidation, distribution, or winding up, the assets of the Company are insufficient to make payment in full to all preferred shareholders, then such assets shall be distributed among the preferred shareholders ratably in proportion to the full amounts to which they would otherwise be respectively entitled thereon. The sequence of liquidation right of all series of preferred shares is as follows: (1) Series F shares (2) Series E shares (3) Series B, C1, C2 and D1 shares (4) Series A shares (5) Series C3 and D2 shares The preferred shares were accounted for as mezzanine equity.

NET INCOME (LOSS) PER SHARE

NET INCOME (LOSS) PER SHARE	12 Months Ended
	Mar. 31, 2015
NET INCOME (LOSS) PER SHARE
NET INCOME (LOSS) PER SHARE	16. NET INCOME (LOSS) PER SHARE The Group has determined that its convertible redeemable preferred shares are participating securities as the preferred shares participate in undistributed earnings on an as-if-converted basis. The holders of the preferred shares are entitled to receive dividends on a pro rata basis, as if their shares had been converted into common shares. Accordingly, the Group uses the two-class method of computing net income per share, for common and preferred shares according to participation rights in undistributed earnings. The calculation of net income (loss) per share is as follows: For the years ended March 31, 2013 2014 2015 Net income attributable to iKang Guobin Healthcare Group, Inc. $ $ $ Deemed dividend to Series A shares — Deemed dividend to Series B shares — Deemed dividend to Series C shares — Deemed dividend to Series D shares Deemed dividend to Series E shares — Deemed dividend to Series F shares Undistributed earnings allocated to Series A shares Undistributed earnings allocated to Series B shares Undistributed earnings allocated to Series C shares Undistributed earnings allocated to Series D shares Undistributed earnings allocated to Series E shares Undistributed earnings allocated to Series F shares For the years ended March 31, 2013 2014 2015 Net (loss) income attributed to common and preferred shareholders for computing net income per common share- basic and diluted (1) ) ) Numerator: Series A shares- Deemed dividend — Undistributed earnings allocation Series B shares- Deemed dividend — Undistributed earnings allocation Series C shares- Deemed dividend — Undistributed earnings allocation Series D shares- Deemed dividend Undistributed earnings allocation Series E shares- Deemed dividend — Undistributed earnings allocation Series F shares- Deemed dividend Undistributed earnings allocation Net (loss) income attributed to common shareholders for computing net income per common share- basic and diluted (1) ) ) For the years ended March 31, 2013 2014 2015 Denominator: Weighted average common shares outstanding used in computing diluted net income per common share-basic (2) Weighted average shares outstanding used in computing net income per common shares-diluted (2) Weighted average shares used in computing basic net income per shares Series A shares Series B shares Series C shares Series D shares Series E shares Series F shares Net (loss) income per common share attributable to iKang Healthcare Group, Inc.-basic $ ) $ ) $ Net (loss) income per common share attributable to iKang Healthcare Group, Inc.-diluted $ ) $ ) $ Net income per Series A shares $ $ $ Net income per Series B shares $ $ $ Net income per Series C shares $ $ $ Net income per Series D shares $ $ $ Net income per Series E shares $ $ $ Net income per Series F shares $ $ $ Notes: (1) The Class A, Class B and Class C common shares enjoy the same dividend participating right, therefore earnings per share of each class was not separately presented. (2) The calculation of the weighted average number of common shares for the purpose of diluted net income (loss) per share has considered the effect of certain potentially dilutive securities. The weighted average common shares outstanding used in computing basic and diluted net income per common share was adjusted retroactively for all periods presented to reflect the stock dividend of 251,079 Class A common shares distributed to shareholders in October 2010. For the year ended March 31, 2013, 1,386,984, 1,054,620, 2,069,410, 6,088,557, 4,289,457, 63,763 and 355,410 common shares resulting from the assumed conversion of the Series A shares, Series B shares, Series C shares, Series D shares, Series E shares, Series F shares and options, respectively, were excluded as their effect was anti-dilutive. For the year ended March 31, 2014, 1,094,668, 686,368, 1,944,954, 5,717,326, 4,289,457, 6,075,702 and 988,507 common shares resulting from the assumed conversion of the Series A shares, Series B shares, Series C shares, Series D shares, Series E shares, Series F shares and options, respectively, were excluded as their effect was anti-dilutive. For the year ended March 31, 2015, no shares or options were excluded.

SHARE-BASED COMPENSATION

SHARE-BASED COMPENSATION	12 Months Ended
	Mar. 31, 2015
SHARE-BASED COMPENSATION.
SHARE-BASED COMPENSATION	17. SHARE-BASED COMPENSATION The Company’s Board of Directors has approved and the Company has granted various tranches of options to its management and consultants as follows: From 2007 to 2010, the Company granted 240,000 share options to its management with various exercise prices per share with different service period from 3 to 4 years. From 2004 to 2011, the Company granted 302,855 options with various exercise prices per share to its executives and consultants, which can be exercised only when the Company’s common stocks become publicly traded or the Company is acquired by other parties (“Company Sale”). On June 8, 2011, the Company granted 41,843 options with exercise prices of $ 0.01 per share to its management, which could be exercised only when the Company’s common stocks become public traded or upon a liquidation of the Company. On February 17, 2012, the Company modified the 60,000 options granted to one of its employees on December 31, 2010 with exercise price of $ 5.13 per share for 80,000 options with the same exercise price which are fully vest but can be exercised only when all of the following conditions are met: (1) The Company’s common stocks become public traded or a Company Sale occurs; (2) The former employee should not engage with any entity or business of healthcare management and consulting business in the PRC (the “Competitive Business”) in the next two years. (3) The former employee should not disclose any confidential information to third parties without authorization. On March 18, 2013, the Company granted 330,000 options with exercise price of $5.13 per share to certain directors and employees, which were exercisable immediately upon the issuance of the options. The Group recorded share-based compensation expenses of $2,273 during the year ended March 31, 2013. On March 18, 2013, The Company granted additional 440,000 options with exercise price of $5.13 per share and 80,000 options with exercise price of $6.00 to its certain directors and employees, which could be exercised only when the Company’s common stocks become public traded or upon a liquidation of the Company. On September 12, 2013, the Company granted 200,000 options with exercise price of $6.00 to its director, which has a vesting period of 3.55 years and can be exercised only when the Company’s common stocks become publicly traded or upon a Company Sale. On February 27, 2014, the Company granted additional 356,300 options with exercise price of $5.13 per share and 72,700 options with exercise price of $6.00 to its certain directors and employees, which have vesting periods of 1.35 and 1.91 years respectively and can be exercised only when the Company’s common stocks become publicly traded or upon a Company Sale. On August 1, 2014, the Company granted additional 300,000 options with exercise price of $ 16.18 per share to one of the former shareholder of Shanghai Huajian Management, which is vested and exercisable on the grant date. On October 28, 2014, the Company granted additional 8,600 options with exercise price of $6.00 per share and 17,200 options with exercise price of $5.13 to its certain directors and employees, which have a vesting period of 2 years. On February 27, 2015, the Company granted additional 4,000 options with exercise price of $5.13 to one of its former employees, which has a vesting period of 2 years. The following table summarizes information regarding options granted: For the years ended March 31, 2013 2014 2015 Weighted Weighted Weighted Weighted Weighted Weighted average average average average average average exercise fair value exercise fair value exercise fair value Number of price per per option Number of price per per option Number of price per per option options option at grant date options option at grant date options option at grant date Outstanding on April 1 of year $ $ $ $ $ $ Granted Exercised — — — — — — ) Forfeited — — — ) ) Outstanding on March 31 of year $ $ $ $ $ $ There were 1,572,281 vested options, and 328,198 options expected to vest as of March 31, 2015. For options expected to vest, the weighted-average exercise price is $5.55 and aggregate intrinsic value is $8,826 as of March 31, 2015. The following table summarizes information with respect to share options outstanding as of March 31, 2015: Option outstanding Option exercisable Weighted Weighted Aggregate Weighted Aggregate average average intrinsic average intrinsic remaining Exercise values as of Exercise values as of Number contractual price per March 31, Number price per March 31, Range of exercise price outstanding life in years option 2015 exercisable option 2015 $0.01 $ $ $ $ $1.00-$2.00 $ $ $5.13 $ $ $6.00 $ $ $16.18 $ $ $ $ The fair value of each option granted was estimated on the date of grant using the binomial tree pricing model with the following assumptions used for grants during the applicable periods: Risk-free interest rate of return Contractual term Volatility Dividend yield Exercise price December 31, 2010 % 10 years % — 5.13 June 8, 2011 % 2.39 years % — 0.01 February 17, 2012 % 10 years % — 5.13 March 18, 2013 % 10 years % — 5.13~6.00 September 12, 2013 % 10 years % — 6.00 February 27, 2014 % 10 years % — 5.13~6.00 August 1, 2014 % 10 years % — 16.18 October 28, 2014 % 10 years % — 5.13~6.00 February 27, 2015 % 10 years % — 5.13 (1) Risk-free interest rate Risk-free interest rate was estimated based on the yield to maturity of China international government bonds with a maturity period close to the expected term of the options. (2) Contractual term The Company used the original contractual term. (3) Volatility The volatility of the underlying common shares during the life of the options was estimated based on the historical stock price volatility of comparable listed companies over a period comparable to the expected term of the options. (4) Dividend yield The dividend yield was estimated by the Group based on its expected dividend policy over the expected term of the options. (5) Exercise price The exercise price of the options was determined by the Group’s board of directors. (6) Fair value of underlying common shares The estimated fair value of the common shares underlying the options as of the respective grant dates was determined based on a retrospective valuation, which used management’s best estimate for projected cash flows as of each valuation date. The Group recorded share-based compensation of $2,273, $930 and $9,153 during the years ended March 31, 2013, 2014 and 2015, respectively, based on the fair value on the grant dates over the requisite service period of award according to the vesting schedule for employee share option. As of March 31, 2015, total unrecognized compensation expense relating to unvested share options was $5,411, which will be recognized over 2 years. The weighted-average remaining contractual term of options outstanding is 7.65 years.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
	Mar. 31, 2015
FAIR VALUE MEASUREMENTS
FAIR VALUE MEASUREMENTS	18. FAIR VALUE MEASUREMENTS (a) Measured on recurring basis The Group measured its financial assets including foreign currency forward contracts at fair value on a recurring basis as March 31, 2014 and 2015. The Group purchased foreign currency forward contracts to protect against the adverse effect that exchange rate fluctuation may have on foreign currency denominated financing activities. Foreign currency forward contracts are marked to market based on the prevailing forward exchange rate quoted by the contracted bank (level 2 inputs). Assets and liabilities resulted from foreign currency forward contracts are recorded at its fair value. Details of the outstanding foreign currency forward contracts as of March 31, 2014 and 2015 were as follows: As of March 31, 2014 2015 Balance at beginning of year $ $ Gain/(loss) from forward contracts ) Settled — ) Balance at end of year $ $ — The fair value of the long term borrowing was classified as level 2 as set out in Note 12. The Group did not have level 3 investments as of March 31, 2014 and 2015. As of March 31, 2014 and 2015, information about inputs for the fair value measurements of the Group’s assets that are measured at fair value on a recurring basis in period subsequent to their initial recognition is as follows: Fair Value Measurement at Reporting Date Using 2014 2015 Quoted Quoted Prices in Significant Prices in Significant Active Market Other Significant Active Market Other Significant March 31, for Identical Observable Unobservable March 31, for Identical Observable Unobservable 2014 Assets Inputs Inputs 2015 Assets Inputs Inputs (Level 1) (Level 2) (Level 3) (Level 1) (Level 2) (Level 3) Foreign currency forward contracts — — — — — — Outstanding on March 31 of year $ $ — $ $ — $ — $ — $ — $ — (b) Measured at fair value on a non-recurring basis Goodwill, other intangible assets, equity method investment and cost method investment are measured at fair value on a nonrecurring basis and they are recorded at fair value only when impairment is recognized. The Group measured the fair value of the purchased intangible assets using the “cost” and “income approach excess earnings” and “with & without” valuation method. The Group measured the fair value of acquired intangible assets, equity method investment and cost method investment using income approach based on which to recognize the impairment loss in respective years. These assets are considered at level 3 assets because the Group used unobservable inputs to determine their fair values.. The Group estimated the fair value of these investee companies and acquired intangible assets based on discounted cash flow approach which requires significant judgments, including the estimation of future cash flows, which is dependent on internal forecasts, the estimation of long term growth rate of a company’s business, the estimation of the useful life over which cash flows will occur, and the determination of the weighted average cost of capital. The Group did not recognize any impairment loss related to goodwill, acquired intangible assets equity method investment and cost method investment for the year ended March 31, 2014 and 2015. The fair value was determined using models with significant unobservable inputs (level 3 inputs), primarily the management projection of discounted future cash flow and the discount rate.

RELATED PARTY BALANCES AND TRAN

RELATED PARTY BALANCES AND TRANSACTIONS	12 Months Ended
	Mar. 31, 2015
RELATED PARTY BALANCES AND TRANSACTIONS
RELATED PARTY BALANCES AND TRANSACTIONS	19. RELATED PARTY BALANCES AND TRANSACTIONS Amounts due from a related party of the Group: As of March 31, 2014 2015 Amounts due from a related party - current: Amounts due from Shanghai Huajian Clinic Ltd. (1) $ — $ — Amounts due to a related party of the Group: As of March 31, 2014 2015 Amounts due to a related party - current: Amounts due to a former non-controlling interest holder (2) $ — $ — (1) Amounts due from a related party represents loan provided by the Group to its equity method investee Shanghai Huajian Management for daily operating use and the loan was repaid in September 2014. (2) On August 1, 2011, iKang Holding signed an agreement with the non-controlling interest holder of iKang Shanghai Xikang Road to purchase the remaining 35% of the equity interest in iKang Shanghai Xikang Road held by the non-controlling interest holders, with consideration of $15,894. The transaction was closed on December 31, 2011. The Group paid first installment of $1,589 in August 2011 within five days after the agreement was signed. The second installment of $1,589 was paid in February 2013. In December 2013, $3,941 was repaid and in March 2014, $991 was paid by the Group for individual income tax on behalf of the former non-controlling interest holder. The remaining balance was settled in June 2014. The amounts due to non-controlling interest holder represents amortized cost of the principal amount. The Group recognized $629, $504 and nil imputed interest expense for the years ended March 31, 2013, 2014 and 2015, respectively. The effective interest rate of the amount due from non-controlling interest holder is 5.5%.

NONCONTROLLING INTEREST

NONCONTROLLING INTEREST	12 Months Ended
	Mar. 31, 2015
NONCONTROLLING INTEREST
NONCONTROLLING INTEREST	20. NONCONTROLLING INTEREST iKang iKang iKang Shenzhen Shanghai Zhejiang WA Shanghai Shanghai Fujian Hospital Jianwei Beijing iKang BVI HK Gubei Lujiazui iKang Management Management Jiandatong MediFast Changzhou Total Balance at March 31, 2012 $ ) $ — $ $ $ $ ) $ — $ — $ — $ — $ Share of profit — ) — — — — Other comprehensive income ) — — — — — — ) Balance at March 31, 2013 $ $ — $ $ $ $ $ — $ — $ — $ — $ Addition of non-controlling interest in connection with establishment of Beijing Jiandatong — — — — — — — — — Addition of non-controlling interest in connection with acquisition of Shanghai iKang Jianwei Health Management Co., Ltd. — — — — — — — — — Addition of non-controlling interest in connection with acquisition of MediFast — — — — — — — — — Addition of non-controlling interest in connection with establishment of iKang Changzhou — — — — — — — — — Dividend distribution to non-controlling interest holder of Shanghai Wangzu Guobin Medical Center Co., Ltd. — — ) — — — — — — — ) Share of profit (loss) — ) ) ) Purchase of non-controlling interest — — — ) — — — — — — ) Other comprehensive income ) — ) ) ) ) ) ) ) ) Balance at March 31, 2014 $ $ — $ $ — $ $ $ $ $ $ $ Capital contribution of non-controlling interest holder of Beijing Jiandatong — — — — — — — — — Capital contribution of non-controlling interest holder of Shanghai Jianwei — — — — — — — — — Addition of non-controlling interest in connection with acquisition of WA Health Care — — — — — — — — — Capital contribution of non-controlling interest holder of WA Centers HK Limited — — — — — — — — — Dividend distribution to non-controlling interest holder of MediFast — — — — — — — — ) — ) Share of profit (loss) ) — ) ) ) ) Other comprehensive income — — — — — — — Balance at March 31, 2015 $ $ $ $ — $ $ ) $ $ $ $ $

SEGMENT INFORMATION

SEGMENT INFORMATION	12 Months Ended
	Mar. 31, 2015
SEGMENT INFORMATION
SEGMENT INFORMATION	21. SEGMENT INFORMATION The Group’s chief operating decision maker has been identified as the Chief Executive Officer who reviews results of operations by business lines when making decisions about allocating resources and assessing performance of the Group. The Group has two operating segments: medical examinations and other medical services and dental services. The Group does not allocate any assets to its operating segments as management does not believe that allocating these assets is useful in evaluating these segments’ performance. Accordingly, the Group has not made disclosure of total assets by reportable segment. For the years ended March 31, 2013 2014 2015 Net revenues: Medical examinations and other medical services $ $ $ Dental services — — Total net revenues Cost of revenues: Medical examinations and other medical services Dental services — — Total cost of revenues Gross profit: Medical examinations and other medical services Dental services — — Total gross profit Operating expenses: Selling and marketing expenses General and administrative expenses Research and development expenses Total operating expenses Income from operations $ $ $ The revenue and cost of revenues in relation to the operating segment of dental services for the years ended March 31, 2013 and 2014 were not presented as they were immaterial. Components of net revenues are presented in the following table: For the years ended March 31, 2013 2014 2015 Medical examinations $ $ $ Disease screening Other services Medical examinations and other medical services Dental services — — Total $ $ $ Substantially all of the Group’s revenues for the years ended March 31, 2013, 2014 and 2015 were generated from the PRC entities. Substantially all of the Group’s long-lived assets are located in the PRC as of March 31, 2013, 2014 and 2015.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Mar. 31, 2015
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES	22. COMMITMENTS AND CONTINGENCIES Commitments The Group leases its clinics, hospitals and offices under non-cancelable operating lease agreements. These leases expire through 2036 and are renewable upon negotiation. Rental expenses under operating leases for the years ended March 31, 2013, 2014 and 2015 were $16,436, $28,129 and $37,733, respectively. Future minimum lease payments under such leases as of March 31, 2015 were as follows: 2016 $ 2017 2018 2019 2020 After 2020 $ Contingent liabilities Pursuant to PRC individual income tax laws, when a corporation purchases equity interest from individuals, the individuals are obligated to pay individual income tax based on 20% of the capital gain from the transaction. The Group has purchased equity interests of certain entities from individual sellers. There is a possibility that if individual sellers fail to meet their income tax obligations, the tax authority may require the Group to pay the taxes for the sellers. Based on the information currently available, the Group was unable to make a reasonable estimate of the related liability due to the uncertainty related to the outcome and amount of payment and relating penalty and interest. Accordingly, the Company did not accrue any provision for this contingency as of March 31, 2015. The Group is subject to governmental supervision and regulations by the relevant PRC regulatory authorities including the Ministry of Health, the Ministry of Industry and Information Technology, and other relevant government authorities. Each of the Group’s medical centers is required to obtain a business license, a medical institution establishment approval, a medical institution practicing license and a radiation-related diagnosis and treatment license. If the Group fails to obtain such licenses or to amend the medical institution practicing licenses for the forgoing medical centers or other competent PRC regulatory authorities consider that the Group is operating the relevant businesses in an illegal manner, the Group may be ordered to shut down the relevant medical centers or cease the relevant services or suffer fines or penalties.

EMPLOYEE BENEFIT PLAN

EMPLOYEE BENEFIT PLAN	12 Months Ended
	Mar. 31, 2015
EMPLOYEE BENEFIT PLAN
EMPLOYEE BENEFIT PLAN	23. EMPLOYEE BENEFIT PLAN Full time employees of the Group in the PRC participate in a government-mandated defined contribution plan pursuant to which certain pension benefits, medical care, unemployment insurance, employee housing fund and other welfare benefits are provided to employees. The Group accrues for these benefits based on certain percentages of the employees’ salaries. The total provisions for such employee benefits were $4,908, $7,249 and $10,417 for the years ended March 31, 2013, 2014 and 2015, respectively.

STATUTORY RESERVE AND RESTRICTE

STATUTORY RESERVE AND RESTRICTED NET ASSETS	12 Months Ended
	Mar. 31, 2015
STATUTORY RESERVE AND RESTRICTED NET ASSETS
STATUTORY RESERVE AND RESTRICTED NET ASSETS	24. STATUTORY RESERVE AND RESTRICTED NET ASSETS In accordance with the Regulations on Enterprises with Foreign Investment of China and their articles of association, the Group’s subsidiaries and VIE entities located in the PRC, being foreign invested enterprises established in the PRC, are required to provide for certain statutory reserves. These statutory reserve funds include one or more of the following: (i) a general reserve, (ii) an enterprise expansion fund or discretionary reserve fund, and (iii) a staff bonus and welfare fund. Subject to certain cumulative limits, the general reserve fund requires a minimum annual appropriation of 10% of after-tax profit (as determined under accounting principles generally accepted in China at each year-end); the other fund appropriations are at the subsidiaries’ or the affiliated PRC entities’ discretion. These statutory reserve funds can only be used for specific purposes of enterprise expansion, staff bonus and welfare, and are not distributable as cash dividends except in the event of liquidation of our subsidiaries, our affiliated PRC entities and their respective subsidiaries. The Group’s subsidiaries and VIE entities are required to allocate at least 10% of their after-tax profits to the general reserve until such reserve has reached 50% of their respective registered capital. As of March 31, 2015, none of the Group’s PRC subsidiaries and VIE entities had a general reserve that reached the 50% of their registered capital threshold except iKang Nanjing Gulou, iKang Chengdu Waishuangnan and iKang Fuzhou Gulou therefore they will continue to allocate at least 10% of their after tax profits to the general reserve fund. Appropriations to the enterprise expansion reserve and the staff welfare and bonus reserve are to be made at the discretion of the board of directors of each of the Group’s subsidiaries. The appropriation to these reserves by the Group’s PRC subsidiaries was $1,296, $2,738 and $3,394 for the years ended March 31, 2013, 2014 and 2015, respectively. As a result of these PRC laws and regulations and the requirement that distributions by PRC entities can only be paid out of distributable profits computed in accordance with PRC GAAP, the PRC entities are restricted from transferring a portion of their net assets to the Group. Amounts restricted include paid-in capital and the statutory reserves of the Group’s PRC subsidiaries and VIE entities. The aggregate amounts of capital and statutory reserves restricted which represented the amount of net assets of the relevant subsidiaries and VIE entities in the Group not available for distribution was $139,994 as of March 31, 2015. As the restricted net assets of the Group’s subsidiaries and VIE entities were over the 25% of the consolidated net assets of the Group as of March 31, 2015, parent-only financials are presented in Schedule I.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Mar. 31, 2015
SUBSEQUENT EVENTS.
SUBSEQUENT EVENTS	25. SUBSEQUENT EVENTS On December 31, 2014, the Group entered into a share purchase agreement to acquire 100% equity interest of Chengdu Ommay Health Examination Hospital Co., Ltd. from four third party shareholders. The total cash consideration is approximately $3,705. The acquisition was closed in May 2015. The Group entered into an share purchase agreement to purchase of 100% equity interest in Beijing Tianzhikangjian Investment Management Co., Ltd. (“Beijing Tianzhikangjian”) on December 31, 2014. Previously, Beijing Tianzhikangjian held 31.85% equity interest in Beijing Tianjian Sunny Healthcare Technology Co., Ltd. (“Tianjian Sunny”), formerly known as Sinopharm Sunny, which is a prominent medical examination center chain in China. Pursuant to the share purchase agreement, Beijing Tianzhikangjian has to purchase additional 51% of equity interest in Tianjian Sunny. After transaction, the Group would acquire the 82.85% equity interest of Tianjian Sunny with a cash consideration of approximately $27,327. The acquisition was closed in May 2015. On April 9, 2015, the Group entered into a share purchase agreement to acquire 100% equity interest in Yantai ikang Guobin Hongkang Health Management Co., Ltd. Ande Clinic (formerly known as “Yantai Hongkang Tijian Co. Ltd.”) and Yantai ikang Guobin Hongkang Health Examination Management Co., Ltd. Clinic (formerly known as “Yantai Hongkang Jiankang Tijian Co. Ltd.”). Each entity owns one medical examination services center in Yantai, PRC. The total cash consideration is approximately $7,421. The acquisition was closed in June 2015. The Group entered into a cooperation agreement with former shareholders of Yinchuan Ciming Clinic Co., Ltd. (“former shareholders”) on April 15, 2015. Both parties agreed to setup a joint venture (“Joint Venture”) with total paid in capital of $8,273. Initially, the Group would hold 46.21% equity interest of the Joint Venture and former shareholders would hold the remaining 53.79%. After the Joint Venture is established, the Group would acquire another 23.79% of equity from former shareholders with cash consideration of approximately $1,968. After all of these processes of transaction, the Group would hold 70% of equity in the Joint Venture. The processes of transaction were closed in June 2015 and the Group has owned 70% equity in the Joint Venture. The purpose of the above acquisitions and investment was to expand its medical examination related services in multiple cities. The Group is in the process of assessing the purchase price allocation of the above acquisitions with the assistance of an independent valuation firm. In July 2015, the Group acquired the remaining 30% equity interest of iKang Shanghai Gubei from its non-controlling interest holder with cash consideration of $789. At the same time, dividend amounted $557 was paid to the non-controlling interest holder. The Group owned 100% equity interest of iKang Shanghai Gubei after this transaction.

FINANCIAL STATEMENT SCHEDULE I

FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY	12 Months Ended
	Mar. 31, 2015
ADDITIONAL INFORMATION-FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY
ADDITIONAL INFORMATION-FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY	CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY CONDENSED BALANCE SHEETS (In thousands of U.S. dollars, except share and per share data) March 31, 2014 2015 ASSETS Current assets: Cash and cash equivalents $ $ Amounts due from related parties Prepaid expenses and other current assets Total current assets Property and equipment, net — Investment in subsidiaries and VIE entities Rental deposit and other non-current assets — TOTAL ASSETS $ $ LIABILITIES, MEZZANINE EQUITY AND EQUITY (DEFICIT): Current liabilities: Accrued expenses and other current liabilities $ $ Amount due to related parties Total current liabilities Mezzanine Equity: Series A convertible redeemable participating preferred shares ($ 0.01 par value; 1,094,668 and nil shares authorized, issued and outstanding as of March 31, 2014 and 2015, respectively, liquidation value of $1,970 and nil as of March 31, 2014 and 2015, respectively) — Series B convertible redeemable participating preferred shares ($0.01 par value; 686,368 and nil shares authorized as of March 31, 2014 and 2015, respectively, 686,368 and nil shares issued and outstanding as of March 31, 2014 and 2015, respectively, liquidation value of $2,162 and nil as of March 31, 2014 and 2015, respectively) — Series C1 convertible redeemable participating preferred shares ($0.01 par value; 794,250 and nil shares authorized, issued and outstanding as of March 31, 2014 and 2015, respectively, liquidation value of $1,893 and nil as of March 31, 2014 and 2015, respectively) — Series C2 convertible redeemable participating preferred shares ($0.01 par value; 126,286 and nil shares authorized, issued and outstanding as of March 31, 2014 and 2015, respectively, liquidation value of $568 and nil as of March 31, 2014 and 2015, respectively) — Series C3 convertible redeemable participating preferred shares ($0.01 par value; 1,024,318 and nil shares authorized, issued and outstanding as of March 31, 2014 and 2015, respectively, liquidation value of and $1,382 and nil as of March 31, 2014and 2015, respectively) — Series D1 convertible redeemable participating preferred shares ($0.01 par value; 3,488,864 and nil shares authorized, issued and outstanding as of March 31, 2014 and 2015, respectively, liquidation value of $10,083 and nil as of March 31, 2014 and 2015, respectively) — Series D2 convertible redeemable participating preferred shares ($0.01 par value; 2,072,624 and nil shares authorized, issued and outstanding as of March 31, 2014 and 2015, respectively, liquidation value of $2,798 and nil as of March 31, 2014 and 2015, respectively) — Series E convertible redeemable participating preferred shares ($0.01 par value; 4,289,457 and nil shares authorized, issued and outstanding as of March 31, 2014 and 2015, respectively, liquidation value of $22,056 and nil as of March 31, 2014 and 2015, respectively) — Series F convertible redeemable participating preferred shares ($0.01 par value; 7,204,680 and nil shares authorized, issued and outstanding as of March 31, 2014 and 2015, respectively, liquidation value of $93,639 and nil as of March 31, 2014 and 2015, respectively) — Equity: Class A common shares ($0.01 par value; 37,648,485 shares authorized as of March 31, 2014 and 2015, respectively, 4,599,674 and 33,556,439 issued and outstanding as of March 31, 2014 and 2015, respectively) Class B common shares ($0.01 par value; 1,570,000 shares authorized as of March 31, 2014 and 2015, 1,570,000 and nil issued and outstanding as of March 31, 2014 and 2015, respectively) — Class C common shares ($0.01 par value; nil and 2,000,000 shares authorized as of March 31, 2014 and 2015, respectively, nil and 805,100 shares issued and outstanding as of March 31, 2014 and 2015, respectively) — Additional paid-in capital Accumulated deficit ) ) Accumulated other comprehensive income Total iKang Healthcare Group, Inc.’s deficit/(equity) ) TOTAL LIABILITIES, MEZZANINE EQUITY AND EQUITY $ $ CONDENSED STATEMENTS OF OPERATIONS (In thousands of U.S. dollars, except share and per share data) Years ended March 31 2013 2014 2015 Operating expenses: Selling and marketing expenses $ — $ — $ General and administrative expenses Total operating expenses Loss from operations ) ) ) Interest income — Interest expense ) ) — Equity in earnings of subsidiaries and VIE entities Income before provision for income taxes Income tax expenses — — — Net income $ $ $ CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (In thousands of US dollars, except share data and per share data) For the years ended March 31, 2013 2014 2015 Net income $ $ $ Other comprehensive income: Other comprehensive income, foreign currency translation adjustment ) Comprehensive income attributable to iKang Healthcare Group, Inc. $ $ $ CONDENSED STATEMENTS OF SHAREHOLDERS’ EQUITY (DEFICIT) (In thousands of US dollars, except share data and per share data) Common Accumulated other Total Comprehensive Additional Accumulated comprehensive shareholders’ Shares Amount paid-in capital deficit income equity/(deficit) Balance at March 31, 2012 $ $ $ ) $ $ ) Share-based compensation expenses — — — — Redesignation to Series F Series F convertible redeemable participating preferred shares ) ) ) — — ) Deemed dividend on convertible redeemable preferred shares - accretion of redemption premium — — — ) — ) Net income — — — — Foreign currency translation adjustment — — — — Balance at March 31, 2013 $ $ $ ) $ $ ) Share-based compensation expenses — — — — iKang Healthcare Group, Inc. one common share of $0.01 entered into a share swap agreement — — — — — Redesignation to Series F Series F convertible redeemable participating preferred shares ) ) ) — — ) Addition of non-controlling interest in connection with acquisition of Shanghai iKang Jianwei Health Management Co., Ltd. — — — ) — ) Purchase of non-controlling interest of Shanghai iKang Guobin Blue Cross Clinic, Co. Ltd. — — ) — — ) Deemed dividend on convertible redeemable preferred shares - accretion of redemption premium — — — ) — ) Net income — — — — Foreign currency translation adjustment — — — — ) ) Balance at March 31, 2014 $ $ $ ) $ $ ) Share-based compensation expenses — — Conversion of participating convertible redeemable preferred shares to common shares — — Issuance of common shares upon initial public offering, net of offering costs of $2,882 — — Issuance of common shares upon Green Shoe — — Issuance of common shares in connection with exercise of options — — Issuance of ordinary shares in connection with share-based compensation arrangements — — — Capital contribution of non-controlling interest holder of Shanghai Jianwei Management — — ) — — ) Capital contribution of non-controlling interest holder of WA Health Care — — ) — — ) Net income — — — — Foreign currency translation adjustment — — — — Balance at March 31, 2015 $ $ $ ) $ $ CONDENSED STATEMENTS OF CASH FLOWS (In thousands of US dollars, except share data and per share data) For the years ended March 31, 2013 2014 2015 CASH FLOWS FROM OPERATING ACTIVITIES: Net income $ $ $ Adjustments to reconcile net income to net cash provided by operating activities: Investment income from subsidiaries ) ) ) Stock-based compensation Changes in assets and liabilities: Prepaid expenses and other current assets ) ) Amount due from related parties ) ) ) Accrued expenses and other current liabilities ) ) Net cash generated from (used in) operating activities ) ) CASH FLOW FROM FINANCING ACTIVITIES: Loan provided to a related party — ) — Repayment of loan provided to a related party — — Payment for loan receivable — — ) Payments for business acquisitions — ) ) Net cash used in investing activities — ) ) CASH FLOW FROM FINANCING ACTIVITIES: Proceeds from issuance of convertible redeemable preferred shares — — Proceeds from convertible loan — — Repayment of convertible loan — ) — Proceeds from exercise of share options — — Proceeds from issuance of common shares upon initial public offering — — Proceeds from issuance of common shares upon Green Shoe — — Payment of initial public offering expenses — — ) Payment for business acquisitions — — ) Proceeds from issuance of convertible redeemable preferred shares — — Proceeds from redesignation of Class A common shares — — Proceeds from redesignation of convertible redeemable preferred shares — — Payment for convertible preferred shares transaction professional fees — ) — Net cash provided by financing activities Net increase/(decrease) in cash and cash equivalents ) CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR CASH AND CASH EQUIVALENTS AT END OF THE YEAR $ $ $ ADDITIONAL INFORMATION-FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY NOTES TO THE FINANCIAL STATEMENTS 1. BASIS FOR PREPARATION The condensed financial information of the Parent Company has been prepared using the same accounting policies as set out in the Group’s consolidated financial statement except that the Parent Company used the equity method to account for investments in its subsidiaries and VIE entities. The condensed financial information is provided since the restricted net assets of the Group’s subsidiaries and VIE entities were over the 25% of the consolidated net assets of the Group as of March 31, 2015. 2. INVESTMENTS IN SUBSIDIARIES The Parent Company, its subsidiaries and VIE entities were included in the consolidated financial statements where inter-company balances and transactions were eliminated upon consolidation. For the purpose of the Parent Company’s stand-alone financial information, its investments in subsidiaries and VIE entities are reported using the equity method of accounting. The Parent Company’s share of income (loss) from its subsidiaries and VIE entities were reported as share of income (loss) of subsidiaries and VIE entities in the accompanying Parent Company’s financial information.

SUMMARY OF SIGNIFICANT ACCOUN37

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Mar. 31, 2015
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of presentation	Basis of presentation The consolidated financial statements of the Group have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”).
Basis of consolidation	Basis of consolidation The consolidated financial statements of the Group include the financial statements of iKang Guobin Healthcare Group Inc., its subsidiaries, its VIEs and its VIEs’ subsidiaries. All inter-company transactions and balances have been eliminated upon consolidation.
Use of estimates	Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and revenues, costs and expenses in the financial statements and accompanying notes. Significant accounting estimates reflected in the Group’s consolidated financial statements include revenue recognition, allowance for doubtful accounts, the useful lives and impairment of property and equipment, the useful lives and impairment of intangible assets, impairment of goodwill, valuation allowance for deferred tax assets, share-based compensation and fair value of the common shares, convertible redeemable preferred shares and forward contracts.
Cash and cash equivalents	Cash and cash equivalents Cash and cash equivalents consist of cash on hand and demand deposits, which are unrestricted as to withdrawal and use, and which have maturities of three months or less when purchased.
Restricted cash	Restricted cash Restricted cash mainly consists of the cash deposit denominated in U.S. dollar in overseas accounts used to collateralize the locally borrowings in China to meet Group’s RMB funding needs, which is primarily to purchase property and equipment within China.
Term deposits	Term deposits Term deposits consist of deposits placed with financial institutions with original maturity terms of greater than three months but less than one year.
Accounts receivable and allowance for doubtful accounts	Accounts receivable and allowance for doubtful accounts Accounts receivable represents those receivables derived in the ordinary course of business. A general allowance for doubtful accounts is provided based on aging analyses of accounts receivable balances, historical bad debt rates, in addition to specific provisions established based on customers’ repayment patterns and customer credit worthiness.
Financial instruments	Financial instruments Financial instruments of the Group primarily consist of cash and cash equivalents, restricted cash, term deposits, accounts receivable, forward contracts, equity method investment, cost method investment, amount due from related parties, accounts payable, amount due to related parties, short-term borrowing and long-term borrowing. The carrying values of cash and cash equivalents, restricted cash, term deposits, accounts receivable, accounts payable, amounts due from related parties, and short-term borrowings approximate their fair values due to short-term maturities. For amounts due to related parties, they are carried at amortized cost using effective interest method.
Effective interest method	Effective interest method The effective interest method is a method of calculating the amortized cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the financial liability, or, where appropriate, a shorter period, to the net carrying amount on initial recognition. Interest expense is recognized on an effective interest basis.
Fair value measurements	Fair value measurements Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Group considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability. Authoritative literature provides a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. An asset or liability categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement as follows: · Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. · Level 2 applies to assets or liabilities for which there are inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data. · Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. The Group measures certain assets, including long-term investments and intangible assets, at fair value on a nonrecurring basis when they are deemed to be impaired. The fair values of intangible assets are determined based on valuation techniques using the best information available, and may include management judgments, future performance projections, etc. An impairment charge to the intangible assets is recorded when their carrying amounts may not be recoverable. Fair value of financial instruments is discussed in Note 18.
Significant risks and uncertainties	Significant risks and uncertainties The Group operates in an industry with rapid changes in regulations, customer demand and competition and believes that changes in any of the following areas could have a material adverse effect on the Group’s future financial position, results of operations, or cash flows: advances and trends in healthcare industry standards, changes in certain strategic relationships or customer relationships, regulatory or other PRC related factors, risks associated with the Group’s ability to keep and increase the customer base, and risks surrounding pending litigations.
Foreign currency risk	Foreign currency risk The Renminbi (“RMB”) is not a freely convertible currency. The State Administration for Foreign Exchange, under the authority of the People’s Bank of China, controls the conversion of RMB into foreign currencies. The value of the RMB is subject to changes in central government policies and to international economic and political developments affecting supply and demand in the China Foreign Exchange Trading System market. Cash and cash equivalents of the Group included aggregate amounts of $15,853 and $30,172 at March 31, 2014 and 2015, respectively, which were denominated in RMB.
Concentration of credit risk	Concentration of credit risk Financial instruments that potentially expose the Group to concentration of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Group places their cash with financial institutions with high-credit ratings and quality. The Group conducts credit evaluations of customers and generally do not require collateral or other security from their customers. No customer accounted for 10% or more of total revenues for the years ended March 31, 2013, 2014 and 2015. No customer accounted for 10% or more of accounts receivable as of March 31, 2014 and 2015.
Inventories	Inventories Inventories are medical consumables and are stated at the lower of cost or market value. Inventories are written down for obsolescence to net realizable value based upon estimates of future demand and expiration date of inventories. The Group did not record a write-down of inventories for the years ended March 31, 2013, 2014 and 2015.
Equity method investment	Equity method investment The investee company over which the Group has the ability to exercise significant influence, but does not have a controlling interest, is accounted for using the equity method. Significant influence is generally considered to exist when the Group has an ownership interest in the voting stock of the investee between 20% and 50%, and other factors, such as representation in the investee’s Board of Directors, voting rights and the impact of commercial arrangements, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the affiliated company’s accounts are not reflected within the Group’s consolidated balance sheets and statements of operations; however, the Group’s share of the earnings or losses of the affiliated company is reflected in the caption “loss/(gain) from equity method investment” in the consolidated statements of operations. An impairment charge is recorded if the carrying amount of the investment exceeds its fair value and this condition is determined to be other-than temporary. The Group estimated the fair value of the investee company based on comparable quoted price for similar investment in active market, if applicable, or discounted cash flow approach which requires significant judgments, including the estimation of future cash flows, which is dependent on internal forecasts, the estimation of long term growth rate of a company’s business, the estimation of the useful life over which cash flows will occur, and the determination of the weighted average cost of capital. The Company did not record impairment losses on its equity method investment during the years ended March 31, 2013, 2014 and 2015.
Property and equipment, net	Property and equipment, net Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation and amortization are calculated on a straight-line basis over the following estimated useful lives: Computer equipment and application software 5 years Furniture and fixture 5 years Medical equipment 10 years Motor vehicles 5 years Leasehold improvement Shorter of useful life of the asset or the lease term Construction in progress represents unfinished leasehold improvement and installment of equipment for new clinics. Construction in progress will be transferred to leasehold improvement or property and equipment when it is finished. Depreciation is recorded at the time when assets are ready for the intended use.
Intangible assets, net	Intangible assets, net Intangible assets, other than goodwill, resulting from the acquisitions of entities accounted for using the purchase method of accounting are estimated by management based on the fair value of assets acquired. Identifiable intangible assets are carried at cost less accumulated amortization. Amortization of customer relationship is computed using the estimated attrition pattern of the acquired customers, and amortization of other finite-lived intangible assets is computed using the straight-line method over the following estimated average useful lives, which are as follows: Weighted average (years) range (years) Customer relationship 5.9 2.1~10.0 Non-compete agreement 3.0 2.0~3.0 Contract backlog 0.7 0.4~0.9 Operating license 2.9 0.3~5.0 Favorable lease contract 7.1 2.8~9.8 The weighted average estimated average useful life of the intangible assets with determinable lives is 5.6 years.
Intangible assets-indefinite lives	Intangible assets-indefinite lives If an intangible asset is determined to have an indefinite life, it should not be amortized until its useful life is determined to be no longer indefinite. An intangible asset that is not subject to amortization is tested for impairment at least annually or if events or changes in circumstances indicate that the asset might be impaired. Such impairment test consists of the fair values of assets with their carrying value amounts and an impairment loss is recognized if and when the carrying amounts exceed the fair values. The estimates of fair values of intangible assets not subject to amortization are determined using various discounted cash flow valuation methodologies. Significant assumptions are inherent in this process, including estimates of discount rates.
Impairment of long-lived assets and intangible assets with definite life	Impairment of long-lived assets and intangible assets with definite life Long-lived assets, such as property and equipment and definite-lived intangible assets are stated at cost less accumulated depreciation or amortization. Depreciation and amortization is computed principally using the straight-line method. The Group evaluates the recoverability of long-lived assets, including identifiable intangible assets, with determinable useful lives whenever events or changes in circumstances indicate that an intangible asset’s carrying amount may not be recoverable. The Group measures the carrying amount of long-lived assets against the estimated undiscounted future cash flows associated with it. Impairment exists when the sum of the expected future net cash flows is less than the carrying value of the asset being evaluated. Impairment loss is calculated as the amount by which the carrying value of the asset exceeds its fair value. Fair value is estimated based on various valuation techniques, including the discounted value of estimated future cash flows. The evaluation of asset impairment requires the Group to make assumptions about future cash flows over the life of the asset being evaluated. These assumptions require significant judgment and actual results may differ from assumed and estimated amounts.
Goodwill	Goodwill Goodwill represents the excess of the fair value of consideration paid over the fair value of identifiable net assets acquired in business combinations. Goodwill and intangible assets deemed to have indefinite useful lives are not amortized, but tested for impairment annually or more frequently if events and circumstances indicate that they might be impaired. Goodwill is tested for impairment at the reporting unit level on an annual basis (March 31 for the Group) and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. These events or circumstances could include a significant change in the stock prices, business climate, legal factors, operating performance indicators, competition, or sale or disposition of a significant portion of a reporting unit. In the evaluation of the goodwill for impairment, the Group may first assess qualitative factors to determine whether it is “more likely than not” that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. If it is more likely than not that the fair value of a reporting unit is less than its carrying amount, goodwill is then tested following a two-step process. The first step compares the fair value of each reporting unit to its carrying amount, including goodwill. If the fair value of each reporting unit exceeds its carrying amount, goodwill is not considered to be impaired and the second step will not be required. If the carrying amount of a reporting unit exceeds its fair value, the second step compares the implied fair value of goodwill to the carrying value of a reporting unit’s goodwill. The implied fair value of goodwill is determined in a manner similar to accounting for a business combination with the allocation of the assessed fair value determined in the first step to the assets and liabilities of the reporting unit. The excess of the fair value of the reporting unit over the amounts assigned to the assets and liabilities is the implied fair value of goodwill. An impairment loss is recognized for any excess in the carrying value of goodwill over the implied fair value of goodwill. Application of the goodwill impairment test requires judgment, including the identification of reporting units, assignment of assets and liabilities to reporting units, assignment of goodwill to reporting units, and determination of the fair value of each reporting unit. The estimation of fair value of each reporting unit using a discounted cash flow methodology also requires significant judgments, including estimation of future cash flows, which is dependent on internal forecasts, estimation of the long-term rate of growth for the Group’s business, estimation of the useful life over which cash flows will occur, and determination of the Group’s weighted average cost of capital. The estimates used to calculate the fair value of a reporting unit change from year to year based on operating results and market conditions. Changes in these estimates and assumptions could materially affect the determination of fair value and goodwill impairment for the reporting unit. The Group did not incur any impairment loss on goodwill for the years ended March 31, 2013, 2014 and 2015.
Cost method investment	Cost method investment For investment over which the Group does not have significant influence, the Group carries the investments at cost. The Group reviews the cost method investment for impairment whenever events or circumstances indicate that an other-than-temporary decline has occurred. The Group considers available quantitative and qualitative evidence in evaluating potential impairment of its cost method investment. If the cost of an investment exceeds the investment’s fair value, the Group considers, among other factors, general market conditions, government economic plans, the duration and the extent to which the fair value of the investment is less than the cost, and the Group’s intent and ability to hold the investment.
Revenue recognition	Revenue recognition Revenue is stated net of business tax. The Group’s PRC subsidiaries and VIE entities are subject to a 5% business tax and related surcharges on the revenues earned from providing services and selling products in the PRC. Certain contracts under specific formalities are exempted from business tax in accordance with the PRC tax laws. The Group recognized $1,576, $2,084, and $2,156 business tax for the years ended March 31, 2013, 2014 and 2015, respectively. The Group recognizes revenues when persuasive evidence of an arrangement exists, service has been provided, the sales price is fixed or determinable, and collectability is reasonably assured. The Group offers medical examination and disease screening services and renders such services at the request of its customers. The Group recognizes revenues when the examination reports are issued and passed to the local couriers if hard copy reports are required by its customers, or when the examination reports are uploaded on line and can be viewed by the customers on line if hard copy reports are not required. The Group notifies its customers when their examination reports are delivered to the local couriers or ready to be viewed and downloaded on line. For individual customers, fees are collected before the performance of the services while corporate customers prepay a portion of service fees upon signing of the master contract, which is recognized as deferred revenue by the Group. All fees for services rendered are first charged against the corporate customer’s deferred revenues until it is entirely exhausted before the Group starts to invoice the corporate customers. The Group records accounts receivables from its corporate customers when the examination reports of the employees of corporate customers have been delivered or uploaded on line but the Group has not received remaining payments from the corporate customers. Sometimes the Group engages third-party providers to provide medical examination and disease screening services on behalf of the Group. The Group evaluates the services provided by third parties on behalf of the Group to determine whether to recognize the revenues on a gross or net basis. The determination is based upon an assessment as to whether the Group acts as a principal or agent when providing the services. All of the revenues involving third-party providers providing medical examination or disease screening services on behalf of the Group are currently accounted for on a gross basis since the Group is the primary obligor, has the latitude in establishing prices, discretion in third-party provider selection and the credit risks. The Group also provides packages of bundled services principally comprising combinations of medical examination, disease screening, health consultation and medical concierge services to its corporate customers, which normally expire within one year from the date of purchase and does not include right of return. The Group allocates revenues from the sale of bundled services to each component using the relative selling price of each component based on the Group’s best estimate. Revenue recognition criteria for components included in the bundled services is identical to as if the components are sold on a standalone basis. The Group recognizes revenue from dental services when the service is rendered and the service fee is collectable.
Value added tax ("VAT")	Value added tax (“VAT”) In July 2012, the Ministry of Finance and the State Administration of Taxation jointly issued a circular regarding the pilot collection of VAT in lieu of business tax in certain areas and industries in the PRC. Such VAT pilot program were phased in Beijing, Jiangsu, Anhui, Fujian, Guangdong, Tianjin, Zhejiang, and Hubei between September and December 2012. Starting from September 1, 2012, certain subsidiaries became subject to VAT at the rate of 3% on certain service revenues which were previously subject to business tax.
Non-monetary exchange	Non-monetary exchange The Group occasionally exchanges medical examination services with advertising agencies for advertising credits. The amount of deferred revenues and prepaid expenses is based on the fair value of the medical examination services surrendered which approximates the price the Group offers to the individual customers and is more readily determinable. The amounts of revenues recognized for non-monetary transactions were $972, $706 and $571 for the years ended March 31, 2013, 2014 and 2015, respectively. Direct costs attributable to the revenues have been immaterial.
Cost of revenues	Cost of revenues Cost of revenues consist of expenditures incurred in the generation of the Group’s revenues, includes but not limited to salaries and welfare paid to physicians, nurses, purchase of medical consumables, depreciation and amortization, rental, and fees paid to third-party service providers.
Research and development expenses	Research and development expenses Research and development expenses primarily consist of (i) salaries and benefits for research and development personnel, and (ii) office rental, general expenses and depreciation and amortization expenses associated with the research and development activities. The Group’s research and development activities primarily consist of the research and development of its information technology platform. Research and development expenses are expensed when incurred.
Income taxes	Income taxes Current income taxes are provided for in accordance with the laws of the relevant tax authorities. Deferred income taxes are recognized when temporary differences exist between the tax bases of assets and liabilities and their reported amounts in the consolidated financial statements. Net operating loss carry forwards and credits are applied using enacted statutory tax rates applicable to future years. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more-likely-than-not that a portion of or all of the deferred tax assets will not be realized. The components of the deferred tax assets and liabilities are individually classified as current and non-current based on their characteristics. The impact of an uncertain income tax position on the income tax return is recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant tax authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Interest and penalties on income taxes will be classified as a component of the provisions for income taxes. The Group did not recognize any income tax due to uncertain tax position or incur any interest and penalties related to potential underpaid income tax expenses for the years ended March 31, 2013, 2014 or 2015, respectively.
Share-based compensation	Share-based compensation Share-based payment transactions with employees, such as share options are measured based on the grant date fair value of the equity instrument. The Group recognizes the compensation costs net of an estimated forfeiture rate using the graded vesting attribution method over the requisite service period of the award, which is generally the vesting period of the award. The estimate of forfeitures will be adjusted over the requisite service period to the extent that actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of change and will also impact the amount of share compensation expense to be recognized in future periods. Share awards issued to non-employees, such as advisors, are measured at fair value at the earlier of the commitment date or the date the service is completed and recognized over the period the service is provided.
Earnings (loss) per share	Earnings (loss) per share Basic earnings (loss) per common share is computed by dividing net income (loss) attributable to common shareholders by the weighted average number of common shares outstanding during the period. The Group’s convertible redeemable preferred shares are participating securities as they participate in undistributed earnings on an as-if-converted basis. Accordingly, the Group uses the two-class method whereby undistributed net income is allocated on a pro rata basis to the common shares and preferred shares to the extent that each class may share in income for the period; whereas the undistributed net loss for the period is allocated to common shares only because preferred shares are not contractually obligated to share the loss. Diluted earnings per common share reflect the potential dilution that could occur if securities were exercised or converted into common shares. The Group had convertible redeemable preferred shares, and stock options, which could potentially dilute basic earnings per share. To calculate the number of shares for diluted income per share, the effect of the convertible redeemable preferred shares is computed using the as-if-converted method; the effect of the stock options is computed using the treasury stock method.
Foreign currency translation	Foreign currency translation The functional and reporting currency of the Company is the United States dollar (“U.S. dollar”). The financial records of the Group’s subsidiaries and VIE entities located in the PRC are maintained in their local currencies, the RMB, which are also the functional currencies of these entities. Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency at the rates of exchange ruling at the balance sheet date. Transactions in currencies other than the functional currency during the year are converted into functional currency at the applicable rates of exchange prevailing when the transactions occurred. Transaction gains and losses are recognized in the statement of operations. The Group’s entities with functional currency of RMB translate their operating results and financial positions into the U.S. dollar, the Group’s reporting currency. Assets and liabilities are translated using the exchange rates in effect on the balance sheet date. Revenues, expenses, gains and losses are translated using the average rate for the year. Translation adjustments are reported as cumulative translation adjustments and are shown as a separate component of other comprehensive income.
Comprehensive income	Comprehensive income Comprehensive income includes net income and cumulative foreign currency translation adjustments and is reported in the statement of shareholder’s equity (deficit).
Operating leases	Operating leases Leases where the rewards and risks of ownership of assets primarily remain with the lessor are accounted for as operating leases. Payments made under operating leases are charged to the consolidated statements of operations on a straight-line basis over the lease periods.
Recently issued accounting pronouncements adopted and not yet adopted	Newly adopted accounting pronouncements In July 2013, the FASB issued a pronouncement which provides guidance on financial statement presentation of an unrecognized tax benefits when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The FASB’s objective in issuing this ASU is to eliminate diversity in practice resulting from a lack of guidance on this topic in current U.S. GAAP. The amendments in this ASU state that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except as follows. To the extent a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. This ASU applies to all entities that have unrecognized tax benefits when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists at the reporting date. The amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. Early adoption is permitted. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date. Retrospective application is permitted. The adoption of this guidance did not have a significant effect on the Group’s consolidated financial statements. Recently issued accounting pronouncements not yet adopted In May 2014, the Financial Accounting Standards Board (“FASB”) issued a new pronouncement which affects any entity using U.S. GAAP that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). This Accounting Standards Update (“ASU”) will supersede the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance. This ASU also supersedes some cost guidance included in Subtopic 605-35, Revenue Recognition—Construction-Type and Production-Type Contracts. In addition, the existing requirements for the recognition of a gain or loss on the transfer of nonfinancial assets that are not in a contract with a customer (e.g., assets within the scope of Topic 360, Property, Plant, and Equipment, and intangible assets within the scope of Topic 350, Intangibles—Goodwill and Other) are amended to be consistent with the guidance on recognition and measurement (including the constraint on revenue) in this ASU. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. For a public entity, the amendments in this ASU are effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early application will be permitted. An entity should apply the amendments in this ASU using one of the following two methods: 1. Retrospectively to each prior reporting period presented and the entity may elect any of the following practical expedients: · For completed contracts, an entity need not restate contracts that begin and end within the same annual reporting period. · For completed contracts that have variable consideration, an entity may use the transaction price at the date the contract was completed rather than estimating variable consideration amounts in the comparative reporting periods. · For all reporting periods presented before the date of initial application, an entity need not disclose the amount of the transaction price allocated to remaining performance obligations and an explanation of when the entity expects to recognize that amount as revenue. 2. Retrospectively with the cumulative effect of initially applying this ASU recognized at the date of initial application. If an entity elects this transition method it also should provide the additional disclosures in reporting periods that include the date of initial application of: The amount by which each financial statement line item is affected in the current reporting period by the application of this ASU as compared to the guidance that was in effect before the change. An explanation of the reasons for significant changes. The Group is in the process of evaluating the impact of this pronouncement to its consolidated financial statements. In June 2014, the FASB issued a new pronouncement which requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Topic 718, Compensation—Stock Compensation, as it relates to awards with performance conditions that affect vesting to account for such awards. The performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The total amount of compensation cost recognized during and after the requisite service period should reflect the number of awards that are expected to vest and should be adjusted to reflect those awards that ultimately vest. The requisite service period ends when the employee can cease rendering service and still be eligible to vest in the award if the performance target is achieved. The amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted. Entities may apply the amendments in this ASU either: (a) prospectively to all awards granted or modified after the effective date; or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. If retrospective transition is adopted, the cumulative effect of applying this ASU as of the beginning of the earliest annual period presented in the financial statements should be recognized as an adjustment to the opening retained earnings balance at that date. In addition, if retrospective transition is adopted, an entity may use hindsight in measuring and recognizing the compensation cost. The Group does not expect the adoption of this pronouncement will have a significant effect on its consolidated financial position or results of operations. In February 2015, the FASB issued a new pronouncement which is intended to improve targeted areas of consolidation guidance for legal entities such as limited partnerships, limited liability corporations, and securitization structures (collateralized debt obligations, collateralized loan obligations, and mortgage-backed security transactions). The ASU focuses on the consolidation evaluation for reporting organizations (public and private companies and not-for-profit organizations) that are required to evaluate whether they should consolidate certain legal entities. In addition to reducing the number of consolidation models from four to two, the new standard simplifies the FASB Accounting Standards Codification (“Codification”) and improves current GAAP by: · Placing more emphasis on risk of loss when determining a controlling financial interest. A reporting organization may no longer have to consolidate a legal entity in certain circumstances based solely on its fee arrangement, when certain criteria are met. · Reducing the frequency of the application of related-party guidance when determining a controlling financial interest in a variable interest entity (VIE). · Changing consolidation conclusions for public and private companies in several industries that typically make use of limited partnerships or VIEs. The ASU will be effective for periods beginning after December 15, 2015, for public companies. Early adoption is permitted, including adoption in an interim period. The Group does not expect the adoption of this pronouncement will have a significant effect on its consolidated financial position or results of operations. In April 2015, the FASB issued a new pronouncement which changes the presentation of debt issuance costs in financial statements. Under the ASU, an entity presents such costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. Amortization of the costs is reported as interest expense. The ASU specifies that “debt issuance costs related to a note shall be reported in the balance sheet as a direct deduction from the face amount of that note” and that “amortization of debt issuance costs also shall be reported as interest expense.” The ASU’s Basis for Conclusions observes that in practice, debt issuance costs incurred before the associated funding is received (i.e., before the issuance of the debt liability) are deferred on the balance sheet until that debt liability amount is recorded. The amendments do not affect the current guidance on the recognition and measurement of debt issuance costs. For example, the costs of issuing convertible debt would not change the calculation of the intrinsic value of an embedded conversion option that represents a beneficial conversion feature under ASC 470-20-30-13. Thus, entities may still need to track debt issuance costs separately from a debt discount. For public business entities, the amendments are effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. Earlier adoption is permitted. The amendments should be applied on a retrospective basis, wherein the balance sheet of each individual period presented should be adjusted to reflect the period-specific effects of applying the new guidance. Upon transition, an entity is required to comply with the applicable disclosures for a change in an accounting principle. These disclosures include the nature of and reason for the change in accounting principle, the transition method, a description of the prior-period information that has been retrospectively adjusted, and the effect of the change on the financial statement line items (i.e., debt issuance cost asset and the debt liability). The Group does not expect the adoption of this pronouncement will have a significant effect on its consolidated financial position or results of operations. In May 2015, the FASB issued a pronouncement which provides amendments on the disclosure for fair value measured investments in certain entities that calculate net asset value per share (or its equivalent). The amendments remove the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using the net asset value per share practical expedient. The amendments also remove the requirement to make certain disclosures for all investments that are eligible to be measured at fair value using the net asset value per share practical expedient. Rather, those disclosures are limited to investments for which the entity has elected to measure the fair value using that practical expedient. The amendments apply to reporting entities that elect to measure the fair value of an investment within the scope of paragraphs 820-10-15-4 through 15-5 using the net asset value per share (or its equivalent) practical expedient in paragraph 820-10-35-59. The amendments are effective for public business entities for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. For all other entities, the amendments in this Update are effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. A reporting entity should apply the amendments retrospectively to all periods presented. The retrospective approach requires that an investment for which fair value is measured using the net asset value per share practical expedient be removed from the fair value hierarchy in all periods presented in an entity’s financial statements. Earlier application is permitted. The Group does not expect the adoption of this pronouncement will have a significant effect on its consolidated financial position or results of operations.

ORGANIZATION AND PRINCIPAL AC38

ORGANIZATION AND PRINCIPAL ACTIVITIES (Table)	12 Months Ended
	Mar. 31, 2015
ORGANIZATION AND PRINCIPAL ACTIVITIES
Schedule of details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries	As of March 31, 2015, details of the Group’s subsidiaries, VIEs and the VIEs’ subsidiaries were as follows: Percentage of Later date of beneficial interest incorporation/ Place of by iKang Names acquisition incorporation Healthcare Group, Inc. Principal activities Subsidiaries: iKang Guobin Healthcare Group, Inc.(“iKang Guobin”) December 24, 2003 BVI % Holding company ShanghaiMed iKang, Inc. (“Beijing iKang”) February 27, 2004 PRC % Sales of healthcare service Shanghai iKang Co., Ltd. (“Shanghai iKang”) December 27, 2004 PRC % Sales of healthcare service iKang Zhejiang, Inc. (“iKang Zhejiang BVI”) April 5, 2006 BVI % Holding company iKang HealthManagement (Zhejiang) Co., Ltd. (“Zhejiang iKang”) July 11, 2006 PRC % Sales of healthcare service Bayley & Jackson (China) Medical Services Limited (“Bayley & Jackson (Hong Kong)”) October 10, 2006 Hong Kong % Holding company Beijing Bayley & Jackson Clinic Co., Ltd. (“iKang Beijing Ritan”) October 10, 2006 PRC % Medical examinations & clinical services Yuanhua Healthcare Limited (“Yuanhua HK”) July 31, 2013 Hong Kong % Holding company MediFast (Hong Kong) Limited (“MediFast”) January 14, 2014 Hong Kong % Medical examinations & clinical services Yuanhua Medical Consultancy Services (Shanghai) Co., Ltd. (“Yuanhua WFOE”) July 31, 2013 PRC % Sales of healthcare service WA Centers HK Limited (“WA Health Care “) March 3, 2015 Hong Kong % Holding company iKang(Shanghai) Financing Lease Co., Ltd. (“iKang(Shanghai) Financing Lease”) December 19, 2014 PRC % Lease services VIEs: iKang Healthcare Technology Group Co., Ltd. (formerly named as “Shanghai iKang Guobin Holding Co., Ltd.”) (“iKang Holding”) April 27, 2007 PRC % Holding company Hangzhou iKang Guobin Clinic Co., Ltd. (“iKang Hangzhou Xixi”) September 26, 2010 PRC % Medical examinations Shanghai Yuanhua Information Technology Co., Ltd. (“Yuanhua Information”) July 31, 2013 PRC % Holding company Jiandatong Health Technology (Beijing) Co., Ltd. (“Beijing Jiandatong”) April 1, 2013 PRC % Sales of healthcare service VIEs’ subsidiaries: iKang Guobin Healthcare Group Co., Ltd. (formerly named as “Beijing iKang Online Technology Co., Ltd.”) (“iKang Online”) September 13, 2004 PRC % Sales of healthcare service Beijing iKang Medical Examination APP Co., Ltd. (formerly named as “Beijing iKang Guobin Health Technology Co., Ltd.”) (“iKang Technology”) February 3, 2005 PRC % Sales of healthcare service Shenzhen iKang Co., Ltd. (“Shenzhen iKang”) July 12, 2006 PRC % Sales of healthcare service Shanghai Yalong Daoyi Services Co., Ltd. (“Yalong Daoyi”) December 20, 2006 PRC % Sales of healthcare service Guangzhou iKang Guobin Health Examination Co., Ltd. (“iKang Guangzhou Huanshi East/Tianhe”) April 27, 2007 PRC % Medical examinations Shanghai Guobin Medical Center Co., Ltd. (“iKang Shanghai Xikang Road”) April 27, 2007 PRC % Medical examinations & clinical services Shanghai Wangzu Guobin Medical Center Co., Ltd. (“iKang Shanghai Gubei”) April 27, 2007 PRC % Medical examinations Shanghai iKang Guobin Mingmen Clinic Co., Ltd. (“iKang Shanghai Pudong Avenue”) April 27, 2007 PRC % Medical examinations Shenzhen iKang Guobin Hospital Management Co., Ltd. (“Shenzhen Hospital Management”) September 10, 2007 PRC % Holding company Shenzhen iKang Guobin Puji Clinic Co., Ltd. (formerly named as “Shenzhen Puji Clinic”) (“iKang Shenzhen Nanshan”) September 10, 2007 PRC % Medical examinations & clinical services Beijing iKang Guobin Lidu Clinic Co., Ltd. (“iKang Beijing Lidu”) December 3, 2007 PRC % Medical examinations Nanjing Joycome Clinic Co., Ltd. (“iKang Nanjing Xinjiekou”) January 10, 2008 PRC % Medical examinations Shenzhen iKang Guobin Clinic Co., Ltd. (formerly named as “Shenzhen iKang Guobin Clinic”) (“iKang Shenzhen Luohu”) March 25, 2008 PRC % Medical examinations Beijing iKang Guobin Jianwai Clinic Co., Ltd. (“iKang Beijing Jianguomen”) September 9, 2008 PRC % Medical examinations Beijing iKang Guobin Zhongguan Clinic Co., Ltd. (“iKang Beijing Zhongguancun”) September 19, 2008 PRC % Medical examinations Beijing iKang Guobin Zhengqingyuan Clinic Co., Ltd. (“iKang Beijing Kunming Lake”) December 1, 2008 PRC % Medical examinations Beijing iKang Guobin Jiuxianqiao Clinic Co., Ltd. (“iKang Beijing Yansha East”) December 1, 2008 PRC % Medical examinations Shanghai iKang Guobin Renren Clinic Co., Ltd. (“iKang Shanghai Yangpu”) December 9, 2008 PRC % Medical examinations Chengdu iKang Guobin Health Examination Hospital Co., Ltd. (“iKang Chengdu Waishuangnan”) January 15, 2009 PRC % Medical examinations Shanghai iKang Guobin Blue Cross Clinic Co., Ltd. (“iKang Shanghai Lujiazui”) January 28, 2010 PRC % Medical examinations Shanghai Wenzhong Clinic Co., Ltd. (“Shanghai Wenzhong”) February 12, 2010 PRC % Medical examinations Beijing iKang Guobin Clinic Co., Ltd. (“iKang Beijing Xuanwumen”) August 5, 2010 PRC % Medical examinations Nanjing iKang Guobin Clinic Co., Ltd. (“iKang Nanjing Gulou”) January 19, 2011 PRC % Medical examinations Shenzhen Xinglin Clinic Co., Ltd. (formerly named as “Shenzhen Xinglin Clinic”) (“iKang Shenzhen Futian”) January 25, 2011 PRC % Medical examinations Fujian iKang Guobin Health Management Co., Ltd. (“Fujian iKang”) April 1, 2011 PRC % Sales of healthcare service Fuzhou iKang Guobin General Clinic Co., Ltd. (“iKang Fuzhou Gulou”) November 14, 2011 PRC % Medical examinations Beijing iKang Guobin Xinei Clinic Co., Ltd. (“iKang Beijing Xinei”) January 30, 2012 PRC % Medical examinations Shanghai iKang Guobin Fukang Clinic Co., Ltd. (“Yan’an West Road”) January 18, 2012 PRC % Medical examinations Shanghai iKang Guobin Zhonghuan Yipin Clinic Co., Ltd. (formerly named as “Shanghai Zhonghuan Yipin Clinic Co., Ltd.”) (“iKang Shanghai Zhonghuan”) January 21, 2012 PRC % Medical examinations Shanghai iKang Guobin Yipin Clinic Co., Ltd. (formerly named as “Shanghai Yipin Clinic Co., Ltd.”) (“iKang Shanghai Jing’an”) January 21, 2012 PRC % Medical examinations Shanghai iKang Guobin Waizhitan Clinic Co., Ltd. (“iKang Shanghai Yan’an East Road”) May 29, 2012 PRC % Medical examinations Shanghai iKang Guobin Jianwei Clinic Co., Ltd. (formerly named as “Shanghai Jianwei Clinic Co., Ltd.”) (“iKang Shanghai Jianwei”) August 17, 2012 PRC % Medical examinations Hangzhou iKang Guobin Wenhui Clinic Co., Ltd. (“iKang Hangzhou Wenhui”) September 3, 2012 PRC % Medical examinations Tianjin Heping Aibin Clinic Co., Ltd. (“iKang Tianjin Heping”) October 15, 2012 PRC % Medical examinations Suzhou iKang Guobin Clinic Co., Ltd. (formerly named as “Suzhou Aibin Clinic, Co., Ltd.”) (“iKang Suzhou”) November 13, 2012 PRC % Medical examinations Changchun iKang Guobin Jiachang General Clinic Co., Ltd. (“iKang Changchun”) November 5, 2012 PRC % Medical examinations Chengdu Jinjiang iKang Guobin Hongzhaobi Health Examination General Clinic Co., Ltd. (“iKang Chengdu Jinjiang”) December 21, 2012 PRC % Medical examinations Chongqing Aibin Clinic Co., Ltd. (“iKang Chongqing”) December 18, 2012 PRC % Medical examinations Guangzhou Wokang Medical Clinic (“iKang Guangzhou Wokang”) December 3, 2012 PRC % Medical examinations Shenzhen iKang Guobin Kefa Clinic Co., Ltd. (formerly named as “Shenzhen iKang Guobin Kefa Clinic”) (“Shenzhen Kefa”) March 26, 2013 PRC % Medical examinations Shanghai iKang Jianwei Health Management Co., Ltd. (“Shanghai Jianwei Management”) September 6, 2013 PRC % Sales of healthcare services Shanghai Yuanhua Clinic Co., Ltd. (“Yuanhua Clinic”) July 31, 2013 PRC % Medical examinations Nanjing iKang Jun’an Clinic Co., Ltd., (“iKang Nanjing Aoyang “) September 1, 2013 PRC % Medical examinations Nanjing Aibin Health Information Consultancy Co., Ltd. (“Nanjing Aoyang Shunkang”) September 1, 2013 PRC % Sales of healthcare service Jiangyin iKang Guobin Clinic Co., Ltd. (“iKang Jiangyin”) December 16, 2013 PRC % Medical examinations Zhejiang Huzhou Ailikang Investment Management Co., Ltd. (“Zhejiang Ailikang”) December 31, 2013 PRC % Sales of healthcare services Hangzhou iKang Jun’an Clinic Co., Ltd. (formerly named as “Hangzhou Aibo Huagang Clinic Co. Ltd.”) (“Hangzhou Aibo”) December 31, 2013 PRC % Medical examinations Beijing iKang Jun’an Clinic Co., Ltd. (“iKang Beijing Jun’an”) November 28, 2013 PRC % Medical examinations & clinical services Beijing iKang Guobin Yayun Clinic Co., Ltd. (“iKang Beijing Yayun”) December 5, 2013 PRC % Medical examinations Changzhou iKang Guobin Clinic Co., Ltd. (“iKang Changzhou”) March 14, 2014 PRC % Medical examinations Beijing iKang Guobin Baishi Clinic Co., Ltd. (“iKang Beijing Baishi”) April 16, 2014 PRC % Medical examinations Chengdu Gaoxin iKang Guobin Chengnan Clinic Co., Ltd. (“Chengdu Gaoxin iKang West City”) May 22, 2014 PRC % Medical examinations iKang Dental Hospital Management Co., Ltd. (“iKang Dental Hospital Management”) August 13, 2014 PRC % Management of dental services Beijing iKang Guobin Wanzhishou Clinic Co., Ltd. (“iKang Beijing Wanzhishou”) August 21, 2014 PRC % Medical examinations Shanghai Huajian Health Examination Management Co., Ltd. (“Shanghai Huajian Management”) July 1, 2014 PRC % Medical examinations Shanghai Huajian Clinic Co., Ltd.(“Shanghai Huajian”) July 1, 2014 PRC % Medical examinations Shanghai Jinxiu Huajian Clinic Co., Ltd.(“Shanghai Jinxiu Huajian”) July 1, 2014 PRC % Medical examinations Shanghai Jinshen Huajian Clinic Co., Ltd.(“Shanghai Jinshen Huajian”) July 1, 2014 PRC % Medical examinations Shenyang iKang Guobin Hospital(“iKang Shenyang Hospital”) November 14, 2014 PRC % Medical examinations Shenyang iKang Guobin Ningshan Hospital Co., Ltd. (“iKang Shenyang Ningshan Hospital”) November 19, 2014 PRC % Medical examinations Shenyang Golden iKang Guobin Hospital Co., Ltd. (“Gold iKang Shenyang Hospital”) December 19, 2014 PRC % Medical examinations Tianjin Hedong District iKang Guobin Dongrun Clinic Co., Ltd. (“iKang Tianjin Hedong Dongrun”) February 17, 2015 PRC % Medical examinations Tianjin Hexi District iKang Guobin Fenghui Clinic Co., Ltd. (“iKang Tianjin Hexi Fenghui”) February 17, 2015 PRC % Medical examinations Wuxi Woshi Hongtai Biotechnology Co., Ltd. (“Wuxi Woshi Hongtai”) March 3, 2015 PRC % Holding company Beijing Woshi Hongtai Investment Management Consultancy Co., Ltd. (“Beijing Woshi Hongtai”) March 3, 2015 PRC % Sales of healthcare services Beijing Zhenjing Clinic Co., Ltd.(“Beijing Zhenjing”) March 3, 2015 PRC % Medical examinations & clinical services Shanghai Zhenjing Hospital Management Co., Ltd. (“Shanghai Zhenjing Hospital Management”) March 3, 2015 PRC % Sales of healthcare services Shanghai Zhenjing Clinic Co., Ltd. (“Shanghai Zhenjing”) March 3, 2015 PRC % Medical examinations & clinical services
Schedule of financial statements amounts and balances of the VIE entities, included in the accompanying consolidated financial statements (after inter-company elimination)	As of March 31, 2014 2015 Cash and cash equivalents $ $ Account receivable and other current assets Total current assets Property and equipment, net Acquired intangible assets, net Other noncurrent assets Total non-current assets Total assets Deferred revenues Account payable and other current liabilities Total current liabilities Total non-current liabilities Total liabilities $ $ For the years ended March 31, 2013 2014 2015 Net revenues $ $ $ Net income $ $ $ For the years ended March 31, 2013 2014 2015 Net cash provided by operating activities $ $ $ Net cash used in investing activities $ ) $ ) $ ) Net cash provided by financing activities $ $ $

SUMMARY OF SIGNIFICANT ACCOUN39

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Mar. 31, 2015
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Schedule of estimated useful lives of property and equipment	Computer equipment and application software 5 years Furniture and fixture 5 years Medical equipment 10 years Motor vehicles 5 years Leasehold improvement Shorter of useful life of the asset or the lease term
Schedule of estimated average useful lives of finite-lived intangible assets	Weighted average (years) range (years) Customer relationship 5.9 2.1~10.0 Non-compete agreement 3.0 2.0~3.0 Contract backlog 0.7 0.4~0.9 Operating license 2.9 0.3~5.0 Favorable lease contract 7.1 2.8~9.8

ACQUISITIONS (Tables)

ACQUISITIONS (Tables)	12 Months Ended
	Mar. 31, 2015
iKang Shanghai Jianwei
Acquisitions
Schedule of purchase price allocated to assets acquired and liabilities assumed as of the date of acquisition	Estimated useful lives Net tangible assets: Current assets $ Non-current assets Deferred tax assets Total Intangible assets acquired: Customer relationship 5.3 years Operating license 1.4 years Goodwill Deferred tax liability ) Total Total consideration $
iKang Changchun
Acquisitions
Schedule of purchase price allocated to assets acquired and liabilities assumed as of the date of acquisition	Estimated useful lives Net tangible assets: Current assets $ Non-current assets Total Intangible assets acquired: Customer relationship 6.1 years Favorable lease contract 5.1 years Operating license 2.5 years Goodwill Deferred tax liability ) Total Total consideration $
iKang Guangzhou Wokang
Acquisitions
Schedule of purchase price allocated to assets acquired and liabilities assumed as of the date of acquisition	Estimated useful lives Net tangible assets: Current assets $ Non-current assets Current liabilities ) Total Intangible assets acquired: Customer relationship 6.0 years Favorable lease contract 9.8 years Operating license 3.1 years Goodwill Deferred tax liability ) Total Total consideration $
Yuanhua
Acquisitions
Schedule of purchase price allocated to assets acquired and liabilities assumed as of the date of acquisition	Estimated useful lives Net tangible assets: Current assets $ Non-current assets Deferred tax assets Current liabilities ) Total Intangible assets acquired: Trade name Customer relationship 5.0-7.4 years Operating license 2.3 years Contract backlog 0.9 years Goodwill Deferred tax liability ) Total Total consideration $
Nanjing Aoyang
Acquisitions
Schedule of purchase price allocated to assets acquired and liabilities assumed as of the date of acquisition	Estimated useful life Net tangible assets: Current assets $ Non-current assets Total Intangible assets acquired: Operating license 1.3 years Goodwill Deferred tax liability ) Total Total consideration $
Zhejiang Ailikang
Acquisitions
Schedule of purchase price allocated to assets acquired and liabilities assumed as of the date of acquisition	Estimated useful lives Net tangible assets: Current assets $ Non-current assets Current liabilities ) Total ) Intangible assets acquired: Favorable lease contract 5.3 years Operating license 2.7 years Goodwill Deferred tax liability ) Total Total consideration $
MediFast
Acquisitions
Schedule of purchase price allocated to assets acquired and liabilities assumed as of the date of acquisition	Estimated useful lives Net tangible assets: Current assets $ Non-current assets Current liabilities ) Total ) Intangible assets acquired: Customer relationship 5.0-10.0 years Non-compete agreement 3.0 years Trade-name Indefinite Goodwill Deferred tax liability ) Total Non-controlling interest ) Total consideration $
Shanghai Huajian Management
Acquisitions
Schedule of purchase price allocated to assets acquired and liabilities assumed as of the date of acquisition	Estimated useful lives Net tangible assets: Current assets $ Non-current assets Current liabilities ) Total Estimated useful lives Intangible assets acquired: Customer relationship 5.5 years Trade name Indefinite Operating license 3.0 years Goodwill Deferred tax liability ) Total Total fair value of business acquired $
iKang Shenyang Hospital
Acquisitions
Schedule of purchase price allocated to assets acquired and liabilities assumed as of the date of acquisition	Estimated useful life Net tangible assets: Non-current assets $ Total Intangible assets acquired: Operating license 4.0 years Goodwill Deferred tax liability ) Total Total consideration $
iKang Shenyang Ningshan Hospital
Acquisitions
Schedule of purchase price allocated to assets acquired and liabilities assumed as of the date of acquisition	Estimated useful lives Net tangible assets: Non-current assets $ Total Intangible assets acquired: Favorable lease contract 2.8 years Operating license 5.0 years Goodwill Deferred tax liability ) Total Total consideration $
Gold iKang Shenyang Hospital
Acquisitions
Schedule of purchase price allocated to assets acquired and liabilities assumed as of the date of acquisition	Estimated useful lives Net tangible assets: Non-current assets $ Current liabilities ) Total Intangible assets acquired: Customer relationship 5.0 years Operating license 2.5 years Goodwill Deferred tax liability ) Total Total consideration $
iKang Tianjin Hedong Dongrun
Acquisitions
Schedule of purchase price allocated to assets acquired and liabilities assumed as of the date of acquisition	Estimated useful lives Net tangible assets: Current assets $ Non-current assets Current liabilities ) Total Intangible assets acquired: Customer relationship 5.0 years Operating license 1.4 years Goodwill Deferred tax liability ) Total Total consideration $
iKang Tianjin Hexi Fenghui
Acquisitions
Schedule of purchase price allocated to assets acquired and liabilities assumed as of the date of acquisition	Estimated useful lives Net tangible assets: Current assets $ Non-current assets Current liabilities ) Total Intangible assets acquired: Customer relationship 5.0 years Operating license 1.9 years Goodwill Deferred tax liability ) Total Total consideration $
WA Health Care
Acquisitions
Schedule of purchase price allocated to assets acquired and liabilities assumed as of the date of acquisition	Estimated useful lives Net tangible assets: Current assets $ Non-current assets Current liabilities ) Total Intangible assets acquired: Customer relationship 3.0 years Operating license 1.9-2.8 years Goodwill Deferred tax liability ) Total Non-controlling interest ) Total consideration $
iKang Shanghai Jianwei, iKang Changchun, iKang Guangzhou Wokang, Yuanhua, Nanjing Aoyang, Zhejiang Ailikang and MediFast
Acquisitions
Summary of the unaudited pro forma information	Years ended March 31, 2013 2014 (Unaudited) (Unaudited) Pro forma net revenue $ $ Pro forma net income attributable to common shareholders of iKang Healthcare Group, Inc. $ $
Yuanhua, Nanjing Aoyang, Zhejiang Ailikang, MediFast, Shanghai Huajian Management, iKang Shenyang Hospital, iKang Shenyang Ningshan Hospital, Gold iKang Shenyang Hospital, iKang Tianjin Hedong Dongrun, iKang Tianjin Hexi Fenghui and WA Health Care
Acquisitions
Summary of the unaudited pro forma information	Years ended March 31, 2014 2015 (Unaudited) (Unaudited) Pro forma net revenue $ $ Pro forma net income attributable to common shareholders of iKang Healthcare Group, Inc. $ $

ACCOUNTS RECEIVABLE, NET (Table

ACCOUNTS RECEIVABLE, NET (Tables)	12 Months Ended
	Mar. 31, 2015
ACCOUNTS RECEIVABLE, NET
Schedule of accounts receivable	As of March 31, 2014 2015 Accounts receivable $ $ Less: allowance for doubtful accounts Accounts receivable, net $ $
Schedule of movement of allowance for doubtful accounts	As of March 31, 2013 2014 2015 Balance at beginning of year $ $ $ Charge to expenses Write off ) ) ) Exchange difference Balance at end of year $ $ $

INVENTORIES (Tables)

INVENTORIES (Tables)	12 Months Ended
	Mar. 31, 2015
INVENTORIES
Schedule of inventories	As of March 31, 2014 2015 Medical consumable $ $

PREPAID EXPENSES AND OTHER CU43

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)	12 Months Ended
	Mar. 31, 2015
PREPAID EXPENSES AND OTHER CURRENT ASSETS
Schedule of prepaid expenses and other current assets	As of March 31, 2014 2015 Prepaid acquisition fees (1) $ $ Advance to suppliers (2) Staff advance Prepaid rental expenses Prepaid expenses (3) Other receivable Interest income receivable — Deferred IPO cost — Change in fair value of the forward contracts (4) — $ $ (1) Prepaid acquisition fees represent advance payments for acquisitions. (2) Advance to suppliers represents advance payment to suppliers to purchase medical equipment and consumables. (3) Prepaid expenses mainly consist of amounts paid for professional fees and advertisement fees for which relating services have not been provided. (4) The Bayley & Jackson (Hong Kong) entered into two foreign currency exchange forward contracts with Bank of East Asia (“BEA”) in June and July 2013, respectively. Pursuant to those contracts, Bayley & Jackson (Hong Kong) bought two buy RMB20,000,000, sell USD foreign exchange forward contracts using the quoted exchange rates at 6.2825 and 6.2620, respectively. The Group carries the forward contracts at fair value in its balance sheet and the changes in the exchange forward contracts fair value during the each period end are recorded in the statement of the operations. The Group carries the forward contracts as assets at fair value at March 31, 2014. The Group measures the fair value of the forward contracts on a recurring basis based on a level 2 measure, i.e. the Group uses the market exchange rate to assess the fair value of the forward contracts and recognizes the changes in fair value attributable to the difference between the market exchange rate and contractual exchange rate in change in fair value of the forward contracts. For the year ended March 31, 2014 and 2015, the Group recorded a gain of $57 and a loss of $8 in change in fair value of the forward contracts, respectively. The forward contracts were settled in June 2014.

PROPERTY AND EQUIPMENT, NET (Ta

PROPERTY AND EQUIPMENT, NET (Tables)	12 Months Ended
	Mar. 31, 2015
PROPERTY AND EQUIPMENT, NET
Schedule of property and equipment, net	As of March 31, 2014 2015 Medical equipment $ $ Leasehold improvements Computer equipment and application software Furniture and fixtures Motor vehicles Construction in progress Less: accumulated depreciation and amortization $ $

ACQUIRED INTANGIBLE ASSETS, N45

ACQUIRED INTANGIBLE ASSETS, NET (Tables)	12 Months Ended
	Mar. 31, 2015
ACQUIRED INTANGIBLE ASSETS, NET
Schedule of gross carrying amount, accumulated amortization and net carrying amount of the intangible assets	As of March 31, 2014 2015 Acquired intangible assets not subject to amortization Trade-name $ $ Acquired intangible assets subject to amortization Customer relationship Operating license Favorable lease contract Contract backlog Non-compete agreement Less: accumulated amortization Customer relationship Operating license Favorable lease contract Contract backlog Non-compete agreement Less: impairment Intangible assets, net $ $

GOODWILL (Tables)

GOODWILL (Tables)	12 Months Ended
	Mar. 31, 2015
GOODWILL.
Schedule of changes in carrying amounts of goodwill	As of March 31, 2014 2015 Gross amount: Beginning balance $ $ Additions for the year by acquisitions of Shanghai Huajian Management — iKang Shenyang Hospital — iKang Shenyang Ningshan Hospital — Gold iKang Shenyang Hospital — iKang Tianjin Hedong Dongrun — iKang Tianjin Hexi Fenghui — WA Health Care — Nanjing Aoyang — Yuanhua — Shanghai Jianwei Management — Zhejiang Ailikang — MediFast — Exchange difference ) Ending balance Accumulated impairment loss: Beginning balance Exchange difference ) Ending balance Goodwill $ $

ACCRUED EXPENSES AND OTHER CU47

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)	12 Months Ended
	Mar. 31, 2015
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
Schedule of accrued expenses and other current liabilities	As of March 31, 2014 2015 Acquisitions consideration payable (1) $ $ Accrued payroll and welfare Accrued rental expense Other payables Other taxes payable Accrued social insurance Accrued outsourcing cost Dividend payable (2) — Interest expense payable Accrued IPO expenses — Accrued professional fees — $ $ (1) Acquisitions consideration payable consists of remaining payables to sellers of the acquired entities for the years ended March 31, 2014 and 2015, which were as follows: As of March 31, 2014 2015 iKang Shanghai Jianwei $ $ Nanjing Aoyang Yuanhua Zhejiang Ailikang MediFast — Shanghai Huajian Management Suzhou Aoyang — iKang Tianjin Hedong Dongrun — iKang Tianjin Hexi Fenghui — Gold iKang Shenyang Hospital — WA Health Care — $ $ (2) As of March 31, 2015, the balance represents the dividend payable for non-controlling interest shareholders of MediFast.
Schedule of acquisitions consideration payable	As of March 31, 2014 2015 iKang Shanghai Jianwei $ $ Nanjing Aoyang Yuanhua Zhejiang Ailikang MediFast — Shanghai Huajian Management Suzhou Aoyang — iKang Tianjin Hedong Dongrun — iKang Tianjin Hexi Fenghui — Gold iKang Shenyang Hospital — WA Health Care — $ $

BANK BORROWINGS (Tables)

BANK BORROWINGS (Tables)	12 Months Ended
	Mar. 31, 2015
BANK BORROWINGS
Schedule of bank borrowings	As of March 31, 2014 2015 Short term borrowings (1) $ $ Long term borrowings (2) — $ $ (1) On June 25, June 28, July 10, September 17 and December 19, 2013 , iKang Holding borrowed five one-year loans of $1,627, $1,304, $1,630, $1,606 and $4,941 respectively from BEA, to purchase the property and equipment and meet temporary working capital needs of the Group. The annual interest rates are the benchmark interest rate announced by the People’s Bank of China plus 10% of the benchmark interest rate. The loans were guaranteed by Beijing iKang and collateralized by restricted cash. As of March 31, 2014, the outstanding short term borrowings were $10,910 and they were repaid during the year ended March 31, 2015. In September 2013, iKang Online signed a ten-year loan framework agreement with an amount no more than $2,451 with BEA, to repay the loans from China Merchants Bank which was due in September 2013. On September 17, 2013, iKang Online borrowed a one-year loan of $2,410 according to the framework agreement. The annual interest rate was equal to the benchmark interest rate announced by the People’s Bank of China plus 10% of the benchmark interest rate. The loan was guaranteed by Beijing iKang and collateralized by restricted cash. As of March 31, 2014, the outstanding long term borrowings was $2,372 and it was repaid in August 2014. In March 2014, seven clinics in Beijing signed seven one-year loan framework agreements with an amount no more than $8,896 with Bank of Beijing, to meet temporary working capital needs of the Group. Clinics borrowed total $4,919 and $1,353 in March 2014 and April 2014 according to the framework agreement, respectively. The annual interest rate is the benchmark interest rate announced by the People’s Bank of China plus 15% of the benchmark interest rate. The loans were guaranteed by iKang Online and iKang Holdings. As of March 31, 2014 and 2015, the outstanding short term borrowing was $4,919 and nil, respectively. In April 2014, iKang Online signed a one-year loan framework agreement with an amount no more than $16,004 with BEA, to meet the property and equipment need of the Group. In May 2014, iKang Online borrowed 2 one-year loans in a total of $4,843 according to the framework agreement. The annual interest rate was equal to the benchmark interest rate announced by the People’s Bank of China plus 10% of the benchmark interest rate. The loan was guaranteed by B&J China and collateralized by restricted cash of $5,500. As of March 31, 2015, the outstanding short term borrowing was $4,839. In May 2014, iKang Holding signed a 2-year loan framework agreement with an amount no more than $8,060 with China Merchants Bank, to meet the working capital and property and equipment needs of the Group. In May 2014, iKang Holding borrowed one-year loans of total $4,290 according to the framework agreement, among which $155 and $1,084 was repaid in June and August 2014, respectively. In June 2014, iKang Holding borrowed a one-year loan of $1,437. The annual interest rate is the interest rate announced by the People’s Bank of China plus 20% of the benchmark interest rate. As of March 31, 2015, the outstanding short term borrowing was $4,485. In June 2014, iKang Online borrowed a one-year loan of $14,561 with Xiamen International Bank, to repay the loans from BEA which was due in June 2014 and paid remaining balance of the consideration to purchase 35% equity interest in iKang Shanghai Xikang Road. The annual interest rate is 2.585%. The loan was collateralized by restricted cash in an amount of $15,002. As of March 31, 2015, the outstanding short term borrowing was $14,551. In June 2014, iKang Online signed a one-year loan framework agreement with an amount no more than $32,099 with Xiamen International Bank, to satisfy the daily operating need of the Group. In July 2014, iKang Online borrowed three one-year loans in a total of $17,537 according to the framework agreement. The annual interest rate is 2.585%. The loans were collateralized by restricted cash in an amount of $18,067. As of March 31, 2015, the outstanding short term borrowing was $17,525. In August 2014, iKang Online signed a one-year loan framework agreement with an amount no more than $32,509 with Xiamen International Bank, to satisfy the daily operating need of the Group. In September, iKang Online borrowed a one-year loan of $15,383 according to the framework agreement. The annual interest rate is 2.585%. The loans were collateralized by restricted cash in an amount of $15,848. As of March 31, 2015, the outstanding short term borrowing was $15,372. (2) In June 2013, iKang Holding signed a ten-year loan framework agreement with total loan amounts no more than $3,268 with BEA, to meet the Group’s needs to purchase the property and equipment. On June 28, 2013, iKang Holding borrowed a two-year loan of $1,897 according to the framework agreement. The annual interest rate is the benchmark interest rate announced by the People’s Bank of China plus 10% of the benchmark interest rate. The loan was guaranteed by Beijing iKang and collateralized by restricted cash. As of March 31, 2014, the outstanding long term borrowings were $1,865 and it was repaid in July 2014.

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Mar. 31, 2015
INCOME TAXES
Schedule of current and deferred portions of income tax expenses included in the consolidated statements of operations, which were all attributable to the Group's PRC subsidiaries and VIE entities	Years ended March 31, 2013 2014 2015 Current tax expenses $ $ $ Deferred tax benefits ) ) ) Income tax expenses $ $ $
Schedule of principal components of the deferred income tax assets and liabilities	As of March 31, 2014 2015 Current deferred tax assets: Accrued expenses $ $ Deferred revenue — Accrued payroll Bad debt provision Less: Valuation allowance ) ) Current deferred tax assets $ $ Non-current deferred tax assets: Depreciation and amortization $ $ Impairment of long-lived assets Net operating tax loss carry-forwards Less: Valuation allowance ) ) Non-current deferred tax assets $ $ As of March 31, 2014 2015 Non-current deferred tax liabilities: Intangible assets Non-current deferred tax liabilities $ $
Schedule of reconciliation between the expense (benefit) of income taxes computed by applying the PRC tax rate to income (loss) before income taxes and the actual provision for income taxes	For the year ended March 31, 2013 2014 2015 Net income before provision for income taxes and (loss)//gain from equity method investment $ $ $ PRC statutory tax rate % % % Income tax at statutory tax rate Change in valuation allowance Expenses not deductible for tax purposes Effect of income tax rate difference for entities under individual income tax rate of 35% Loss utilized for entities under individual income tax rate of 35% ) ) ) Effect of income tax rate differences in other jurisdictions Tax holidays and preferential tax rates — — ) Income tax expenses $ $ $

NET INCOME (LOSS) PER SHARE (Ta

NET INCOME (LOSS) PER SHARE (Tables)	12 Months Ended
	Mar. 31, 2015
NET INCOME (LOSS) PER SHARE
Schedule of calculation of net income (loss) per share	For the years ended March 31, 2013 2014 2015 Net income attributable to iKang Guobin Healthcare Group, Inc. $ $ $ Deemed dividend to Series A shares — Deemed dividend to Series B shares — Deemed dividend to Series C shares — Deemed dividend to Series D shares Deemed dividend to Series E shares — Deemed dividend to Series F shares Undistributed earnings allocated to Series A shares Undistributed earnings allocated to Series B shares Undistributed earnings allocated to Series C shares Undistributed earnings allocated to Series D shares Undistributed earnings allocated to Series E shares Undistributed earnings allocated to Series F shares For the years ended March 31, 2013 2014 2015 Net (loss) income attributed to common and preferred shareholders for computing net income per common share- basic and diluted (1) ) ) Numerator: Series A shares- Deemed dividend — Undistributed earnings allocation Series B shares- Deemed dividend — Undistributed earnings allocation Series C shares- Deemed dividend — Undistributed earnings allocation Series D shares- Deemed dividend Undistributed earnings allocation Series E shares- Deemed dividend — Undistributed earnings allocation Series F shares- Deemed dividend Undistributed earnings allocation Net (loss) income attributed to common shareholders for computing net income per common share- basic and diluted (1) ) ) For the years ended March 31, 2013 2014 2015 Denominator: Weighted average common shares outstanding used in computing diluted net income per common share-basic (2) Weighted average shares outstanding used in computing net income per common shares-diluted (2) Weighted average shares used in computing basic net income per shares Series A shares Series B shares Series C shares Series D shares Series E shares Series F shares Net (loss) income per common share attributable to iKang Healthcare Group, Inc.-basic $ ) $ ) $ Net (loss) income per common share attributable to iKang Healthcare Group, Inc.-diluted $ ) $ ) $ Net income per Series A shares $ $ $ Net income per Series B shares $ $ $ Net income per Series C shares $ $ $ Net income per Series D shares $ $ $ Net income per Series E shares $ $ $ Net income per Series F shares $ $ $ Notes: (1) The Class A, Class B and Class C common shares enjoy the same dividend participating right, therefore earnings per share of each class was not separately presented. (2) The calculation of the weighted average number of common shares for the purpose of diluted net income (loss) per share has considered the effect of certain potentially dilutive securities.

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	12 Months Ended
	Mar. 31, 2015
SHARE-BASED COMPENSATION.
Summary of information regarding options granted	For the years ended March 31, 2013 2014 2015 Weighted Weighted Weighted Weighted Weighted Weighted average average average average average average exercise fair value exercise fair value exercise fair value Number of price per per option Number of price per per option Number of price per per option options option at grant date options option at grant date options option at grant date Outstanding on April 1 of year $ $ $ $ $ $ Granted Exercised — — — — — — ) Forfeited — — — ) ) Outstanding on March 31 of year $ $ $ $ $ $
Summary of information with respect to share options outstanding	Option outstanding Option exercisable Weighted Weighted Aggregate Weighted Aggregate average average intrinsic average intrinsic remaining Exercise values as of Exercise values as of Number contractual price per March 31, Number price per March 31, Range of exercise price outstanding life in years option 2015 exercisable option 2015 $0.01 $ $ $ $ $1.00-$2.00 $ $ $5.13 $ $ $6.00 $ $ $16.18 $ $ $ $
Schedule of assumptions used on the grant date to estimate fair value of each option granted using the binomial tree pricing model for grants during the applicable periods	Risk-free interest rate of return Contractual term Volatility Dividend yield Exercise price December 31, 2010 % 10 years % — 5.13 June 8, 2011 % 2.39 years % — 0.01 February 17, 2012 % 10 years % — 5.13 March 18, 2013 % 10 years % — 5.13~6.00 September 12, 2013 % 10 years % — 6.00 February 27, 2014 % 10 years % — 5.13~6.00 August 1, 2014 % 10 years % — 16.18 October 28, 2014 % 10 years % — 5.13~6.00 February 27, 2015 % 10 years % — 5.13 (1) Risk-free interest rate Risk-free interest rate was estimated based on the yield to maturity of China international government bonds with a maturity period close to the expected term of the options. (2) Contractual term The Company used the original contractual term. (3) Volatility The volatility of the underlying common shares during the life of the options was estimated based on the historical stock price volatility of comparable listed companies over a period comparable to the expected term of the options. (4) Dividend yield The dividend yield was estimated by the Group based on its expected dividend policy over the expected term of the options. (5) Exercise price The exercise price of the options was determined by the Group’s board of directors. (6) Fair value of underlying common shares The estimated fair value of the common shares underlying the options as of the respective grant dates was determined based on a retrospective valuation, which used management’s best estimate for projected cash flows as of each valuation date.

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Mar. 31, 2015
FAIR VALUE MEASUREMENTS
Schedule of outstanding foreign currency forward contracts	As of March 31, 2014 2015 Balance at beginning of year $ $ Gain/(loss) from forward contracts ) Settled — ) Balance at end of year $ $ —
Schedule of assets that are measured at fair value on a recurring basis	Fair Value Measurement at Reporting Date Using 2014 2015 Quoted Quoted Prices in Significant Prices in Significant Active Market Other Significant Active Market Other Significant March 31, for Identical Observable Unobservable March 31, for Identical Observable Unobservable 2014 Assets Inputs Inputs 2015 Assets Inputs Inputs (Level 1) (Level 2) (Level 3) (Level 1) (Level 2) (Level 3) Foreign currency forward contracts — — — — — — Outstanding on March 31 of year $ $ — $ $ — $ — $ — $ — $ —

RELATED PARTY BALANCES AND TR53

RELATED PARTY BALANCES AND TRANSACTIONS (Tables)	12 Months Ended
	Mar. 31, 2015
RELATED PARTY BALANCES AND TRANSACTIONS
Schedule of amounts due from related parties of the Group	As of March 31, 2014 2015 Amounts due from a related party - current: Amounts due from Shanghai Huajian Clinic Ltd. (1) $ — $ — (1) Amounts due from a related party represents loan provided by the Group to its equity method investee Shanghai Huajian Management for daily operating use and the loan was repaid in September 2014.
Schedule of amounts due to related parties of the Group	As of March 31, 2014 2015 Amounts due to a related party - current: Amounts due to a former non-controlling interest holder (2) $ — $ — (1) On August 1, 2011, iKang Holding signed an agreement with the non-controlling interest holder of iKang Shanghai Xikang Road to purchase the remaining 35% of the equity interest in iKang Shanghai Xikang Road held by the non-controlling interest holders, with consideration of $15,894. The transaction was closed on December 31, 2011. The Group paid first installment of $1,589 in August 2011 within five days after the agreement was signed. The second installment of $1,589 was paid in February 2013. In December 2013, $3,941 was repaid and in March 2014, $991 was paid by the Group for individual income tax on behalf of the former non-controlling interest holder. The remaining balance was settled in June 2014.

NONCONTROLLING INTEREST (Tables

NONCONTROLLING INTEREST (Tables)	12 Months Ended
	Mar. 31, 2015
NONCONTROLLING INTEREST
Schedule of noncontrolling interest	iKang iKang iKang Shenzhen Shanghai Zhejiang WA Shanghai Shanghai Fujian Hospital Jianwei Beijing iKang BVI HK Gubei Lujiazui iKang Management Management Jiandatong MediFast Changzhou Total Balance at March 31, 2012 $ ) $ — $ $ $ $ ) $ — $ — $ — $ — $ Share of profit — ) — — — — Other comprehensive income ) — — — — — — ) Balance at March 31, 2013 $ $ — $ $ $ $ $ — $ — $ — $ — $ Addition of non-controlling interest in connection with establishment of Beijing Jiandatong — — — — — — — — — Addition of non-controlling interest in connection with acquisition of Shanghai iKang Jianwei Health Management Co., Ltd. — — — — — — — — — Addition of non-controlling interest in connection with acquisition of MediFast — — — — — — — — — Addition of non-controlling interest in connection with establishment of iKang Changzhou — — — — — — — — — Dividend distribution to non-controlling interest holder of Shanghai Wangzu Guobin Medical Center Co., Ltd. — — ) — — — — — — — ) Share of profit (loss) — ) ) ) Purchase of non-controlling interest — — — ) — — — — — — ) Other comprehensive income ) — ) ) ) ) ) ) ) ) Balance at March 31, 2014 $ $ — $ $ — $ $ $ $ $ $ $ Capital contribution of non-controlling interest holder of Beijing Jiandatong — — — — — — — — — Capital contribution of non-controlling interest holder of Shanghai Jianwei — — — — — — — — — Addition of non-controlling interest in connection with acquisition of WA Health Care — — — — — — — — — Capital contribution of non-controlling interest holder of WA Centers HK Limited — — — — — — — — — Dividend distribution to non-controlling interest holder of MediFast — — — — — — — — ) — ) Share of profit (loss) ) — ) ) ) ) Other comprehensive income — — — — — — — Balance at March 31, 2015 $ $ $ $ — $ $ ) $ $ $ $ $

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	12 Months Ended
	Mar. 31, 2015
SEGMENT INFORMATION
Schedule of reconciliation of gross profit by segment to consolidated income from operations	For the years ended March 31, 2013 2014 2015 Net revenues: Medical examinations and other medical services $ $ $ Dental services — — Total net revenues Cost of revenues: Medical examinations and other medical services Dental services — — Total cost of revenues Gross profit: Medical examinations and other medical services Dental services — — Total gross profit Operating expenses: Selling and marketing expenses General and administrative expenses Research and development expenses Total operating expenses Income from operations $ $ $
Schedule of components of net revenues	For the years ended March 31, 2013 2014 2015 Medical examinations $ $ $ Disease screening Other services Medical examinations and other medical services Dental services — — Total $ $ $

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Mar. 31, 2015
COMMITMENTS AND CONTINGENCIES
Schedule of future minimum lease payments	Future minimum lease payments under such leases as of March 31, 2015 were as follows: 2016 $ 2017 2018 2019 2020 After 2020 $

ORGANIZATION AND PRINCIPAL AC57

ORGANIZATION AND PRINCIPAL ACTIVITIES (Details)	Mar. 01, 2014	Jan. 31, 2012	Mar. 31, 2015item	Jul. 31, 2013
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Ratio of shares swap with existing shareholders of iKang Guobin Healthcare Group, Inc.	1
Maximum percentage of direct foreign ownership allowed in business entities providing healthcare services in the PRC		70.00%
Yuanhua
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Interest acquired (as a percent)				100.00%
iKang Holding
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Number of shareholders who are directors and shareholders of the Company			2
Mr. Ligang Zhang
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Equity interest held (as a percent)			25.60%
Mr. Ligang Zhang | iKang Holding
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Equity interest held (as a percent)			50.00%
Mr. Boquan He
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Equity interest held (as a percent)			14.80%
Mr. Boquan He | iKang Holding
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Equity interest held (as a percent)			50.00%
iKang Holding | iKang Hangzhou Xixi
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Equity interest held (as a percent)			80.00%
Total equity interest held, including indirect ownership			100.00%
Yalong Daoyi | iKang Hangzhou Xixi
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Equity interest held (as a percent)			20.00%
Mr. Haiqing Hu | Beijing Jiandatong
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Equity interest held (as a percent)			80.00%
Mr. Haiqing Hu | Yuanhua Information
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Equity interest held (as a percent)			80.00%
Mr. Lei Zhao | Yuanhua Information
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Equity interest held (as a percent)			20.00%
Exclusive Equity Option Agreement
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Term of agreement			10 years
Exclusive Services Agreement
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Term of agreement			10 years
iKang Holding
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Hangzhou Xixi
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			73.00%
Yuanhua Information
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Beijing Jiandatong
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			80.00%
iKang Online
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Technology
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Shenzhen iKang
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Yalong Daoyi
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Guangzhou Huanshi East/Tianhe
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Shanghai Xikang Road
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Shanghai Gubei
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			70.00%
iKang Shanghai Pudong Avenue
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Shenzhen Hospital Management
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			66.00%
iKang Shenzhen Nanshan
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			66.00%
iKang Beijing Lidu
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Nanjing Xinjiekou
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Shenzhen Luohu
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Beijing Jianguomen
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Beijing Zhongguancun
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Beijing Kunming Lake
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Beijing Yansha East
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Shanghai Yangpu
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Chengdu Waishuangnan
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Shanghai Lujiazui
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Shanghai Wenzhong
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			71.00%
iKang Beijing Xuanwumen
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Nanjing Gulou
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Shenzhen Futian
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Fujian iKang
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			71.00%
iKang Fuzhou Gulou
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			71.00%
iKang Beijing Xinei
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Yan'an West Road
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Shanghai Zhonghuan
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Shanghai Jing'an
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Shanghai Yan'an East Road
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Shanghai Jianwei
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Hangzhou Wenhui
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Tianjin Heping
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Suzhou
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Changchun
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Chengdu Jinjiang
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Chongqing
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Guangzhou Wokang
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Shenzhen Kefa
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Shanghai Jianwei Management
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			90.00%
Yuanhua Clinic
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Nanjing Aoyang
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Nanjing Aoyang Shunkang
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Jiangyin
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Zhejiang Ailikang
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Hangzhou Aibo
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Beijing Jun'an
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Beijing Yayun
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Changzhou
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			63.00%
iKang Beijing Baishi
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Chengdu Gaoxin iKang West City
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Dental Hospital Management
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Beijing Wanzhishou
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Shanghai Huajian Management
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Shanghai Huajian
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Shanghai Jinxiu Huajian
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Shanghai Jinshen Huajian
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Shenyang Hospital
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Shenyang Ningshan Hospital
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Gold iKang Shenyang Hospital
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Tianjin Hedong Dongrun
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
iKang Tianjin Hexi Fenghui
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			100.00%
Wuxi Woshi Hongtai
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			70.00%
Beijing Woshi Hongtai
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			70.00%
Beijing Zhenjing
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			70.00%
Shanghai Zhenjing Hospital Management
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			70.00%
Shanghai Zhenjing
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in VIEs and its subsidiaries			70.00%
iKang Guobin
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in subsidiaries			100.00%
Beijing iKang
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in subsidiaries			100.00%
Shanghai iKang
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in subsidiaries			100.00%
iKang Zhejiang BVI
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in subsidiaries			73.00%
Zhejiang iKang
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in subsidiaries			73.00%
Bayley & Jackson (Hong Kong)
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in subsidiaries			100.00%
iKang Beijing Ritan
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in subsidiaries			100.00%
Yuanhua HK (HongKong)
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in subsidiaries			100.00%
MediFast
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in subsidiaries			80.00%
Yuanhua WFOE
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in subsidiaries			100.00%
WA Health Care
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in subsidiaries			70.00%
(iKang Shanghai) Financing Lease
Details of the Group's subsidiaries, VIEs and the VIEs' subsidiaries
Percentage of beneficial interest in subsidiaries			100.00%

ORGANIZATION AND PRINCIPAL AC58

ORGANIZATION AND PRINCIPAL ACTIVITIES (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Financial statements amounts and balances of the VIE entities included in the accompanying consolidated financial statements
Cash and cash equivalents	$ 97,336	$ 30,221	$ 63,154	$ 11,875
Total current assets	278,665	110,830
Property and equipment, net	105,022	63,644
Acquired intangible assets, net	30,634	17,530
TOTAL ASSETS	499,001	250,226
Deferred revenues	38,457	29,523
Total current liabilities	163,147	103,442
TOTAL LIABILITIES	170,653	108,848
Net revenues	290,781	202,304	133,871
Net income	27,396	21,926	12,449
Net cash provided by operating activities	41,097	34,303	16,314
Net cash used in investing activities	(147,062)	(96,714)	(16,058)
Net cash provided by financing activities	$ 173,570	$ 29,342	$ 50,824
Net revenues from VIE entities as a percentage of consolidated net revenues	85.40%	84.10%	84.80%
Assets from VIE entities as a percentage of consolidated total assets	58.00%	71.40%
Liabilities from VIE entities as a percentage of consolidated total liabilities	88.90%	82.60%
VIE entities
Financial statements amounts and balances of the VIE entities included in the accompanying consolidated financial statements
Cash and cash equivalents	$ 22,870	$ 11,326
Account receivable and other current assets	94,658	54,508
Total current assets	117,528	65,834
Property and equipment, net	101,237	60,325
Acquired intangible assets, net	29,081	14,070
Other noncurrent assets	41,562	38,466
Total non-current assets	171,880	112,861
TOTAL ASSETS	289,408	178,695
Deferred revenues	31,786	22,234
Account payable and other current liabilities	113,250	62,837
Total current liabilities	145,036	85,071
Total non-current liabilities	6,670	4,857
TOTAL LIABILITIES	151,706	89,928
Net revenues	248,202	170,226	$ 113,506
Net income	35,643	20,948	11,728
Net cash provided by operating activities	76,495	16,927	14,978
Net cash used in investing activities	(91,833)	(29,649)	(15,944)
Net cash provided by financing activities	$ 26,882	$ 10,740	$ 3,824

SUMMARY OF SIGNIFICANT ACCOUN59

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Maturity terms of term deposits- minimum	3 months
Maturity terms of term deposits- maximum	1 year
Foreign currency risk
Aggregate amounts of cash and cash equivalent denominated in RMB	$ 97,336	$ 30,221	$ 63,154	$ 11,875
Foreign currency risk | China, Yuan Renminbi
Foreign currency risk
Aggregate amounts of cash and cash equivalent denominated in RMB	$ 30,172	$ 15,853

SUMMARY OF SIGNIFICANT ACCOUN60

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)	12 Months Ended
	Mar. 31, 2015
Computer equipment and application software
Property and equipment, net
Estimated useful life	5 years
Furniture and fixtures
Property and equipment, net
Estimated useful life	5 years
Medical equipment
Property and equipment, net
Estimated useful life	10 years
Motor vehicles
Property and equipment, net
Estimated useful life	5 years

SUMMARY OF SIGNIFICANT ACCOUN61

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3)	12 Months Ended
	Mar. 31, 2015
Weighted average
Intangible assets, net
Estimated useful lives	5 years 7 months 6 days
Customer relationship | Weighted average
Intangible assets, net
Estimated useful lives	5 years 10 months 24 days
Customer relationship | Minimum
Intangible assets, net
Estimated useful lives	2 years 1 month 6 days
Customer relationship | Maximum
Intangible assets, net
Estimated useful lives	10 years
Non-compete agreement | Weighted average
Intangible assets, net
Estimated useful lives	3 years
Non-compete agreement | Minimum
Intangible assets, net
Estimated useful lives	2 years
Non-compete agreement | Maximum
Intangible assets, net
Estimated useful lives	3 years
Contract backlog | Weighted average
Intangible assets, net
Estimated useful lives	8 months 12 days
Contract backlog | Minimum
Intangible assets, net
Estimated useful lives	4 months 24 days
Contract backlog | Maximum
Intangible assets, net
Estimated useful lives	10 months 24 days
Operating license | Weighted average
Intangible assets, net
Estimated useful lives	2 years 10 months 24 days
Operating license | Minimum
Intangible assets, net
Estimated useful lives	3 months 18 days
Operating license | Maximum
Intangible assets, net
Estimated useful lives	5 years
Favorable lease contract | Weighted average
Intangible assets, net
Estimated useful lives	7 years 1 month 6 days
Favorable lease contract | Minimum
Intangible assets, net
Estimated useful lives	2 years 9 months 18 days
Favorable lease contract | Maximum
Intangible assets, net
Estimated useful lives	9 years 9 months 18 days

SUMMARY OF SIGNIFICANT ACCOUN62

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 4) - USD ($) $ in Thousands	12 Months Ended			31 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2015
Maximum
Revenue recognition
Expiry period of components from date of purchase	1 year
PRC
Value added tax ("VAT")
VAT rate (as a percent)				3.00%
PRC subsidiaries and VIE entities | PRC
Revenue recognition
Business tax on the revenues earned from providing services and selling products (as a percent)	5.00%
Business tax recognized	$ 2,156	$ 2,084	$ 1,576

SUMMARY OF SIGNIFICANT ACCOUN63

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 5) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Non-monetary exchange
Revenues recognized for non-monetary transactions	$ 571	$ 706	$ 972

ACQUISITIONS (Details)

ACQUISITIONS (Details) - USD ($) $ in Thousands	Aug. 17, 2012	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Net tangible assets:
Goodwill		$ 72,101	$ 41,412
iKang Shanghai Jianwei
Acquisitions
Percentage of equity interest acquired	100.00%
Cash consideration	$ 1,249
Acquisition-related costs	0
Net tangible assets:
Current assets	39
Non-current assets	463
Deferred tax assets	274
Total	776
Goodwill	396
Deferred tax liability	(26)
Total	473
Total consideration	1,249
Net revenue		3,116	1,122	$ 300
Net (loss) income		$ 527	$ (773)	$ (647)
iKang Shanghai Jianwei | Customer relationship
Net tangible assets:
Intangible assets acquired	$ 71
Estimated useful lives	5 years 3 months 18 days
iKang Shanghai Jianwei | Operating license
Net tangible assets:
Intangible assets acquired	$ 32
Estimated useful lives	1 year 4 months 24 days

ACQUISITIONS (Details 2)

ACQUISITIONS (Details 2) - USD ($) $ in Thousands	Nov. 05, 2012	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Net tangible assets:
Goodwill		$ 72,101	$ 41,412
iKang Changchun
Acquisitions
Percentage of equity interest acquired	100.00%
Cash consideration	$ 915
Acquisition-related costs	0
Net tangible assets:
Current assets	5
Non-current assets	307
Total	312
Goodwill	427
Deferred tax liability	(58)
Total	603
Total consideration	915
Net revenue		996	593	$ 25
Net loss		$ 384	$ 832	$ 301
iKang Changchun | Customer relationship
Net tangible assets:
Intangible assets acquired	$ 165
Estimated useful lives	6 years 1 month 6 days
iKang Changchun | Favorable lease contract
Net tangible assets:
Intangible assets acquired	$ 21
Estimated useful lives	5 years 1 month 6 days
iKang Changchun | Operating license
Net tangible assets:
Intangible assets acquired	$ 48
Estimated useful lives	2 years 6 months

ACQUISITIONS (Details 3)

ACQUISITIONS (Details 3) - USD ($) $ in Thousands	Dec. 03, 2012	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Net tangible assets:
Goodwill		$ 72,101	$ 41,412
iKang Guangzhou Wokang
Acquisitions
Percentage of equity interest acquired	100.00%
Cash consideration	$ 2,986
Acquisition-related costs	0
Net tangible assets:
Current assets	117
Non-current assets	550
Current liabilities	(44)
Total	623
Goodwill	1,390
Deferred tax liability	(324)
Total	2,363
Total consideration	2,986
Net revenue		4,184	2,737	$ 7
Net (loss) income		$ 1,364	$ 964	$ (273)
iKang Guangzhou Wokang | Customer relationship
Net tangible assets:
Intangible assets acquired	$ 175
Estimated useful lives	6 years
iKang Guangzhou Wokang | Favorable lease contract
Net tangible assets:
Intangible assets acquired	$ 1,074
Estimated useful lives	9 years 9 months 18 days
iKang Guangzhou Wokang | Operating license
Net tangible assets:
Intangible assets acquired	$ 48
Estimated useful lives	3 years 1 month 6 days

ACQUISITIONS (Details 4)

ACQUISITIONS (Details 4) - USD ($) $ in Thousands	Jul. 31, 2013	Mar. 31, 2015	Mar. 31, 2014
Net tangible assets:
Goodwill		$ 72,101	$ 41,412
Customer relationship | Minimum
Net tangible assets:
Estimated useful lives		2 years 1 month 6 days
Customer relationship | Maximum
Net tangible assets:
Estimated useful lives		10 years
Operating license | Minimum
Net tangible assets:
Estimated useful lives		3 months 18 days
Operating license | Maximum
Net tangible assets:
Estimated useful lives		5 years
Contract backlog | Minimum
Net tangible assets:
Estimated useful lives		4 months 24 days
Contract backlog | Maximum
Net tangible assets:
Estimated useful lives		10 months 24 days
Yuanhua
Acquisitions
Percentage of equity interest acquired	100.00%
Cash consideration	$ 27,600
Acquisition-related costs	0
Net tangible assets:
Current assets	8,059
Non-current assets	1,150
Deferred tax assets	371
Current liabilities	(6,060)
Total	3,520
Goodwill	15,654
Deferred tax liability	(2,809)
Total	24,080
Total consideration	27,600
Net revenue		$ 15,757	10,091
Net (loss) income		$ 423	$ (1,023)
Yuanhua | Trade-name
Net tangible assets:
Intangible assets acquired	4,830
Yuanhua | Customer relationship
Net tangible assets:
Intangible assets acquired	$ 6,307
Yuanhua | Customer relationship | Minimum
Net tangible assets:
Estimated useful lives	5 years
Yuanhua | Customer relationship | Maximum
Net tangible assets:
Estimated useful lives	7 years 4 months 24 days
Yuanhua | Operating license
Net tangible assets:
Intangible assets acquired	$ 49
Estimated useful lives	2 years 3 months 18 days
Yuanhua | Contract backlog
Net tangible assets:
Intangible assets acquired	$ 49
Estimated useful lives	10 months 24 days

ACQUISITIONS (Details 5)

ACQUISITIONS (Details 5) - USD ($) $ in Thousands	Sep. 01, 2013	Mar. 31, 2015	Mar. 31, 2014
Net tangible assets:
Goodwill		$ 72,101	$ 41,412
Nanjing Aoyang
Acquisitions
Percentage of equity interest acquired	100.00%
Cash consideration	$ 4,085
Acquisition-related costs	0
Net tangible assets:
Current assets	15
Non-current assets	3,314
Total	3,329
Goodwill	731
Deferred tax liability	(8)
Total	756
Total consideration	4,085
Net revenue		318	218
Net loss		$ 1,645	$ 1,145
Nanjing Aoyang | Operating license
Net tangible assets:
Intangible assets acquired	$ 33
Estimated useful lives	1 year 3 months 18 days

ACQUISITIONS (Details 6)

ACQUISITIONS (Details 6) - USD ($) $ in Thousands	Dec. 31, 2013	Mar. 31, 2015	Mar. 31, 2014
Net tangible assets:
Goodwill		$ 72,101	$ 41,412
Zhejiang Ailikang | Hangzhou Aibo
Acquisitions
Percentage of equity interest acquired	100.00%
Zhejiang Ailikang
Acquisitions
Percentage of equity interest acquired	100.00%
Cash consideration	$ 1,663
Acquisition-related costs	0
Net tangible assets:
Current assets	2
Non-current assets	576
Current liabilities	(818)
Total	(240)
Goodwill	1,628
Deferred tax liability	(91)
Total	1,903
Total consideration	1,663
Net revenue		2	0
Net loss		$ 321	$ 158
Zhejiang Ailikang | Favorable lease contract
Net tangible assets:
Intangible assets acquired	$ 283
Estimated useful lives	5 years 3 months 18 days
Zhejiang Ailikang | Operating license
Net tangible assets:
Intangible assets acquired	$ 83
Estimated useful lives	2 years 8 months 12 days

ACQUISITIONS (Details 7)

ACQUISITIONS (Details 7) - USD ($) $ in Thousands	Jan. 14, 2014	Mar. 31, 2015	Mar. 31, 2014
Net tangible assets:
Goodwill		$ 72,101	$ 41,412
Customer relationship | Minimum
Net tangible assets:
Estimated useful lives		2 years 1 month 6 days
Customer relationship | Maximum
Net tangible assets:
Estimated useful lives		10 years
Non-compete agreement | Minimum
Net tangible assets:
Estimated useful lives		2 years
Non-compete agreement | Maximum
Net tangible assets:
Estimated useful lives		3 years
MediFast
Acquisitions
Percentage of equity interest acquired	80.00%
Cash consideration	$ 8,113
Acquisition-related costs	0
Net tangible assets:
Current assets	1,944
Non-current assets	927
Current liabilities	(1,431)
Total	1,440
Goodwill	5,332
Deferred tax liability	(619)
Total	8,363
Non-controlling interest	(1,690)
Total consideration	8,113
Net revenue		$ 12,563	2,570
Net income		$ 486	$ 328
MediFast | Trade-name
Net tangible assets:
Intangible assets acquired	374
MediFast | Customer relationship
Net tangible assets:
Intangible assets acquired	$ 2,825
MediFast | Customer relationship | Minimum
Net tangible assets:
Estimated useful lives	5 years
MediFast | Customer relationship | Maximum
Net tangible assets:
Estimated useful lives	10 years
MediFast | Non-compete agreement
Net tangible assets:
Intangible assets acquired	$ 451
Estimated useful lives	3 years

ACQUISITIONS (Details 8)

ACQUISITIONS (Details 8) $ / shares in Units, $ in Thousands	Aug. 01, 2014USD ($)$ / sharesshares	Jul. 01, 2014USD ($)	Jun. 30, 2014USD ($)	May. 31, 2014USD ($)	Jan. 31, 2014USD ($)shareholder	Mar. 31, 2015USD ($)	Mar. 31, 2014USD ($)
Net tangible assets:
Goodwill						$ 72,101	$ 41,412
Shanghai Huajian Management
Acquisitions
Percentage of equity interest acquired					33.00%
Aggregate price					$ 6,376
Shanghai Huajian Management
Acquisitions
Percentage of equity interest acquired		67.00%
Number of shareholders with remaining interest | shareholder					2
Existing interest (as a percentage)		33.00%
Fair value remeasured for existing interest		$ 7,661
Fair value remeasurement gain						883
Net tangible assets:
Current assets		4,738
Non-current assets		5,673
Current liabilities		(5,413)
Total		4,998
Goodwill		14,032
Deferred tax liability		(3,108)
Total		22,731
Total consideration		27,729
Net revenue						10,772
Net loss						$ 676
Shanghai Huajian Management | Remaining shareholder one
Acquisitions
Percentage of equity interest acquired				37.00%
Cash consideration				$ 7,484
Shanghai Huajian Management | Remaining shareholder two
Acquisitions
Percentage of equity interest acquired			30.00%
Cash consideration			$ 5,382
Shanghai Huajian Management | Former shareholder | Options
Acquisitions
Number of options granted | shares	300,000
Fair value of the options granted	$ 7,202
Shanghai Huajian Management | Former shareholder | Options | Class A common shares
Acquisitions
Exercise price for the option (USD per share) | $ / shares	$ 16.18
Shanghai Huajian Management | Former shareholder | Options | ADS
Acquisitions
Exercise price for the option (USD per share) | $ / shares	$ 8.09
Shanghai Huajian Management | Trade-name
Net tangible assets:
Intangible assets acquired		4,371
Shanghai Huajian Management | Customer relationship
Net tangible assets:
Intangible assets acquired		$ 7,339
Estimated useful lives		5 years 6 months
Shanghai Huajian Management | Operating license
Net tangible assets:
Intangible assets acquired		$ 97
Estimated useful lives		3 years

ACQUISITIONS (Details 9)

ACQUISITIONS (Details 9) - USD ($) $ in Thousands	Nov. 14, 2014	Mar. 31, 2015	Mar. 31, 2014
Net tangible assets:
Goodwill		$ 72,101	$ 41,412
iKang Shenyang Hospital
Acquisitions
Percentage of equity interest acquired	100.00%
Cash consideration	$ 1,636
Acquisition-related costs	0
Net tangible assets:
Non-current assets	645
Total	645
Goodwill	982
Deferred tax liability	(101)
Total	991
Total consideration	1,636
Net revenue		469
Net loss		$ 392
iKang Shenyang Hospital | Operating license
Net tangible assets:
Intangible assets acquired	$ 110
Estimated useful lives	4 years

ACQUISITIONS (Details 10)

ACQUISITIONS (Details 10) - USD ($) $ in Thousands	Nov. 19, 2014	Mar. 31, 2015	Mar. 31, 2014
Net tangible assets:
Goodwill		$ 72,101	$ 41,412
iKang Shenyang Ningshan Hospital
Acquisitions
Percentage of equity interest acquired	100.00%
Cash consideration	$ 1,628
Acquisition-related costs	0
Net tangible assets:
Non-current assets	7
Total	7
Goodwill	1,124
Deferred tax liability	(166)
Total	1,621
Total consideration	1,628
Net revenue		144
Net loss		$ 124
iKang Shenyang Ningshan Hospital | Favorable lease contract
Net tangible assets:
Intangible assets acquired	$ 554
Estimated useful lives	2 years 9 months 18 days
iKang Shenyang Ningshan Hospital | Operating license
Net tangible assets:
Intangible assets acquired	$ 109
Estimated useful lives	5 years

ACQUISITIONS (Details 11)

ACQUISITIONS (Details 11) - Indefinite-lived Intangible Assets, Major Class Name [Domain] - USD ($) $ in Thousands	Dec. 19, 2014	Mar. 31, 2015	Mar. 31, 2014
Net tangible assets:
Goodwill		$ 72,101	$ 41,412
Gold iKang Shenyang Hospital
Acquisitions
Percentage of equity interest acquired	100.00%
Cash consideration	$ 6,447
Acquisition-related costs	0
Net tangible assets:
Non-current assets	2,832
Current liabilities	(55)
Total	2,777
Goodwill	3,464
Deferred tax liability	(68)
Total	3,670
Total consideration	6,447
Net revenue		44
Net loss		$ 475
Gold iKang Shenyang Hospital | Customer relationship
Net tangible assets:
Intangible assets acquired	$ 210
Estimated useful lives	5 years
Gold iKang Shenyang Hospital | Operating license
Net tangible assets:
Intangible assets acquired	$ 64
Estimated useful lives	2 years 6 months

ACQUISITIONS (Details 12)

ACQUISITIONS (Details 12) - USD ($) $ in Thousands	Feb. 17, 2015	Mar. 31, 2015	Mar. 31, 2014
Net tangible assets:
Goodwill		$ 72,101	$ 41,412
iKang Tianjin Hedong Dongrun
Acquisitions
Percentage of equity interest acquired	100.00%
Cash consideration	$ 3,032
Acquisition-related costs	0
Net tangible assets:
Current assets	141
Non-current assets	634
Current liabilities	(90)
Total	685
Goodwill	2,099
Deferred tax liability	(279)
Total	2,347
Total consideration	3,032
Net revenue		30
Net loss		$ 47
iKang Tianjin Hedong Dongrun | Customer relationship
Net tangible assets:
Intangible assets acquired	$ 479
Estimated useful lives	5 years
iKang Tianjin Hedong Dongrun | Operating license
Net tangible assets:
Intangible assets acquired	$ 48
Estimated useful lives	1 year 4 months 24 days

ACQUISITIONS (Details 13)

ACQUISITIONS (Details 13) - USD ($) $ in Thousands	Feb. 17, 2015	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2013
Net tangible assets:
Goodwill		$ 72,101	$ 41,412
Zhejiang Ailikang | Hangzhou Aibo
Acquisitions
Acquiree ownership interest in subsidiary (as a percent)				100.00%
iKang Tianjin Hexi Fenghui
Acquisitions
Percentage of equity interest acquired	100.00%
Cash consideration	$ 2,073
Acquisition-related costs	0
Net tangible assets:
Current assets	133
Non-current assets	356
Current liabilities	(3)
Total	486
Goodwill	1,228
Deferred tax liability	(120)
Total	1,587
Total consideration	2,073
Net revenue		59
Net loss		$ 73
iKang Tianjin Hexi Fenghui | Customer relationship
Net tangible assets:
Intangible assets acquired	$ 415
Estimated useful lives	5 years
iKang Tianjin Hexi Fenghui | Operating license
Net tangible assets:
Intangible assets acquired	$ 64
Estimated useful lives	1 year 10 months 24 days

ACQUISITIONS (Details 14)

ACQUISITIONS (Details 14) $ in Thousands	Mar. 03, 2015USD ($)item	Mar. 31, 2015USD ($)	Mar. 31, 2014USD ($)
Net tangible assets:
Goodwill		$ 72,101	$ 41,412
Customer relationship | Minimum
Net tangible assets:
Estimated useful lives		2 years 1 month 6 days
Customer relationship | Maximum
Net tangible assets:
Estimated useful lives		10 years
Operating license | Minimum
Net tangible assets:
Estimated useful lives		3 months 18 days
Operating license | Maximum
Net tangible assets:
Estimated useful lives		5 years
WA Health Care
Acquisitions
Percentage of equity interest acquired	70.00%
Number of medical centers | item	2
Cash consideration	$ 9,934
Acquisition-related costs	0
Net tangible assets:
Current assets	1,413
Non-current assets	5,459
Current liabilities	(3,006)
Total	3,866
Goodwill	7,570
Deferred tax liability	(666)
Total	9,456
Non-controlling interest	(3,388)
Total consideration	9,934
Net revenue		$ 494
Net loss		$ 203
WA Health Care | Customer relationship
Net tangible assets:
Intangible assets acquired	$ 2,472
Estimated useful lives	3 years
WA Health Care | Operating license
Net tangible assets:
Intangible assets acquired	$ 80
WA Health Care | Operating license | Minimum
Net tangible assets:
Estimated useful lives	1 year 10 months 24 days
WA Health Care | Operating license | Maximum
Net tangible assets:
Estimated useful lives	2 years 9 months 18 days

ACQUISITIONS (Details 15)

ACQUISITIONS (Details 15) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013	Oct. 15, 2014	Sep. 22, 2014	Mar. 26, 2013
Acquisition of operating license of iKang Shenzhen Kefa
Pro forma financial information
Cash consideration						$ 167
Acquisition of operating license of Foshan iKang Guobin Clinic Co., Ltd.
Pro forma financial information
Cash consideration					$ 242
Acquisition of operating license of Suzhou Aoyang
Pro forma financial information
Cash consideration				$ 1,129
iKang Shanghai Jianwei, iKang Changchun, iKang Guangzhou Wokang, Yuanhua, Nanjing Aoyang, Zhejiang Ailikang and MediFast
Pro forma financial information
Pro forma net revenue		$ 215,104	$ 161,447
Pro forma net income attributable to common shareholders of iKang Healthcare Group, Inc		21,110	$ 12,818
Yuanhua, Nanjing Aoyang, Zhejiang Ailikang, MediFast, Shanghai Huajian Management, iKang Shenyang Hospital, iKang Shenyang Ningshan Hospital, Gold iKang Shenyang Hospital, iKang Tianjin Hedong Dongrun, iKang Tianjin Hexi Fenghui and WA Health Care
Pro forma financial information
Pro forma net revenue	$ 305,493	238,706
Pro forma net income attributable to common shareholders of iKang Healthcare Group, Inc	$ 25,299	$ 18,387

ACCOUNTS RECEIVABLE, NET (Detai

ACCOUNTS RECEIVABLE, NET (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2015	Mar. 31, 2014
Accounts receivable
Accounts receivable				$ 67,705	$ 41,949
Less: allowance for doubtful accounts	$ 4,330	$ 3,272	$ 1,561	8,055	4,330
Accounts receivable, net				$ 59,650	$ 37,619
Movement of allowance for doubtful accounts
Balance at beginning of year	4,330	3,272	1,561
Charge to expenses	3,758	1,100	1,800
Write off	(42)	(97)	(132)
Exchange difference	9	55	43
Balance at end of year	$ 8,055	$ 4,330	$ 3,272

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Thousands	Mar. 31, 2015	Mar. 31, 2014
INVENTORIES
Medical consumable	$ 2,661	$ 1,693
Medical consumable
INVENTORIES
Medical consumable	$ 2,661	$ 1,693

PREPAID EXPENSES AND OTHER CU81

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) $ in Thousands	12 Months Ended
	Mar. 31, 2015USD ($)	Mar. 31, 2014USD ($)	Jul. 31, 2013CNY (¥)item
PREPAID EXPENSES AND OTHER CURRENT ASSETS
Prepaid acquisition fees	$ 22,215	$ 1,705
Advance to suppliers	9,150	9,022
Staff advance	5,261	2,141
Prepaid rental expenses	3,724	2,226
Prepaid expenses	3,327	792
Other receivable	316	587
Interest income receivable	38
Deferred IPO cost		3,482
Change in fair value of the forward contracts		57
Total	44,031	20,012
Bayley & Jackson (Hong Kong)
Forward contracts
Number of forward contracts | item			2
Notional amount | ¥			¥ 20,000,000
Gain (loss) from change in fair value of the forward contracts	$ (8)	$ 57
Bayley & Jackson (Hong Kong) | Foreign currency exchange forward contracts, one | Buy
Forward contracts
Exchange rates			6.2825
Bayley & Jackson (Hong Kong) | Foreign currency exchange forward contracts, two | Buy
Forward contracts
Exchange rates			6.2620

EQUITY-METHOD INVESTMENTS (Deta

EQUITY-METHOD INVESTMENTS (Details) $ in Thousands	1 Months Ended	12 Months Ended
	Jan. 31, 2014USD ($)shareholder	Mar. 31, 2015USD ($)	Mar. 31, 2014USD ($)	Mar. 31, 2013USD ($)	Jul. 01, 2014	Jun. 30, 2014	May. 31, 2014
EQUITY-METHOD INVESTMENTS
Carrying value of equity method investments		$ 0	$ 6,220
Shanghai Huajian Management
EQUITY-METHOD INVESTMENTS
Number of shareholders with remaining interest | shareholder	2
Remaining equity interest acquired (as a percent)					67.00%
Shanghai Huajian Management | Remaining shareholder one
EQUITY-METHOD INVESTMENTS
Remaining equity interest acquired (as a percent)							37.00%
Shanghai Huajian Management | Remaining shareholder two
EQUITY-METHOD INVESTMENTS
Remaining equity interest acquired (as a percent)						30.00%
Shanghai Huajian Management
EQUITY-METHOD INVESTMENTS
Percentage of equity interest acquired	33.00%
Aggregate price	$ 6,376
(Loss)/gain from equity method investment		$ 521	$ (156)	$ 0

PROPERTY AND EQUIPMENT, NET (De

PROPERTY AND EQUIPMENT, NET (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Property and equipment, net
Less: accumulated depreciation and amortization	$ 53,309	$ 38,874
Property and equipment, net	105,022	63,644
Depreciation expenses	14,691	8,874	$ 7,112
Medical equipment
Property and equipment, net
Property and equipment, gross	77,095	46,275
Leasehold improvements
Property and equipment, net
Property and equipment, gross	55,242	33,807
Computer equipment and application software
Property and equipment, net
Property and equipment, gross	11,734	7,815
Furniture and fixtures
Property and equipment, net
Property and equipment, gross	8,380	5,329
Motor vehicles
Property and equipment, net
Property and equipment, gross	944	732
Construction in progress
Property and equipment, net
Property and equipment, gross	$ 4,936	$ 8,560

ACQUIRED INTANGIBLE ASSETS, N84

ACQUIRED INTANGIBLE ASSETS, NET (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Acquired intangible assets, net
Less: impairment	$ 427	$ 426
Intangible assets, net	30,634	17,530
Amortization expenses	5,221	1,885	$ 598
Future amortization expenses
2,016	6,345
2,017	4,901
2,018	3,150
2,019	1,813
2,020	1,265
thereafter	1,557
Impairment loss recognized on acquired intangible assets	0	0	$ 0
Customer relationship
Acquired intangible assets, net
Acquired intangible assets subject to amortization	23,286	12,303
Less: accumulated amortization	8,163	4,059
Operating license
Acquired intangible assets, net
Acquired intangible assets subject to amortization	4,566	2,161
Less: accumulated amortization	1,988	1,289
Favorable lease contract
Acquired intangible assets, net
Acquired intangible assets subject to amortization	1,925	1,372
Less: accumulated amortization	433	169
Contract backlog
Acquired intangible assets, net
Acquired intangible assets subject to amortization	88	88
Less: accumulated amortization	88	80
Non-compete agreement
Acquired intangible assets, net
Acquired intangible assets subject to amortization	454	454
Less: accumulated amortization	189	37
Trade-name
Acquired intangible assets, net
Acquired intangible assets not subject to amortization	$ 11,603	$ 7,212

GOODWILL (Details)

GOODWILL (Details) - USD ($) $ in Thousands

12 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Mar. 03, 2015

Feb. 17, 2015

Dec. 19, 2014

Nov. 19, 2014

Nov. 14, 2014

Jul. 01, 2014

Jan. 14, 2014

Dec. 31, 2013

Sep. 01, 2013

Jul. 31, 2013

Changes in carrying amounts of goodwill

Gross amount, Beginning balance

$ 66,936

$ 43,503

Gross amount, Exchange difference

200

(484)

Gross amount, Ending balance

97,635

66,936

Accumulated impairment loss, Beginning balance

25,524

25,712

Accumulated impairment loss, Exchange difference

10

(188)

Accumulated impairment loss, Ending balance

25,534

25,524

Goodwill

72,101

41,412

Shanghai Huajian Management

Changes in carrying amounts of goodwill

Gross amount, Additions for the year by acquisitions

14,032

Goodwill

$ 14,032

iKang Shenyang Hospital

Changes in carrying amounts of goodwill

Gross amount, Additions for the year by acquisitions

982

Goodwill

$ 982

iKang Shenyang Ningshan Hospital

Changes in carrying amounts of goodwill

Gross amount, Additions for the year by acquisitions

1,124

Goodwill

$ 1,124

Gold iKang Shenyang Hospital

Changes in carrying amounts of goodwill

Gross amount, Additions for the year by acquisitions

3,464

Goodwill

$ 3,464

iKang Tianjin Hedong Dongrun

Changes in carrying amounts of goodwill

Gross amount, Additions for the year by acquisitions

2,099

Goodwill

$ 2,099

iKang Tianjin Hexi Fenghui

Changes in carrying amounts of goodwill

Gross amount, Additions for the year by acquisitions

1,228

Goodwill

$ 1,228

WA Health Care

Changes in carrying amounts of goodwill

Gross amount, Additions for the year by acquisitions

$ 7,570

Goodwill

$ 7,570

Nanjing Aoyang

Changes in carrying amounts of goodwill

Gross amount, Additions for the year by acquisitions

731

Goodwill

$ 731

Yuanhua

Changes in carrying amounts of goodwill

Gross amount, Additions for the year by acquisitions

15,654

Goodwill

$ 15,654

Shanghai Jianwei Management

Changes in carrying amounts of goodwill

Gross amount, Additions for the year by acquisitions

572

Zhejiang Ailikang

Changes in carrying amounts of goodwill

Gross amount, Additions for the year by acquisitions

1,628

Goodwill

$ 1,628

MediFast

Changes in carrying amounts of goodwill

Gross amount, Additions for the year by acquisitions

$ 5,332

Goodwill

$ 5,332

ACCRUED EXPENSES AND OTHER CU86

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($) $ in Thousands	Mar. 31, 2015	Mar. 31, 2014
Accrued expenses and other current liabilities
Acquisitions consideration payable	$ 11,795	$ 3,628
Accrued payroll and welfare	8,750	4,231
Accrued rental expense	5,737	4,944
Other payables	4,350	2,591
Other taxes payable	2,788	2,254
Accrued social insurance	2,557	2,368
Accrued outsourcing cost	519	1,909
Dividend payable	194
Interest expense payable	100	27
Accrued IPO expenses		2,268
Accrued professional fees		55
Total	36,790	24,275
iKang Shanghai Jianwei
Accrued expenses and other current liabilities
Acquisitions consideration payable	129	129
Nanjing Aoyang
Accrued expenses and other current liabilities
Acquisitions consideration payable	161	402
Yuanhua
Accrued expenses and other current liabilities
Acquisitions consideration payable	292	540
Zhejiang Ailikang
Accrued expenses and other current liabilities
Acquisitions consideration payable	62	62
MediFast
Accrued expenses and other current liabilities
Acquisitions consideration payable		839
Shanghai Huajian Management
Accrued expenses and other current liabilities
Acquisitions consideration payable	7,203	$ 1,656
Suzhou Aoyang
Accrued expenses and other current liabilities
Acquisitions consideration payable	1,032
iKang Tianjin Hedong Dongrun
Accrued expenses and other current liabilities
Acquisitions consideration payable	774
iKang Tianjin Hexi Fenghui
Accrued expenses and other current liabilities
Acquisitions consideration payable	774
Gold iKang Shenyang Hospital
Accrued expenses and other current liabilities
Acquisitions consideration payable	368
WA Health Care
Accrued expenses and other current liabilities
Acquisitions consideration payable	$ 1,000

BANK BORROWINGS (Details)

BANK BORROWINGS (Details) - USD ($) $ in Thousands	Mar. 31, 2015	Mar. 31, 2014
BANK BORROWINGS
Short term borrowings	$ 56,772	$ 18,201
Long term borrowings		1,865
Total	$ 56,772	$ 20,066

BANK BORROWINGS (Details 2)

BANK BORROWINGS (Details 2) $ in Thousands

Sep. 17, 2013USD ($)

Jun. 30, 2013loan

Sep. 30, 2014USD ($)

Aug. 31, 2014USD ($)

Jul. 31, 2014USD ($)loan

Jun. 30, 2014USD ($)

May. 31, 2014USD ($)loan

Apr. 30, 2014USD ($)

Mar. 31, 2014USD ($)agreementclinic

Dec. 19, 2013USD ($)loan

Sep. 30, 2013USD ($)

Jun. 30, 2014USD ($)

Apr. 30, 2014USD ($)

Nov. 30, 2013loan

Sep. 30, 2013USD ($)loan

Mar. 31, 2015USD ($)

Mar. 31, 2014USD ($)

Mar. 31, 2013USD ($)

Jul. 10, 2013USD ($)

Jun. 28, 2013USD ($)

Jun. 25, 2013USD ($)

Aug. 01, 2011

Short term borrowings

Amount outstanding

$ 18,201

$ 56,772

$ 18,201

Amount repaid

20,860

7,383

$ 3,976

One-year loan framework agreement with Bank of Beijing signed in March 2014

Short term borrowings

Number of loan agreements signed | agreement

7

Term of framework loan facility

1 year

Maximum borrowing capacity

$ 8,896

8,896

Number of clinics signed loan framework agreements | clinic

7

One-year loan framework agreement with Bank of Beijing signed in March 2014 | Bank of Beijing

Short term borrowings

Amount borrowed

$ 1,353

$ 4,919

$ 1,353

4,919

Variable rate basis

benchmark interest rate announced by the People's Bank of China

Percentage of benchmark interest rate added to benchmark interest rate to calculate annual interest rate

15.00%

Amount outstanding

4,919

0

4,919

iKang Holding | BEA

Short term borrowings

Number of loans borrowed | loan

5

5

5

5

Term of loan

1 year

1 year

1 year

1 year

Amount borrowed

$ 1,606

$ 4,941

$ 1,630

$ 1,304

$ 1,627

Variable rate basis

benchmark interest rate announced by the People's Bank of China

benchmark interest rate announced by the People's Bank of China

benchmark interest rate announced by the People's Bank of China

benchmark interest rate announced by the People's Bank of China

Percentage of benchmark interest rate added to benchmark interest rate to calculate annual interest rate

10.00%

10.00%

10.00%

10.00%

Amount outstanding

10,910

10,910

iKang Holding | Two-year loan framework agreement with China Merchants Bank signed in May 2014

Short term borrowings

Term of framework loan facility

2 years

Maximum borrowing capacity

$ 8,060

iKang Holding | Two-year loan framework agreement with China Merchants Bank signed in May 2014 | China Merchants Bank

Short term borrowings

Term of loan

1 year

1 year

Amount borrowed

$ 1,437

$ 4,290

$ 1,437

Variable rate basis

interest rate announced by the People's Bank of China

Percentage of benchmark interest rate added to benchmark interest rate to calculate annual interest rate

20.00%

Amount outstanding

4,485

Amount repaid

$ 1,084

$ 155

iKang Online | iKang Shanghai Xikang Road

Short term borrowings

Remaining equity interest acquired (as a percent)

35.00%

iKang Online | Xiamen International Bank

Short term borrowings

Term of loan

1 year

Amount borrowed

$ 14,561

$ 14,561

Amount outstanding

14,551

Amount of collateralized restricted cash

$ 15,002

$ 15,002

Annual interest rate (as a percent)

2.585%

2.585%

iKang Online | Ten-year loan framework agreement with BEA signed on September 2013

Short term borrowings

Term of framework loan facility

10 years

Maximum borrowing capacity

$ 2,451

$ 2,451

iKang Online | Ten-year loan framework agreement with BEA signed on September 2013 | BEA

Short term borrowings

Term of loan

1 year

Amount borrowed

$ 2,410

Variable rate basis

benchmark interest rate announced by the People's Bank of China

Percentage of benchmark interest rate added to benchmark interest rate to calculate annual interest rate

10.00%

Amount outstanding

$ 2,372

$ 2,372

iKang Online | One-year loan framework agreement with BEA signed in April 2014

Short term borrowings

Term of framework loan facility

1 year

Maximum borrowing capacity

$ 16,004

$ 16,004

iKang Online | One-year loan framework agreement with BEA signed in April 2014 | BEA

Short term borrowings

Number of loans borrowed | loan

2

Term of loan

1 year

Amount borrowed

$ 4,843

Variable rate basis

benchmark interest rate announced by the People's Bank of China

Percentage of benchmark interest rate added to benchmark interest rate to calculate annual interest rate

10.00%

Amount outstanding

4,839

Amount of collateralized restricted cash

$ 5,500

iKang Online | One-year loan framework agreement with Xiamen International Bank signed in June 2014

Short term borrowings

Term of framework loan facility

1 year

Maximum borrowing capacity

$ 32,099

$ 32,099

iKang Online | One-year loan framework agreement with Xiamen International Bank signed in June 2014 | Xiamen International Bank

Short term borrowings

Number of loans borrowed | loan

3

Term of loan

1 year

Amount borrowed

$ 17,537

Amount outstanding

17,525

Amount of collateralized restricted cash

$ 18,067

Annual interest rate (as a percent)

2.585%

iKang Online | One-year loan framework agreement with Xiamen International Bank signed in August 2014

Short term borrowings

Term of framework loan facility

1 year

Maximum borrowing capacity

$ 32,509

iKang Online | One-year loan framework agreement with Xiamen International Bank signed in August 2014 | Xiamen International Bank

Short term borrowings

Term of loan

1 year

Amount borrowed

$ 15,383

Amount outstanding

$ 15,372

Amount of collateralized restricted cash

$ 15,848

Annual interest rate (as a percent)

2.585%

BANK BORROWINGS (Details 3)

BANK BORROWINGS (Details 3) - USD ($) $ in Thousands	Jun. 28, 2013	Jun. 30, 2013	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Long term borrowings
Long term borrowings				$ 1,865
Interest expense			$ 2,466	$ 827	$ 477
Weighted average effective interest rate (as a percent)			5.60%	7.00%	7.80%
Fair value of long-term borrowing				$ 1,884
iKang Holding | Loan framework agreement with BEA signed in June 2014
Long term borrowings
Term of framework loan facility		10 years
Maximum borrowing capacity		$ 3,268
BEA- long term | iKang Holding | Loan framework agreement with BEA signed in June 2014
Long term borrowings
Term of loan	2 years
Amount borrowed	$ 1,897
Variable rate basis	benchmark interest rate announced by the People's Bank of China's interest rate
Percentage of benchmark interest rate added to benchmark interest rate to calculate annual interest rate	10.00%
Long term borrowings				$ 1,865

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended			87 Months Ended
	Mar. 31, 2015	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2015
Income taxes
Income tax rate (as a percent)		25.00%	25.00%	25.00%
Individual income tax rate (as a percent)		35.00%	35.00%	35.00%
Hong Kong | Bayley & Jackson (Hong Kong)
Income taxes
Income tax rate (as a percent)		16.50%
Hong Kong | MediFast
Income taxes
Income tax rate (as a percent)		16.50%
Hong Kong | WA Health Care
Income taxes
Income tax rate (as a percent)		16.50%
Hong Kong | Yuanhua HK (HongKong)
Income taxes
Income tax rate (as a percent)		16.50%
PRC
Income taxes
Income tax rate (as a percent)					25.00%
Withholding tax rate (as a percent)		10.00%
Minimum percentage of equity interest in a PRC-resident enterprise to be held by a qualified Hong Kong tax resident for reduced withholding tax rate		25.00%
Reduced withholding tax rate, if 25% or more equity interest in a PRC-resident enterprise is held by a qualified Hong Kong tax resident (as a percent)		5.00%
Aggregate undistributed earnings of Company's subsidiaries	$ 4,246	$ 4,246			$ 4,246
Accrued deferred tax liability	0	0			0
Aggregate undistributed earnings of the Company's VIEs and its VIEs' subsidiaries	$ 90,876	$ 90,876			$ 90,876
PRC | iKang Shenzhen Nanshan
Income taxes
Individual income tax rate (as a percent)		35.00%
PRC | iKang Shenzhen Luohu
Income taxes
Individual income tax rate (as a percent)		35.00%
PRC | iKang Shenzhen Futian
Income taxes
Individual income tax rate (as a percent)		35.00%
PRC | iKang Shenzhen Kefa
Income taxes
Individual income tax rate (as a percent)		35.00%
PRC | iKang Chengdu Waishuangnan
Income taxes
Preferential tax rate (as a percent)	15.00%
PRC | iKang Chengdu Jinjiang
Income taxes
Preferential tax rate (as a percent)	15.00%
PRC | Chengdu Gaoxin iKang West City
Income taxes
Preferential tax rate (as a percent)	15.00%
PRC | iKang Chongqing
Income taxes
Preferential tax rate (as a percent)	15.00%

INCOME TAXES (Details 2)

INCOME TAXES (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Current and deferred portions of income tax expenses included in the consolidated statements of operations, which were all attributable to the Group's PRC subsidiaries and VIE entities
Current tax expenses	$ 16,342	$ 12,048	$ 7,311
Deferred tax benefits	(3,062)	(1,947)	(1,177)
Income tax expenses	13,280	10,101	$ 6,134
Current deferred tax assets:
Accrued expenses	2,151	2,185
Deferred revenue		125
Accrued payroll	2,076	1,056
Bad debt provision	1,860	995
Less: Valuation allowance	(138)	(370)
Current deferred tax assets	5,949	3,991
Non-current deferred tax assets:
Depreciation and amortization	257	212
Impairment of long-lived assets	76	88
Net operating tax loss carry-forwards	4,369	3,748
Less: Valuation allowance	(2,490)	(2,041)
Non-current deferred tax assets	2,212	2,007
Non-current deferred tax liabilities:
Intangible assets	7,506	3,478
Non-current deferred tax liabilities	$ 7,506	$ 3,478

INCOME TAXES (Details 3)

INCOME TAXES (Details 3) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
INCOME TAXES
Tax loss carry-forward	$ 17,791
Reconciliation between the expense (benefit) of income taxes computed by applying the PRC tax rate to income (loss) before income taxes and the actual provision for income taxes
Net income before provision for income taxes and (loss)//gain from equity method investment	$ 40,155	$ 32,183	$ 18,583
PRC statutory tax rate (as a percent)	25.00%	25.00%	25.00%
Income tax at statutory tax rate	$ 10,039	$ 8,046	$ 4,646
Change in valuation allowance	217	704	126
Expenses not deductible for tax purposes	593	440	631
Effect of income tax rate difference for entities under individual income tax rate of 35%	401	390	129
Loss utilized for entities under individual income tax rate of 35%	(315)	(99)	(153)
Effect of income tax rate differences in other jurisdictions	2,429	620	755
Tax holidays and preferential tax rates	(84)
Income tax expenses	$ 13,280	$ 10,101	$ 6,134
Individual income tax rate (as a percent)	35.00%	35.00%	35.00%

COMMON SHARE (Details)

COMMON SHARE (Details)	May. 09, 2014shares	Apr. 09, 2014shares	Apr. 30, 2014shares	Mar. 31, 2015Voteclass
Common share
Class B to Class A common share conversion ratio			1
Class A redesignated to Class C common shares (in shares)			805,100
Number of classes of authorized ordinary shares | class				2
Class A common shares
Common share
Number of vote each share entitled to | Vote				1
Common shares issued (in shares)		5,215,794
Class A common shares | IPO
Common share
Common shares issued (in shares)		3,787,223
Class A common shares | Private placement
Common share
Common shares issued (in shares)		1,428,571
Conversion of convertible preferred shares to common shares (in shares)		20,781,515
Class A common shares | Green Shoe
Common share
Common shares issued (in shares)	514,556
Class C common shares
Common share
Number of vote each share entitled to | Vote				15

CONVERTIBLE REDEEMABLE PREFER94

CONVERTIBLE REDEEMABLE PREFERRED SHARES (Details) $ / shares in Units, $ in Thousands	Apr. 09, 2014shares	Oct. 16, 2013USD ($)$ / sharesshares	Aug. 28, 2013USD ($)shares	Oct. 31, 2013USD ($)	Mar. 31, 2015USD ($)Voteshares	Mar. 31, 2014USD ($)shares	Mar. 31, 2013USD ($)shares	Mar. 31, 2012USD ($)
Convertible redeemable preferred shares
Issued amount | $						$ 25,181	$ 45,000
Redemption premium amount upon issuance of series F | $						$ 17,763	$ 74,075
Rate of dividend on preferred stock (as a percent)					6.00%
Preferred stock conversion ratio					1
Liquidation payment as percentage of original purchase price					100.00%
If the IPO occurs on or before the first anniversary of the First Closing Date
Convertible redeemable preferred shares
Minimum pre-offering valuation amount | $					$ 555,000
If the IPO occurs after the first anniversary, but on or before the second anniversary of the First Closing Date
Convertible redeemable preferred shares
Minimum pre-offering valuation amount | $					675,000
If the IPO occurs after the second anniversary, but on or before the third anniversary of the First Closing Date
Convertible redeemable preferred shares
Minimum pre-offering valuation amount | $					723,000
If the IPO occurs after the third anniversary of the First Closing Date
Convertible redeemable preferred shares
Minimum pre-offering valuation amount | $					$ 740,000
Series A,B,C,D,E shares
Convertible redeemable preferred shares
Interest on preferred shares compounded annually (as a percent)					10.00%
Redemption premium amount recognized upon issuance | $					$ 26,353
Interest on preferred shares compounded annually upon issuance of series F preferred stock (as a percent)					10.00%
Series A convertible redeemable participating preferred shares
Convertible redeemable preferred shares
Preferred shares outstanding					0	1,094,668	1,094,668
Shares converted	1,094,668
Series B convertible redeemable participating preferred shares
Convertible redeemable preferred shares
Preferred shares outstanding					0	686,368	686,368
Shares converted	686,368
Series C1 convertible redeemable participating preferred shares
Convertible redeemable preferred shares
Preferred shares outstanding					0	794,250	794,250
Shares converted	794,250
Series C2 convertible redeemable participating preferred shares
Convertible redeemable preferred shares
Preferred shares outstanding					0	126,286	126,286
Shares converted	126,286
Series C3 convertible redeemable participating preferred shares
Convertible redeemable preferred shares
Preferred shares outstanding					0	1,024,318	1,024,318
Shares converted	1,024,318
Series D1 convertible redeemable participating preferred shares
Convertible redeemable preferred shares
Preferred shares outstanding					0	3,488,864	3,538,864
Shares converted	3,488,864
Series D2 convertible redeemable participating preferred shares
Convertible redeemable preferred shares
Preferred shares outstanding					0	2,072,624	2,307,536
Shares converted	2,072,624
Series E convertible redeemable participating preferred shares
Convertible redeemable preferred shares
Preferred shares outstanding					0	4,289,457	4,289,457
Shares converted	4,289,457
Redemption premium amount | $								$ 2,312
Series F convertible redeemable participating preferred shares
Convertible redeemable preferred shares
Preferred shares outstanding					0	7,204,680	4,654,697
Shares issued			1,953,499
Issued amount | $			$ 25,181
Share price (in dollars per share) | $ / shares		$ 14.1792
Number of shares redesignated to		596,484
Difference amount received due to conversion | $				$ 1,281
Shares converted	7,204,680
Restructuring period from expiry condition					18 months
Period in which restructuring to be completed from date of Restricted Venue Resolution					2 years
Interest on preferred shares compounded annually in the event of redemption for any event other than the restructuring not being completed and consummation of qualified initial public offering (as a percent)					10.00%
Interest on preferred shares compounded annually if qualified IPO has not been consummated (as a percent)					12.00%
Number of votes of the board directors required to approve redemption of preferred shares | Vote					5
Number of votes of the board directors | Vote					9
Minimum percentage of the outstanding preferred shares required to approve other public offering for qualified IPO					75.00%
Series F convertible redeemable participating preferred shares | If the IPO occurs on or before the first anniversary of the First Closing Date
Convertible redeemable preferred shares
Minimum percentage of the Original Purchase Price of preferred share, to calculate the pre-offering valuation amount as threshold for qualified IPO					50.00%
Series F convertible redeemable participating preferred shares | If the IPO occurs after the first anniversary, but on or before the second anniversary of the First Closing Date
Convertible redeemable preferred shares
Minimum percentage of the Original Purchase Price of preferred share, to calculate the pre-offering valuation amount as threshold for qualified IPO					35.00%
Series F convertible redeemable participating preferred shares | If the IPO occurs after the second anniversary, but on or before the third anniversary of the First Closing Date
Convertible redeemable preferred shares
Minimum percentage of the Original Purchase Price of preferred share, to calculate the pre-offering valuation amount as threshold for qualified IPO					25.00%
Series F convertible redeemable participating preferred shares | Minimum
Convertible redeemable preferred shares
Interest in consolidated revenue (as a percent)					3.00%
Interest in consolidated assets (as a percent)					3.00%
Class A common shares and Series D1 and D2 preferred shares
Convertible redeemable preferred shares
Number of shares sold		596,484
Share price (in dollars per share) | $ / shares		$ 12.0309
Total sold price | $		$ 7,176

NET INCOME (LOSS) PER SHARE (De

NET INCOME (LOSS) PER SHARE (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Oct. 31, 2010	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Net income (loss) per share
Net income attributable to iKang Healthcare Group, Inc.		$ 27,113	$ 21,607	$ 12,111
Deemed dividend		100	20,436	84,306
Undistributed earnings allocated to preferred shareholders		201	7,310	2,818
Net (loss)/income attributable to common and preferred shareholders of iKang Healthcare Group, Inc		26,812	(6,139)	(75,013)
Numerator:
Net (loss) income attributed to common shareholders for computing net income per common share- basic and diluted		$ 26,812	$ (6,139)	$ (75,013)
Denominator:
Weighted average common shares outstanding used in computing diluted net income per common share-basic		32,884,357	6,340,005	6,683,678
Weighted average shares outstanding used in computing net income per common shares-diluted		34,114,872	6,340,005	6,683,678
Net (loss) income per common share attributable to iKang Guobin Healthcare Group, Inc.-basic (in dollars per share)		$ 0.82	$ (0.97)	$ (11.22)
Net (loss) income per common share attributable to iKang Guobin Healthcare Group, Inc.-diluted (in dollars per share)		$ 0.79	$ (0.97)	$ (11.22)
Additional disclosures
Common shares resulting from the assumed conversion or options, excluded with anti-dilutive effect		0
Options
Additional disclosures
Common shares resulting from the assumed conversion or options, excluded with anti-dilutive effect			988,507	355,410
Series A convertible redeemable participating preferred shares
Net income (loss) per share
Deemed dividend		$ 5		$ 5,112
Undistributed earnings allocated to preferred shareholders		3	$ 118	150
Numerator:
Total attribution to participating preferred stockholders		$ 8	$ 118	$ 5,262
Denominator:
Weighted average shares outstanding used in computing net income per common shares-diluted		23,993	1,094,668	1,386,984
Net income per convertible redeemable participating preferred shares (in dollars per share)		$ 0.33	$ 0.11	$ 3.79
Additional disclosures
Common shares resulting from the assumed conversion or options, excluded with anti-dilutive effect			1,094,668	1,386,984
Series B convertible redeemable participating preferred shares
Net income (loss) per share
Deemed dividend		$ 3		$ 5,204
Undistributed earnings allocated to preferred shareholders		3	$ 130	200
Numerator:
Total attribution to participating preferred stockholders		$ 6	$ 130	$ 5,404
Denominator:
Weighted average shares outstanding used in computing net income per common shares-diluted		15,044	686,368	1,054,620
Net income per convertible redeemable participating preferred shares (in dollars per share)		$ 0.40	$ 0.19	$ 5.13
Additional disclosures
Common shares resulting from the assumed conversion or options, excluded with anti-dilutive effect			686,368	1,054,620
Series C shares
Net income (loss) per share
Deemed dividend		$ 9		$ 4,366
Undistributed earnings allocated to preferred shareholders		6	$ 231	265
Numerator:
Total attribution to participating preferred stockholders		$ 15	$ 231	$ 4,631
Denominator:
Weighted average shares outstanding used in computing net income per common shares-diluted		42,627	1,944,854	2,069,410
Net income per convertible redeemable participating preferred shares (in dollars per share)		$ 0.35	$ 0.12	$ 2.24
Additional disclosures
Common shares resulting from the assumed conversion or options, excluded with anti-dilutive effect			1,944,954	2,069,410
Series D shares
Net income (loss) per share
Deemed dividend		$ 27	$ 1,945	$ 14,875
Undistributed earnings allocated to preferred shareholders		19	789	831
Numerator:
Total attribution to participating preferred stockholders		$ 46	$ 2,734	$ 15,706
Denominator:
Weighted average shares outstanding used in computing net income per common shares-diluted		121,896	5,717,326	6,088,557
Net income per convertible redeemable participating preferred shares (in dollars per share)		$ 0.38	$ 0.48	$ 2.58
Additional disclosures
Common shares resulting from the assumed conversion or options, excluded with anti-dilutive effect			5,717,326	6,088,557
Series E convertible redeemable participating preferred shares
Net income (loss) per share
Deemed dividend		$ 21		$ 20,308
Undistributed earnings allocated to preferred shareholders		33	$ 1,323	1,324
Numerator:
Total attribution to participating preferred stockholders		$ 54	$ 1,323	$ 21,632
Denominator:
Weighted average shares outstanding used in computing net income per common shares-diluted		94,015	4,289,457	4,289,457
Net income per convertible redeemable participating preferred shares (in dollars per share)		$ 0.57	$ 0.31	$ 5.04
Additional disclosures
Common shares resulting from the assumed conversion or options, excluded with anti-dilutive effect			4,289,457	4,289,457
Series F convertible redeemable participating preferred shares
Net income (loss) per share
Deemed dividend		$ 35	$ 18,491	$ 34,441
Undistributed earnings allocated to preferred shareholders		137	4,719	48
Numerator:
Total attribution to participating preferred stockholders		$ 172	$ 23,210	$ 34,489
Denominator:
Weighted average shares outstanding used in computing net income per common shares-diluted		157,911	6,075,702	63,763
Net income per convertible redeemable participating preferred shares (in dollars per share)		$ 1.09	$ 3.82	$ 540.89
Additional disclosures
Common shares resulting from the assumed conversion or options, excluded with anti-dilutive effect			6,075,702	63,763
Class A common shares
Additional disclosures
Stock dividend (in shares)	251,079

SHARE-BASED COMPENSATION (Detai

SHARE-BASED COMPENSATION (Details) - USD ($) $ / shares in Units, $ in Thousands

Feb. 27, 2015

Oct. 28, 2014

Aug. 01, 2014

Feb. 27, 2014

Sep. 12, 2013

Mar. 18, 2013

Feb. 17, 2012

Jun. 08, 2011

Mar. 31, 2015

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2010

Mar. 31, 2011

Share-based compensation

Share options granted (in shares)

329,800

629,000

850,000

Exercise price (in dollars per share)

$ 15.20

$ 5.51

$ 5.21

Exercise price of options modified (in dollars per share)

$ 5.23

$ 6

Share-based compensation expenses

$ 9,153

$ 930

$ 2,273

Management

Share-based compensation

Share options granted (in shares)

41,843

240,000

Exercise price (in dollars per share)

$ 0.01

Management | Minimum

Share-based compensation

Service period

3 years

Management | Maximum

Share-based compensation

Service period

4 years

Executives and consultants

Share-based compensation

Share options granted (in shares)

302,855

Employee

Share-based compensation

Share options granted (in shares)

80,000

Exercise price (in dollars per share)

$ 5.13

Number of options modified (in shares)

60,000

Exercise price of options modified (in dollars per share)

$ 5.13

Period for which former employee should not engage with any entity or business of healthcare management and consulting business in the PRC for exercise of options

2 years

Directors and employees

Share-based compensation

Share options granted (in shares)

330,000

Exercise price (in dollars per share)

$ 5.13

Directors and employees | $5.13

Share-based compensation

Share options granted (in shares)

17,200

356,300

440,000

Exercise price (in dollars per share)

$ 5.13

$ 5.13

$ 5.13

Vesting period

2 years

1 year 4 months 6 days

Directors and employees | $6.00

Share-based compensation

Share options granted (in shares)

8,600

72,700

80,000

Exercise price (in dollars per share)

$ 6

$ 6

$ 6

Vesting period

2 years

1 year 10 months 28 days

Director

Share-based compensation

Share options granted (in shares)

200,000

Exercise price (in dollars per share)

$ 6

Vesting period

3 years 6 months 18 days

Former shareholder

Share-based compensation

Share options granted (in shares)

300,000

Exercise price (in dollars per share)

$ 16.18

Former employee

Share-based compensation

Share options granted (in shares)

4,000

Exercise price (in dollars per share)

$ 5.13

Vesting period

2 years

SHARE-BASED COMPENSATION (Det97

SHARE-BASED COMPENSATION (Details 2) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Number of options
Outstanding at the beginning of the period (in shares)	1,888,698	1,284,698	434,698
Granted (in shares)	329,800	629,000	850,000
Exercised (in shares)	(277,319)
Forfeited (in shares)	(40,700)	(25,000)
Outstanding at the end of the period (in shares)	1,900,479	1,888,698	1,284,698
Weighted average exercise price per option
Outstanding at the beginning of the period (in dollars per share)	$ 4.56	$ 4.13	$ 2.02
Granted (in dollars per share)	15.20	5.51	5.21
Exercised (in dollars per share)	2.97
Forfeited (in dollars per share)	5.23	6
Outstanding at the end of the period (in dollars per share)	6.63	4.56	4.13
Weighted average fair value per option at grant date
Outstanding at the beginning of the period (in dollars per share)	9.24	6.08	3.94
Granted (in dollars per share)	24.69	15.61	7.17
Exercised (in dollars per share)	5.81
Forfeited (in dollars per share)	12.04	7.13
Outstanding at the end of the period (in dollars per share)	$ 12.36	$ 9.24	$ 6.08
Additional information
Vested options (in shares)	1,572,281
Options expected to vest (in shares)	328,198
Weighted-average exercise price of options expected to vest (in dollars per share)	$ 5.55
Aggregate intrinsic value of options expected to vest	$ 8,826

SHARE-BASED COMPENSATION (Det98

SHARE-BASED COMPENSATION (Details 3) - Mar. 31, 2015 - USD ($) $ / shares in Units, $ in Thousands	Total
Option outstanding
Number outstanding (in shares)	1,900,479
Aggregate intrinsic value	$ 49,054
Option exercisable
Number exercisable (in shares)	1,572,281
Aggregate intrinsic value	$ 40,228
$ 0.01
Information with respect to share options outstanding at the end of the period
Low end of range of exercise prices (in dollars per share)	$ 0.01
Option outstanding
Number outstanding (in shares)	120,842
Weighted average remaining contractual life in years	6 months 15 days
Weighted average Exercise price per option (in dollars per share)	$ 0.01
Aggregate intrinsic value	$ 3,919
Option exercisable
Number exercisable (in shares)	120,842
Weighted average Exercise price per option (in dollars per share)	$ 0.01
Aggregate intrinsic value	$ 3,919
$1.00-$2.00
Information with respect to share options outstanding at the end of the period
Low end of range of exercise prices (in dollars per share)	$ 1
High end of range of exercise prices (in dollars per share)	$ 2
Option outstanding
Number outstanding (in shares)	30,000
Weighted average remaining contractual life in years	1 year 9 months 22 days
Weighted average Exercise price per option (in dollars per share)	$ 1.33
Aggregate intrinsic value	$ 933
Option exercisable
Number exercisable (in shares)	30,000
Weighted average Exercise price per option (in dollars per share)	$ 1.33
Aggregate intrinsic value	$ 933
$ 5.13
Information with respect to share options outstanding at the end of the period
Low end of range of exercise prices (in dollars per share)	$ 5.13
Option outstanding
Number outstanding (in shares)	1,142,528
Weighted average remaining contractual life in years	7 years 10 months 17 days
Weighted average Exercise price per option (in dollars per share)	$ 5.13
Aggregate intrinsic value	$ 31,204
Option exercisable
Number exercisable (in shares)	972,585
Weighted average Exercise price per option (in dollars per share)	$ 5.13
Aggregate intrinsic value	$ 26,562
$ 6
Information with respect to share options outstanding at the end of the period
Low end of range of exercise prices (in dollars per share)	$ 6
Option outstanding
Number outstanding (in shares)	307,109
Weighted average remaining contractual life in years	8 years 6 months 7 days
Weighted average Exercise price per option (in dollars per share)	$ 6
Aggregate intrinsic value	$ 8,120
Option exercisable
Number exercisable (in shares)	148,854
Weighted average Exercise price per option (in dollars per share)	$ 6
Aggregate intrinsic value	$ 3,936
$ 16.18
Information with respect to share options outstanding at the end of the period
Low end of range of exercise prices (in dollars per share)	$ 16.18
Option outstanding
Number outstanding (in shares)	300,000
Weighted average remaining contractual life in years	9 years 4 months 2 days
Weighted average Exercise price per option (in dollars per share)	$ 16.18
Aggregate intrinsic value	$ 4,878
Option exercisable
Number exercisable (in shares)	300,000
Weighted average Exercise price per option (in dollars per share)	$ 16.18
Aggregate intrinsic value	$ 4,878

SHARE-BASED COMPENSATION (Det99

SHARE-BASED COMPENSATION (Details 4) - USD ($) $ / shares in Units, $ in Thousands	Feb. 27, 2015	Oct. 28, 2014	Aug. 01, 2014	Feb. 27, 2014	Sep. 12, 2013	Mar. 18, 2013	Feb. 17, 2012	Jun. 08, 2011	Dec. 31, 2010	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Assumptions used on the grant date to estimate fair value of each option granted using the binomial tree pricing model for grants during the applicable periods
Risk-free interest rate of return (as a percent)	3.33%	3.09%	3.09%	3.24%	3.22%	2.15%	2.99%	1.11%	4.67%
Contractual term	10 years	10 years	10 years	10 years	10 years	10 years	10 years	2 years 4 months 21 days	10 years
Volatility (as a percent)	58.87%	45.38%	40.00%	38.09%	38.20%	40.00%	41.00%	42.00%	40.90%
Exercise price (in dollars per share)	$ 5.13		$ 16.18		$ 6		$ 5.13	$ 0.01	$ 5.13
Additional disclosure
Share-based compensation										$ 9,153	$ 930	$ 2,273
Unrecognized compensation expense										$ 5,411
Period over which total unrecognized compensation expense relating to unvested share options will be recognized										2 years
Weighted-average remaining contractual term of options outstanding										7 years 7 months 24 days
Minimum
Assumptions used on the grant date to estimate fair value of each option granted using the binomial tree pricing model for grants during the applicable periods
Exercise price (in dollars per share)		$ 5.13		$ 5.13		$ 5.13
Maximum
Assumptions used on the grant date to estimate fair value of each option granted using the binomial tree pricing model for grants during the applicable periods
Exercise price (in dollars per share)		$ 6		$ 6		$ 6

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details) - Recurring basis - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Fair Value Derivative Asset Measured on Recurring Basis [Roll Forward]
Balance at beginning of year	$ 6,377
Balance at end of year		$ 6,377
Level 2
Fair Value Derivative Asset Measured on Recurring Basis [Roll Forward]
Balance at beginning of year	6,377
Balance at end of year		6,377
Foreign currency exchange forward contracts | Level 2
Fair Value Derivative Asset Measured on Recurring Basis [Roll Forward]
Balance at beginning of year	6,377	6,320
Gain/(loss) from forward contracts	(8)	57
Settled	$ (6,369)
Balance at end of year		$ 6,377

FAIR VALUE MEASUREMENTS (Det101

FAIR VALUE MEASUREMENTS (Details 2) - Recurring basis $ in Thousands	Mar. 31, 2014USD ($)
Fair value measurements
Foreign currency forward contracts	$ 6,377
Outstanding on March 31 year	6,377
Level 2
Fair value measurements
Foreign currency forward contracts	6,377
Outstanding on March 31 year	$ 6,377

RELATED PARTY BALANCES AND T102

RELATED PARTY BALANCES AND TRANSACTIONS (Details) - USD ($) $ in Thousands	Aug. 01, 2011	Mar. 31, 2014	Dec. 31, 2013	Feb. 28, 2013	Aug. 31, 2011	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Amounts due from a related party - current:
Amounts due from a related party - current		$ 1,287					$ 1,287
Amounts due to a related party - current:
Amounts due to a related party - current		8,049					8,049
Imputed interest expense						$ 0	504	$ 629
Effective interest rate of the amount due from non-controlling interest holder (as a percent)						5.50%
iKang Holding | iKang Shanghai Xikang Road
Amounts due to a related party - current:
Remaining equity interest acquired (as a percent)	35.00%
Consideration to purchase equity interest	$ 15,894
Amount paid		991	$ 3,941	$ 1,589	$ 1,589
Period within which the first installment of consideration was paid after signing of the agreement					5 days
Shanghai Huajian Clinic Ltd
Amounts due from a related party - current:
Amounts due from a related party - current		1,287					1,287
Former non-controlling interest holder
Amounts due to a related party - current:
Amounts due to a related party - current		$ 8,049					$ 8,049

NONCONTROLLING INTEREST (Detail

NONCONTROLLING INTEREST (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Noncontrolling interest
Balance at the beginning of the period	$ 3,818	$ 1,030	$ 708
Share of profit (loss)	283	319	338
Purchase of non-controlling interest		(142)
Other comprehensive income	24	(21)	(16)
Balance at the end of the period	9,218	3,818	1,030
iKang Zhejiang BVI
Noncontrolling interest
Balance at the beginning of the period	106	4	(25)
Share of profit (loss)	133	104	59
Other comprehensive income	21	(2)	(30)
Balance at the end of the period	260	106	4
WA Health Care
Noncontrolling interest
Addition of non-controlling interest	3,388
Capital contribution of non-controlling interest holder	1,984
Share of profit (loss)	(42)
Balance at the end of the period	5,330
iKang Shanghai Gubei
Noncontrolling interest
Balance at the beginning of the period	824	639	484
Dividend distribution to non-controlling interest holder		(44)
Share of profit (loss)	210	236	146
Other comprehensive income		(7)	9
Balance at the end of the period	1,034	824	639
iKang Shanghai Lujiazui
Noncontrolling interest
Balance at the beginning of the period		116	115
Share of profit (loss)		25	(1)
Purchase of non-controlling interest		(142)
Other comprehensive income		1	2
Balance at the end of the period			116
Fujian iKang
Noncontrolling interest
Balance at the beginning of the period	389	250	208
Share of profit (loss)	228	143	39
Other comprehensive income		(4)	3
Balance at the end of the period	617	389	250
Shenzhen Hospital Management
Noncontrolling interest
Balance at the beginning of the period	53	21	(74)
Share of profit (loss)	(105)	33	95
Other comprehensive income		(1)
Balance at the end of the period	(52)	53	$ 21
Shanghai Jianwei Management
Noncontrolling interest
Balance at the beginning of the period	161
Addition of non-controlling interest		172
Capital contribution of non-controlling interest holder	50
Share of profit (loss)	(145)	(9)
Other comprehensive income	2	(2)
Balance at the end of the period	68	161
Beijing Jiandatong
Noncontrolling interest
Balance at the beginning of the period	45
Addition of non-controlling interest		82
Capital contribution of non-controlling interest holder	58
Share of profit (loss)	(9)	(36)
Other comprehensive income		(1)
Balance at the end of the period	94	45
MediFast
Noncontrolling interest
Balance at the beginning of the period	1,737
Addition of non-controlling interest		1,690
Dividend distribution to non-controlling interest holder	(387)
Share of profit (loss)	202	48
Other comprehensive income	1	(1)
Balance at the end of the period	1,553	1,737
iKang Changzhou
Noncontrolling interest
Balance at the beginning of the period	503
Addition of non-controlling interest		732
Share of profit (loss)	(189)	(225)
Other comprehensive income		(4)
Balance at the end of the period	$ 314	$ 503

SEGMENT INFORMATION (Details)

SEGMENT INFORMATION (Details) $ in Thousands	12 Months Ended
	Mar. 31, 2015USD ($)segment	Mar. 31, 2014USD ($)	Mar. 31, 2013USD ($)
Segment information
Number of operating segments | segment	2
Net revenues
Net revenues	$ 290,781	$ 202,304	$ 133,871
Cost of Goods and Services Sold [Abstract]
Cost of revenues	154,943	106,405	71,079
Gross profit
Gross profit	135,838	95,899	62,792
Operating expenses:
Selling and marketing expenses	41,059	28,879	18,486
General and administrative expenses	52,331	32,053	23,447
Research and development expenses	1,401	1,603	1,270
Total operating expenses	94,791	62,535	43,203
Income from operations	41,047	33,364	19,589
Medical examinations and other medical services
Net revenues
Net revenues	285,292	202,304	133,871
Cost of Goods and Services Sold [Abstract]
Cost of revenues	151,348	106,405	71,079
Gross profit
Gross profit	133,944	95,899	62,792
Medical examinations and other medical services | Medical examinations
Net revenues
Net revenues	244,945	173,903	116,449
Medical examinations and other medical services | Disease screening
Net revenues
Net revenues	19,689	15,017	9,240
Medical examinations and other medical services | Other services
Net revenues
Net revenues	20,658	$ 13,384	$ 8,182
Dental services
Net revenues
Net revenues	5,489
Cost of Goods and Services Sold [Abstract]
Cost of revenues	3,595
Gross profit
Gross profit	$ 1,894

COMMITMENTS AND CONTINGENCIE105

COMMITMENTS AND CONTINGENCIES (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
COMMITMENTS AND CONTINGENCIES
Rental expenses under operating leases	$ 37,733	$ 28,129	$ 16,436
Future minimum lease payments
2,016	41,732
2,017	38,497
2,018	33,735
2,019	28,731
2,020	22,433
After 2,020	59,511
Total	$ 224,639
Contingent liabilities
Income tax on capital gain payable by individual when corporation purchases equity interest from individuals pursuant to PRC individual income tax law (as a percent)	20.00%

EMPLOYEE BENEFIT PLAN (Details)

EMPLOYEE BENEFIT PLAN (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
EMPLOYEE BENEFIT PLAN
Total provision under government-mandated defined contribution plan	$ 10,417	$ 7,249	$ 4,908

STATUTORY RESERVE AND RESTRI107

STATUTORY RESERVE AND RESTRICTED NET ASSETS (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
STATUTORY RESERVE AND RESTRICTED NET ASSETS
Percentage of after-tax profits required to be appropriated to general reserve	10.00%
General reserve as a percentage of registered capital up to which after-tax profit of PRC subsidiaries and VIEs shall be transferred	50.00%
Amount appropriated to statutory reserve	$ 3,394	$ 2,738	$ 1,296
Aggregate amounts of capital and statutory reserves restricted	$ 139,994
Restricted net assets of subsidiaries and VIE entities as a percentage of consolidated net assets of the Group	25.00%

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) $ in Thousands	Apr. 15, 2015USD ($)	Jul. 31, 2015USD ($)	Jun. 30, 2015USD ($)	May. 31, 2015USD ($)shareholder	Mar. 31, 2015
iKang Shanghai Gubei
Subsequent events
Percentage of equity interest owned					70.00%
Subsequent events | iKang Shanghai Gubei
Subsequent events
Dividend paid to non-controlling interest		$ 557
Percentage of equity interest owned		100.00%
Subsequent events | Tianjian Sunny | Beijing Tianzhikangjian
Subsequent events
Equity interest previously held by counterparty (as a percentage)				31.85%
Subsequent events | iKang Shanghai Gubei
Subsequent events
Percentage of equity interest acquired		30.00%
Cash consideration		$ 789
Subsequent events | Share purchase agreement | Chengdu Ommay Health Examination Hospital Co., Ltd. | Four third party shareholders Of Ommay Health Management Co., Ltd.
Subsequent events
Percentage of equity interest acquired				100.00%
Number of third party shareholders | shareholder				4
Cash consideration				$ 3,705
Subsequent events | Share purchase agreement | Beijing Tianzhikangjian
Subsequent events
Percentage of equity interest acquired				100.00%
Subsequent events | Share purchase agreement | Tianjian Sunny | Beijing Tianzhikangjian
Subsequent events
Percentage of equity interest acquired				82.85%
Cash consideration				$ 27,327
Additional equity interest to be acquired (as a percentage)				51.00%
Subsequent events | Share purchase agreement | Yantai iKang Guobin HongKang Health Management Co., Ltd. Ande Clinic and Yantai iKang Guobin HongKang Health Examination Management Co., Ltd. Clinic
Subsequent events
Percentage of equity interest acquired			100.00%
Cash consideration			$ 7,421
Subsequent events | Cooperation agreement | Joint Venture
Subsequent events
Equity interest held by the entity before acquisiton(as a percentage)	46.21%
Equity interest held by the entity after acquisition (as a percentage)			70.00%
Subsequent events | Cooperation agreement | Former shareholders | Joint Venture
Subsequent events
Total Paid In Capital Of New Company Per Agreement	$ 8,273
Subsequent events | Cooperation agreement | Joint Venture | Former shareholders
Subsequent events
Percentage of equity interest acquired			23.79%
Cash consideration			$ 1,968
Equity interest previously held by counterparty (as a percentage)	53.79%

FINANCIAL STATEMENT SCHEDULE109

FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY (Details) - USD ($) $ in Thousands	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2012
Current assets:
Cash and cash equivalents	$ 97,336	$ 30,221	$ 63,154	$ 11,875
Amounts due from a related party		1,287
Prepaid expenses and other current assets	44,031	20,012
Total current assets	278,665	110,830
Property and equipment, net	105,022	63,644
Rental deposit and other non-current assets	10,238	6,301
TOTAL ASSETS	499,001	250,226
Current liabilities:
Accrued expenses and other current liabilities	36,790	24,275
Amount due to related parties		8,049
Total current liabilities	163,147	103,442
Equity:
Additional paid-in capital	419,862	1,342
Accumulated other comprehensive income	3,936	3,764
Total iKang Healthcare Group, Inc. shareholders' (deficit)/equity	319,130	(126,957)
TOTAL LIABILITIES, MEZZANINE EQUITY AND EQUITY	499,001	250,226
PARENT COMPANY
Current assets:
Cash and cash equivalents	55,883	13,937	47,290	80
Amounts due from a related party	127,694	27,622
Prepaid expenses and other current assets	1,488	334
Total current assets	185,065	41,893
Property and equipment, net		1
Investment in subsidiaries and VIE entities	136,670	99,584
Rental deposit and other non-current assets	740
TOTAL ASSETS	322,475	141,478
Current liabilities:
Accrued expenses and other current liabilities	2,151	2,767
Amount due to related parties	1,194	1,151
Total current liabilities	3,345	3,918
Equity:
Additional paid-in capital	419,862	1,342
Accumulated deficit	(105,011)	(132,124)
Accumulated other comprehensive income	3,936	3,764
Total iKang Healthcare Group, Inc. shareholders' (deficit)/equity	319,130	(126,957)	$ (124,195)	$ (52,212)
TOTAL LIABILITIES, MEZZANINE EQUITY AND EQUITY	322,475	141,478
Series A convertible redeemable participating preferred shares
Mezzanine Equity:
Convertible redeemable participating preferred shares		6,496
Series A convertible redeemable participating preferred shares | PARENT COMPANY
Mezzanine Equity:
Convertible redeemable participating preferred shares		6,496
Series B convertible redeemable participating preferred shares
Mezzanine Equity:
Convertible redeemable participating preferred shares		6,512
Series B convertible redeemable participating preferred shares | PARENT COMPANY
Mezzanine Equity:
Convertible redeemable participating preferred shares		6,512
Series C1 convertible redeemable participating preferred shares
Mezzanine Equity:
Convertible redeemable participating preferred shares		5,700
Series C1 convertible redeemable participating preferred shares | PARENT COMPANY
Mezzanine Equity:
Convertible redeemable participating preferred shares		5,700
Series C2 convertible redeemable participating preferred shares
Mezzanine Equity:
Convertible redeemable participating preferred shares		1,709
Series C2 convertible redeemable participating preferred shares | PARENT COMPANY
Mezzanine Equity:
Convertible redeemable participating preferred shares		1,709
Series C3 convertible redeemable participating preferred shares
Mezzanine Equity:
Convertible redeemable participating preferred shares		4,157
Series C3 convertible redeemable participating preferred shares | PARENT COMPANY
Mezzanine Equity:
Convertible redeemable participating preferred shares		4,157
Series D1 convertible redeemable participating preferred shares
Mezzanine Equity:
Convertible redeemable participating preferred shares		29,750
Series D1 convertible redeemable participating preferred shares | PARENT COMPANY
Mezzanine Equity:
Convertible redeemable participating preferred shares		29,750
Series D2 convertible redeemable participating preferred shares
Mezzanine Equity:
Convertible redeemable participating preferred shares		11,300
Series D2 convertible redeemable participating preferred shares | PARENT COMPANY
Mezzanine Equity:
Convertible redeemable participating preferred shares		11,300
Series E convertible redeemable participating preferred shares
Mezzanine Equity:
Convertible redeemable participating preferred shares		54,098
Series E convertible redeemable participating preferred shares | PARENT COMPANY
Mezzanine Equity:
Convertible redeemable participating preferred shares		54,098
Series F convertible redeemable participating preferred shares
Mezzanine Equity:
Convertible redeemable participating preferred shares		144,795
Series F convertible redeemable participating preferred shares | PARENT COMPANY
Mezzanine Equity:
Convertible redeemable participating preferred shares		144,795
Class A common shares
Equity:
Common shares	335	45
Class A common shares | PARENT COMPANY
Equity:
Common shares	335	45
Class B common shares
Equity:
Common shares		16
Class B common shares | PARENT COMPANY
Equity:
Common shares		$ 16
Class C common shares
Equity:
Common shares	8
Class C common shares | PARENT COMPANY
Equity:
Common shares	$ 8

FINANCIAL STATEMENT SCHEDULE110

FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY (Details) (Parenthetical) - USD ($) $ / shares in Units, $ in Thousands	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
CONDENSED BALANCE SHEETS
Common shares, par value (in dollars per share)		$ 0.01
PARENT COMPANY
CONDENSED BALANCE SHEETS
Common shares, par value (in dollars per share)		0.01
Series A convertible redeemable participating preferred shares
CONDENSED BALANCE SHEETS
Convertible redeemable participating preferred shares, par value (in dollars per share)	$ 0.01	$ 0.01
Convertible redeemable participating preferred shares, authorized	0	1,094,668
Convertible redeemable participating preferred shares, issued	0	1,094,668
Convertible redeemable participating preferred shares, outstanding	0	1,094,668	1,094,668
Convertible redeemable participating preferred shares, liquidation value (in dollars)	$ 0	$ 1,970
Series A convertible redeemable participating preferred shares | PARENT COMPANY
CONDENSED BALANCE SHEETS
Convertible redeemable participating preferred shares, par value (in dollars per share)	$ 0.01	$ 0.01
Convertible redeemable participating preferred shares, authorized	0	1,094,668
Convertible redeemable participating preferred shares, issued	0	1,094,668
Convertible redeemable participating preferred shares, outstanding	0	1,094,668
Convertible redeemable participating preferred shares, liquidation value (in dollars)	$ 0	$ 1,970
Series B convertible redeemable participating preferred shares
CONDENSED BALANCE SHEETS
Convertible redeemable participating preferred shares, par value (in dollars per share)	$ 0.01	$ 0.01
Convertible redeemable participating preferred shares, authorized	0	686,368
Convertible redeemable participating preferred shares, issued	0	686,368
Convertible redeemable participating preferred shares, outstanding	0	686,368	686,368
Convertible redeemable participating preferred shares, liquidation value (in dollars)	$ 0	$ 2,162
Series B convertible redeemable participating preferred shares | PARENT COMPANY
CONDENSED BALANCE SHEETS
Convertible redeemable participating preferred shares, par value (in dollars per share)	$ 0.01	$ 0.01
Convertible redeemable participating preferred shares, authorized	0	686,368
Convertible redeemable participating preferred shares, issued	0	686,368
Convertible redeemable participating preferred shares, outstanding	0	686,368
Convertible redeemable participating preferred shares, liquidation value (in dollars)	$ 0	$ 2,162
Series C1 convertible redeemable participating preferred shares
CONDENSED BALANCE SHEETS
Convertible redeemable participating preferred shares, par value (in dollars per share)	$ 0.01	$ 0.01
Convertible redeemable participating preferred shares, authorized	0	794,250
Convertible redeemable participating preferred shares, issued	0	794,250
Convertible redeemable participating preferred shares, outstanding	0	794,250	794,250
Convertible redeemable participating preferred shares, liquidation value (in dollars)	$ 0	$ 1,893
Series C1 convertible redeemable participating preferred shares | PARENT COMPANY
CONDENSED BALANCE SHEETS
Convertible redeemable participating preferred shares, par value (in dollars per share)	$ 0.01	$ 0.01
Convertible redeemable participating preferred shares, authorized	0	794,250
Convertible redeemable participating preferred shares, issued	0	794,250
Convertible redeemable participating preferred shares, outstanding	0	794,250
Convertible redeemable participating preferred shares, liquidation value (in dollars)	$ 0	$ 1,893
Series C2 convertible redeemable participating preferred shares
CONDENSED BALANCE SHEETS
Convertible redeemable participating preferred shares, par value (in dollars per share)	$ 0.01	$ 0.01
Convertible redeemable participating preferred shares, authorized	0	126,286
Convertible redeemable participating preferred shares, issued	0	126,286
Convertible redeemable participating preferred shares, outstanding	0	126,286	126,286
Convertible redeemable participating preferred shares, liquidation value (in dollars)	$ 0	$ 568
Series C2 convertible redeemable participating preferred shares | PARENT COMPANY
CONDENSED BALANCE SHEETS
Convertible redeemable participating preferred shares, par value (in dollars per share)	$ 0.01	$ 0.01
Convertible redeemable participating preferred shares, authorized	0	126,286
Convertible redeemable participating preferred shares, issued	0	126,286
Convertible redeemable participating preferred shares, outstanding	0	126,286
Convertible redeemable participating preferred shares, liquidation value (in dollars)	$ 0	$ 568
Series C3 convertible redeemable participating preferred shares
CONDENSED BALANCE SHEETS
Convertible redeemable participating preferred shares, par value (in dollars per share)	$ 0.01	$ 0.01
Convertible redeemable participating preferred shares, authorized	0	1,024,318
Convertible redeemable participating preferred shares, issued	0	1,024,318
Convertible redeemable participating preferred shares, outstanding	0	1,024,318	1,024,318
Convertible redeemable participating preferred shares, liquidation value (in dollars)	$ 0	$ 1,382
Series C3 convertible redeemable participating preferred shares | PARENT COMPANY
CONDENSED BALANCE SHEETS
Convertible redeemable participating preferred shares, par value (in dollars per share)	$ 0.01	$ 0.01
Convertible redeemable participating preferred shares, authorized	0	1,024,318
Convertible redeemable participating preferred shares, issued	0	1,024,318
Convertible redeemable participating preferred shares, outstanding	0	1,024,318
Convertible redeemable participating preferred shares, liquidation value (in dollars)	$ 0	$ 1,382
Series D1 convertible redeemable participating preferred shares
CONDENSED BALANCE SHEETS
Convertible redeemable participating preferred shares, par value (in dollars per share)	$ 0.01	$ 0.01
Convertible redeemable participating preferred shares, authorized	0	3,488,864
Convertible redeemable participating preferred shares, issued	0	3,488,864
Convertible redeemable participating preferred shares, outstanding	0	3,488,864	3,538,864
Convertible redeemable participating preferred shares, liquidation value (in dollars)	$ 0	$ 10,083
Series D1 convertible redeemable participating preferred shares | PARENT COMPANY
CONDENSED BALANCE SHEETS
Convertible redeemable participating preferred shares, par value (in dollars per share)	$ 0.01	$ 0.01
Convertible redeemable participating preferred shares, authorized	0	3,488,864
Convertible redeemable participating preferred shares, issued	0	3,488,864
Convertible redeemable participating preferred shares, outstanding	0	3,488,864
Convertible redeemable participating preferred shares, liquidation value (in dollars)	$ 0	$ 10,083
Series D2 convertible redeemable participating preferred shares
CONDENSED BALANCE SHEETS
Convertible redeemable participating preferred shares, par value (in dollars per share)	$ 0.01	$ 0.01
Convertible redeemable participating preferred shares, authorized	0	2,072,624
Convertible redeemable participating preferred shares, issued	0	2,072,624
Convertible redeemable participating preferred shares, outstanding	0	2,072,624	2,307,536
Convertible redeemable participating preferred shares, liquidation value (in dollars)	$ 0	$ 2,798
Series D2 convertible redeemable participating preferred shares | PARENT COMPANY
CONDENSED BALANCE SHEETS
Convertible redeemable participating preferred shares, par value (in dollars per share)	$ 0.01	$ 0.01
Convertible redeemable participating preferred shares, authorized	0	2,072,624
Convertible redeemable participating preferred shares, issued	0	2,072,624
Convertible redeemable participating preferred shares, outstanding	0	2,072,624
Convertible redeemable participating preferred shares, liquidation value (in dollars)	$ 0	$ 2,798
Series E convertible redeemable participating preferred shares
CONDENSED BALANCE SHEETS
Convertible redeemable participating preferred shares, par value (in dollars per share)	$ 0.01	$ 0.01
Convertible redeemable participating preferred shares, authorized	0	4,289,457
Convertible redeemable participating preferred shares, issued	0	4,289,457
Convertible redeemable participating preferred shares, outstanding	0	4,289,457	4,289,457
Convertible redeemable participating preferred shares, liquidation value (in dollars)	$ 0	$ 22,056
Series E convertible redeemable participating preferred shares | PARENT COMPANY
CONDENSED BALANCE SHEETS
Convertible redeemable participating preferred shares, par value (in dollars per share)	$ 0.01	$ 0.01
Convertible redeemable participating preferred shares, authorized	0	4,289,457
Convertible redeemable participating preferred shares, issued	0	4,289,457
Convertible redeemable participating preferred shares, outstanding	0	4,289,457
Convertible redeemable participating preferred shares, liquidation value (in dollars)	$ 0	$ 22,056
Series F convertible redeemable participating preferred shares
CONDENSED BALANCE SHEETS
Convertible redeemable participating preferred shares, par value (in dollars per share)	$ 0.01	$ 0.01
Convertible redeemable participating preferred shares, authorized	0	7,204,680
Convertible redeemable participating preferred shares, issued	0	7,204,680
Convertible redeemable participating preferred shares, outstanding	0	7,204,680	4,654,697
Convertible redeemable participating preferred shares, liquidation value (in dollars)	$ 0	$ 93,639
Series F convertible redeemable participating preferred shares | PARENT COMPANY
CONDENSED BALANCE SHEETS
Convertible redeemable participating preferred shares, par value (in dollars per share)	$ 0.01	$ 0.01
Convertible redeemable participating preferred shares, authorized	0	7,204,680
Convertible redeemable participating preferred shares, issued	0	7,204,680
Convertible redeemable participating preferred shares, outstanding	0	7,204,680
Convertible redeemable participating preferred shares, liquidation value (in dollars)	$ 0	$ 93,639
Class A common shares
CONDENSED BALANCE SHEETS
Common shares, par value (in dollars per share)	$ 0.01	$ 0.01
Common shares, authorized	37,648,485	37,648,485
Common shares, issued	33,556,439	4,599,674
Common shares, outstanding	33,556,439	4,599,674
Class A common shares | PARENT COMPANY
CONDENSED BALANCE SHEETS
Common shares, par value (in dollars per share)	$ 0.01	$ 0.01
Common shares, authorized	37,648,485	37,648,485
Common shares, issued	33,556,439	4,599,674
Common shares, outstanding	33,556,439	4,599,674
Class B common shares
CONDENSED BALANCE SHEETS
Common shares, par value (in dollars per share)	$ 0.01	$ 0.01
Common shares, authorized	1,570,000	1,570,000
Common shares, issued	0	1,570,000
Common shares, outstanding	0	1,570,000
Class B common shares | PARENT COMPANY
CONDENSED BALANCE SHEETS
Common shares, par value (in dollars per share)	$ 0.01	$ 0.01
Common shares, authorized	1,570,000	1,570,000
Common shares, issued	0	1,570,000
Common shares, outstanding	0	1,570,000
Class C common shares
CONDENSED BALANCE SHEETS
Common shares, par value (in dollars per share)	$ 0.01	$ 0.01
Common shares, authorized	2,000,000	0
Common shares, issued	805,100	0
Common shares, outstanding	805,100	0
Class C common shares | PARENT COMPANY
CONDENSED BALANCE SHEETS
Common shares, par value (in dollars per share)	$ 0.01	$ 0.01
Common shares, authorized	2,000,000	0
Common shares, issued	805,100	0
Common shares, outstanding	805,100	0

FINANCIAL STATEMENT SCHEDULE111

FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Operating expenses:
Selling and marketing expenses	$ 41,059	$ 28,879	$ 18,486
General and administrative expenses	52,331	32,053	23,447
Total operating expenses	94,791	62,535	43,203
Income from operations	41,047	33,364	19,589
Interest income	699	93	100
Interest expense	(2,466)	(1,331)	(1,106)
Income tax expenses	13,280	10,101	6,134
Net income attributable to iKang Healthcare Group, Inc.	27,113	21,607	12,111
PARENT COMPANY
Operating expenses:
Selling and marketing expenses	15
General and administrative expenses	10,536	2,457	2,849
Total operating expenses	10,551	2,457	2,849
Income from operations	(10,551)	(2,457)	(2,849)
Interest income	25	11
Interest expense		(18)	(169)
Equity in earnings of subsidiaries and VIE entities	37,639	24,071	15,129
Income before provision for income taxes	27,113	21,607	12,111
Net income attributable to iKang Healthcare Group, Inc.	$ 27,113	$ 21,607	$ 12,111

FINANCIAL STATEMENT SCHEDULE112

FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY (Details 3) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Other comprehensive income:
Net income	$ 27,113	$ 21,607	$ 12,111
Comprehensive income attributable iKang Healthcare Group, Inc.	27,285	20,849	12,695
PARENT COMPANY
Other comprehensive income:
Net income	27,113	21,607	12,111
Other comprehensive income, foreign currency translation adjustment	172	(758)	584
Comprehensive income attributable iKang Healthcare Group, Inc.	$ 27,285	$ 20,849	$ 12,695

FINANCIAL STATEMENT SCHEDULE113

FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY (Details 4) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Increase (Decrease) in Stockholders' Equity
Balance	$ (126,957)
Share-based compensation expenses	9,153	$ 930	$ 2,273
Conversion of participating convertible redeemable preferred shares to common shares	264,509
Redesignation to Series F convertible redeemable participating preferred shares		(3,749)	(2,645)
Issuance of common shares in connection with exercise of options	$ 822
Issuance of common shares in connection with exercise of options (in shares)	277,319
Issuance of ordinary shares in connection with share-based compensation arrangements	$ 16
Purchase of non-controlling interest		(142)
Deemed dividend on convertible redeemable preferred shares - accretion of redemption premium	(100)	(20,436)	(84,306)
Net income	27,113	21,607	12,111
Balance	319,130	(126,957)
iKang Shanghai Lujiazui
Increase (Decrease) in Stockholders' Equity
Purchase of non-controlling interest		(326)
WA Health Care
Increase (Decrease) in Stockholders' Equity
Addition of non-controlling interest in connection with acquisition	3,388
PARENT COMPANY
Increase (Decrease) in Stockholders' Equity
Balance	(126,957)	(124,195)	(52,212)
Share-based compensation expenses	9,153	930	2,273
Conversion of participating convertible redeemable preferred shares to common shares	264,509
Redesignation to Series F convertible redeemable participating preferred shares		(3,749)	(2,645)
Issuance of common shares in connection with exercise of options	822
Issuance of ordinary shares in connection with share-based compensation arrangements	16
Deemed dividend on convertible redeemable preferred shares - accretion of redemption premium		(20,436)	(84,306)
Net income	27,113	21,607	12,111
Foreign currency translation adjustment	172	(758)	584
Balance	319,130	(126,957)	$ (124,195)
PARENT COMPANY | Shanghai Jianwei Management
Increase (Decrease) in Stockholders' Equity
Addition of non-controlling interest in connection with acquisition		(172)
Capital contribution of non-controlling interest holder	(50)
PARENT COMPANY | iKang Shanghai Lujiazui
Increase (Decrease) in Stockholders' Equity
Purchase of non-controlling interest		$ (184)
PARENT COMPANY | WA Health Care
Increase (Decrease) in Stockholders' Equity
Capital contribution of non-controlling interest holder	$ (1,984)
Common
Increase (Decrease) in Stockholders' Equity
Balance (in shares)	6,169,674	6,481,245	6,686,490
Conversion of participating convertible redeemable preferred shares to common shares	$ 208
Conversion of participating convertible redeemable preferred shares to common shares (in shares)	20,781,515
iKang Healthcare Group, Inc. one common share of US$0.01 entered into a share swap agreement (in shares)		1
Redesignation to Series F convertible redeemable participating preferred shares		$ (4)	$ (2)
Redesignation to Series F convertible redeemable participating preferred shares (in shares)		(311,572)	(205,245)
Issuance of common shares in connection with exercise of options	$ 1
Issuance of common shares in connection with exercise of options (in shares)	80,000
Issuance of ordinary shares in connection with share-based compensation arrangements	$ 16
Issuance of ordinary shares in connection with share-based compensation arrangements (in shares)	1,600,000
Balance (in shares)	34,361,539	6,169,674	6,481,245
Common | PARENT COMPANY
Increase (Decrease) in Stockholders' Equity
Balance	$ 61	$ 65	$ 67
Balance (in shares)	6,169,674	6,481,245	6,686,490
Conversion of participating convertible redeemable preferred shares to common shares	$ 208
Conversion of participating convertible redeemable preferred shares to common shares (in shares)	20,781,515
iKang Healthcare Group, Inc. one common share of US$0.01 entered into a share swap agreement (in shares)		1
Redesignation to Series F convertible redeemable participating preferred shares		$ (4)	$ (2)
Redesignation to Series F convertible redeemable participating preferred shares (in shares)		(311,572)	(205,245)
Issuance of common shares in connection with exercise of options	$ 1
Issuance of common shares in connection with exercise of options (in shares)	80,000
Issuance of ordinary shares in connection with share-based compensation arrangements	$ 16
Issuance of ordinary shares in connection with share-based compensation arrangements (in shares)	1,600,000
Balance	$ 343	$ 61	$ 65
Balance (in shares)	34,361,539	6,169,674	6,481,245
Additional paid-in capital
Increase (Decrease) in Stockholders' Equity
Share-based compensation expenses	$ 9,153	$ 930	$ 2,273
Conversion of participating convertible redeemable preferred shares to common shares	264,301
Redesignation to Series F convertible redeemable participating preferred shares		(3,745)	(2,643)
Issuance of common shares in connection with exercise of options	821
Additional paid-in capital | Shanghai Jianwei Management
Increase (Decrease) in Stockholders' Equity
Capital contribution of non-controlling interest holder	(50)
Additional paid-in capital | iKang Shanghai Lujiazui
Increase (Decrease) in Stockholders' Equity
Purchase of non-controlling interest		(184)
Additional paid-in capital | WA Health Care
Increase (Decrease) in Stockholders' Equity
Capital contribution of non-controlling interest holder	(1,984)
Additional paid-in capital | PARENT COMPANY
Increase (Decrease) in Stockholders' Equity
Balance	1,342	4,341	4,711
Share-based compensation expenses	9,153	930	2,273
Conversion of participating convertible redeemable preferred shares to common shares	264,301
Redesignation to Series F convertible redeemable participating preferred shares		(3,745)	(2,643)
Issuance of common shares in connection with exercise of options	821
Balance	419,862	1,342	4,341
Additional paid-in capital | PARENT COMPANY | Shanghai Jianwei Management
Increase (Decrease) in Stockholders' Equity
Capital contribution of non-controlling interest holder	(50)
Additional paid-in capital | PARENT COMPANY | iKang Shanghai Lujiazui
Increase (Decrease) in Stockholders' Equity
Purchase of non-controlling interest		(184)
Additional paid-in capital | PARENT COMPANY | WA Health Care
Increase (Decrease) in Stockholders' Equity
Capital contribution of non-controlling interest holder	(1,984)
Accumulated deficit. | PARENT COMPANY
Increase (Decrease) in Stockholders' Equity
Balance	(132,124)	(133,123)	(60,928)
Deemed dividend on convertible redeemable preferred shares - accretion of redemption premium		(20,436)	(84,306)
Net income	27,113	21,607	12,111
Balance	(105,011)	(132,124)	(133,123)
Accumulated deficit. | PARENT COMPANY | Shanghai Jianwei Management
Increase (Decrease) in Stockholders' Equity
Addition of non-controlling interest in connection with acquisition		(172)
Accumulated other comprehensive income | PARENT COMPANY
Increase (Decrease) in Stockholders' Equity
Balance	3,764	4,522	3,938
Foreign currency translation adjustment	172	(758)	584
Balance	3,936	$ 3,764	$ 4,522
IPO
Increase (Decrease) in Stockholders' Equity
Issuance of common shares	132,937
IPO | PARENT COMPANY
Increase (Decrease) in Stockholders' Equity
Issuance of common shares	132,937
IPO | Common
Increase (Decrease) in Stockholders' Equity
Issuance of common shares	$ 52
Issuance of common shares (in shares)	5,215,794
IPO | Common | PARENT COMPANY
Increase (Decrease) in Stockholders' Equity
Issuance of common shares	$ 52
Issuance of common shares (in shares)	5,215,794
IPO | Additional paid-in capital
Increase (Decrease) in Stockholders' Equity
Issuance of common shares	$ 132,885
IPO | Additional paid-in capital | PARENT COMPANY
Increase (Decrease) in Stockholders' Equity
Issuance of common shares	132,885
Green Shoe
Increase (Decrease) in Stockholders' Equity
Issuance of common shares	13,399
Green Shoe | PARENT COMPANY
Increase (Decrease) in Stockholders' Equity
Issuance of common shares	13,399
Green Shoe | Common
Increase (Decrease) in Stockholders' Equity
Issuance of common shares	$ 5
Issuance of common shares (in shares)	514,556
Green Shoe | Common | PARENT COMPANY
Increase (Decrease) in Stockholders' Equity
Issuance of common shares	$ 5
Issuance of common shares (in shares)	514,556
Green Shoe | Additional paid-in capital
Increase (Decrease) in Stockholders' Equity
Issuance of common shares	$ 13,394
Green Shoe | Additional paid-in capital | PARENT COMPANY
Increase (Decrease) in Stockholders' Equity
Issuance of common shares	$ 13,394

FINANCIAL STATEMENT SCHEDULE114

FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY (Details 4) (Parenthetical) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
CONDENSED STATEMENTS OF SHAREHOLDERS' EQUITY(DEFICIT)
Common shares, par value (in dollars per share)		$ 0.01
Offering costs	$ 2,882
PARENT COMPANY
CONDENSED STATEMENTS OF SHAREHOLDERS' EQUITY(DEFICIT)
Common shares, par value (in dollars per share)		$ 0.01
Offering costs	$ 2,882

FINANCIAL STATEMENT SCHEDULE115

FINANCIAL STATEMENT SCHEDULE I CONDENSED FINANCIAL INFORMATION OF PARENT COMPANY (Details 5) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 27,113	$ 21,607	$ 12,111
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation	9,153	930	2,273
Changes in assets and liabilities:
Prepaid expenses and other current assets	(5,300)	(1,193)	176
Amount due from related parties			(477)
Accrued expenses and other current liabilities	2,123	2,884	3,071
Net cash generated from (used in) operating activities	41,097	34,303	16,314
CASH FLOWS FROM INVESTING ACTIVITIES
Loan provided to a related party		(4,306)
Repayment of loan provided to a related party	1,291	3,483
Payment for loan receivable	(740)
Payments for business acquisitions	(34,432)	(41,311)	(6,038)
Net cash used in investing activities	(147,062)	(96,714)	(16,058)
CASH FLOW FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible redeemable preferred shares		25,181	45,000
Proceeds from convertible loan			2,000
Repayment of convertible loan		(2,000)
Proceeds from exercise of share options	824
Proceeds from issuance of common shares upon initial public offering	135,819
Proceeds from issuance of common shares upon Green Shoe	13,399
Payments of initial public offering expenses	(3,574)
Payments for business acquisitions	(1,329)	(3,010)
Proceeds from redesignation of Class A common shares		612
Proceeds from redesignation of convertible redeemable preferred shares		669
Payment for convertible preferred shares transaction professional fees		(2,847)
Net cash provided by financing activities	173,570	29,342	50,824
Net increase (decrease) in cash and cash equivalent	67,115	(32,933)	51,279
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR	30,221	63,154	11,875
CASH AND CASH EQUIVALENTS AT END OF THE YEAR	97,336	30,221	63,154
PARENT COMPANY
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	27,113	21,607	12,111
Adjustments to reconcile net income to net cash provided by operating activities:
Investment income from subsidiaries	(37,639)	(24,071)	(15,129)
Stock-based compensation	9,153	930	2,273
Changes in assets and liabilities:
Prepaid expenses and other current assets	(410)	(315)	2,754
Amount due from related parties	(103,142)	(17,732)	(1,502)
Accrued expenses and other current liabilities	3,349	(2,409)	(297)
Net cash generated from (used in) operating activities	(101,576)	(21,990)	210
CASH FLOWS FROM INVESTING ACTIVITIES
Loan provided to a related party		(3,000)
Repayment of loan provided to a related party		3,000
Payment for loan receivable	(740)
Payments for business acquisitions	(2,417)	(32,978)
Net cash used in investing activities	(3,157)	(32,978)
CASH FLOW FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible redeemable preferred shares		25,181	45,000
Proceeds from convertible loan			2,000
Repayment of convertible loan		(2,000)
Proceeds from exercise of share options	824
Proceeds from issuance of common shares upon initial public offering	135,819
Proceeds from issuance of common shares upon Green Shoe	13,399
Payments of initial public offering expenses	(2,276)
Payments for business acquisitions	(1,087)
Proceeds from redesignation of Class A common shares		669
Proceeds from redesignation of convertible redeemable preferred shares		612
Payment for convertible preferred shares transaction professional fees		(2,847)
Net cash provided by financing activities	146,679	21,615	47,000
Net increase (decrease) in cash and cash equivalent	41,946	(33,353)	47,210
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR	13,937	47,290	80
CASH AND CASH EQUIVALENTS AT END OF THE YEAR	$ 55,883	$ 13,937	$ 47,290